Supplementary Material 11

Overall Results Based on All Recruited Patients

Overall Results Based on All Recruited Patients

D.9.1 Primary Outcome Measure: Response at Day 99

Table S41: Summary of number of patients achieving a target reduction in centrally processed serum alkaline phosphatase (ALP) for mITT trial population.

Reduction of 25% or greater	**N(%)**
FALSE	19 (86.36%)
TRUE	2 (9.09%)
Not Known	1 (4.55%)
Total	**22 (100.00%)**

Table S42: Average Difference in ALP.

Absolute Difference (IU/L)	
N	21
Mean	14.1
Median	2
Range	(-161,452)
IQR	(-47,13)
Percentage Change	
N	21
Mean	-0.2
Median	1.05
Range	(-42.75,61.08)
IQR	(-12.22,3.07)

D.9.2 Safety and Toxicity Reporting

Table S43: Number of adverse events by grade and treatment visit in the safety population.

	CTCAE Grade				
Visit	**1**	**2**	**3**	**4**	**Total**
Pre-screening	29 (3.50%)	11 (4.98%)	1 (1.35%)	1 (9.09%)	42 (3.70%)
Screening visit 1	123 (14.86%)	37 (16.74%)	16 (21.62%)	5 (45.45%)	181 (15.96%)
Screening visit 2	35 (4.23%)	7 (3.17%)	5 (6.76%)	1 (9.09%)	48 (4.23%)
Visit 3	106 (12.80%)	16 (7.24%)	7 (9.46%)	0 (0.00%)	129 (11.38%)
Visit 4	75 (9.06%)	26 (11.76%)	3 (4.05%)	0 (0.00%)	104 (9.17%)
Visit 5	101 (12.20%)	27 (12.22%)	4 (5.41%)	0 (0.00%)	132 (11.64%)
Visit 6	63 (7.61%)	14 (6.33%)	3 (4.05%)	0 (0.00%)	80 (7.05%)
Visit 7	71 (8.57%)	23 (10.41%)	5 (6.76%)	1 (9.09%)	100 (8.82%)
Visit 8	76 (9.18%)	20 (9.05%)	6 (8.11%)	0 (0.00%)	102 (8.99%)
Visit 9	71 (8.57%)	16 (7.24%)	4 (5.41%)	0 (0.00%)	91 (8.02%)
Follow up visit 10	44 (5.31%)	14 (6.33%)	16 (21.62%)	1 (9.09%)	75 (6.61%)
Follow up visit 11	29 (3.50%)	7 (3.17%)	4 (5.41%)	2 (18.18%)	42 (3.70%)
Other	5 (0.60%)	3 (1.36%)	0 (0.00%)	0 (0.00%)	8 (0.71%)
Total	**828 (100.00%)**	**221 (100.00%)**	**74 (100.00%)**	**11 (100.00%)**	**1134 (100.00%)**

Table S44: Number of patients in the safety population experiencing adverse events by grade and treatment visit.

	CTCAE Grade				
Visit	**1**	**2**	**3**	**4**	**Total**
Pre-screening	8/22	5/22	1/22	1/22	10/22
Screening visit 1	22/22	18/22	13/22	5/22	22/22
Screening visit 2	16/22	6/22	4/22	1/22	18/22
Visit 3	22/22	11/22	5/22	0	22/22
Visit 4	19/22	15/22	3/22	0	21/22
Visit 5	21/22	17/22	4/22	0	21/22
Visit 6	20/22	12/22	3/22	0	21/22
Visit 7	19/22	15/22	4/22	1/22	19/22
Visit 8	21/22	14/22	4/22	0	21/22
Visit 9	19/22	9/22	4/22	0	19/22
Follow up visit 10	19/22	9/22	9/22	1/22	22/22
Follow up visit 11	15/22	5/22	2/22	1/22	15/22
Other	1/22	1/22	0	0	1/22
Total	**22/22**	**22/22**	**21/22**	**7/22**	**22/22**

Table S45: Adverse events occurring in at least one patient.

Category	Toxicity	Exposed	Affected	Occurrences	Related	% Patients Affected
Blood and lymphatic system disorders	Leukocytosis	22	2	6	0	9.09
	Anemia	22	17	44	2	77.27
	Other: Borderline prolonged OT interval	22	1	1	0	4.55
	Other: Borderline QTc on ECG	22	1	1	0	4.55
	Other: Hypotension	22	1	1	0	4.55
	Other: low grade hypertension	22	1	4	0	4.55
	Other: sinus rhythm - abnormal ECG	22	1	1	0	4.55
Cardiac disorders	Sinus bradycardia	22	2	2	0	9.09
	Hyperthyroidism	22	1	2	0	4.55
	Hypothyroidism	22	1	1	1	4.55
Endocrine disorders	Other: Type 1 diabetes	22	1	1	0	4.55
Eye disorders	Other: allergic retinitis	22	1	1	0	4.55
	Anal pain	22	1	1	0	4.55
	Constipation	22	1	1	0	4.55
	Gastritis	22	1	1	0	4.55
	Gastrointestinal pain	22	1	1	0	4.55
	Other: 4 columns of varices seen. The columns of varix seem to become bigger at 35cm.Grade 3	22	1	1	0	4.55
	Other: Barrett's Oesophagus	22	1	1	0	4.55
	Other: Increased stool frequency due to pouchitis	22	1	1	0	4.55

Table S45: Adverse events occurring in at least one patient. *(continued)*

Category	Toxicity	Exposed	Affected	Occurrences	Related	% Patients Affected
	Other: intermittent tenesmus	22	1	1	0	4.55
	Other: Loose bloody stools x2	22	1	1	0	4.55
	Other: loss of appetite	22	1	1	0	4.55
	Other: Mouth ulcers	22	1	1	0	4.55
	Other: Oesophageal Candidiasis	22	1	1	0	4.55
	Other: Portal hypertensive gastropathy.	22	1	1	0	4.55
	Other: Spider naevi	22	1	1	0	4.55
	Other: Ulcerative colitis	22	1	1	0	4.55
	Vomiting	22	1	1	0	4.55
	Nausea	22	3	3	1	13.64
	Diarrhea	22	4	4	0	18.18
Gastrointestinal	Abdominal pain	22	5	7	0	22.73
disorders	Colitis	22	5	5	0	22.73
	Irritability	22	1	1	0	4.55
	Localized edema	22	1	1	1	4.55
	Non-cardiac chest pain	22	1	1	0	4.55
	Other: Aching chest, right side of body	22	1	1	0	4.55
	Other: Bilateral rash to arms where cannula dressings were placed	22	1	2	0	4.55
	Other: Cold, cough and tickly throat	22	1	1	0	4.55
	Other: emotional	22	1	1	0	4.55

Table S45: Adverse events occurring in at least one patient. *(continued)*

Category	Toxicity	Exposed	Affected	Occurrences	Related	% Patients Affected
	Other: Hay fever	22	1	1	0	4.55
	Other: Infusion reaction	22	1	1	1	4.55
	Other: intermittent bursitis left shoulder	22	1	1	0	4.55
	Other: Intermittent pharyngeal fascitis	22	1	1	0	4.55
	Other: Left side groin pain during infusion	22	1	1	1	4.55
	Other: night sweats	22	1	1	0	4.55
	Other: pain in left shoulder / back / hip	22	1	1	0	4.55
	Other: Right shoulder pain.	22	1	1	0	4.55
	Other: Sluggish/Aching	22	1	1	1	4.55
	Chills	22	2	2	0	9.09
	Flu like symptoms	22	2	3	0	9.09
General disorders and	Infusion related reaction	22	2	2	2	9.09
administration site	Pain	22	3	4	0	13.64
conditions	Fatigue	22	10	20	8	45.45
	Other: Cholangitis	22	1	1	0	4.55
	Other: Chronic liver failure requiring pre-emptive liver transplantation	22	1	1	0	4.55
	Other: mild hepatomegaly	22	1	1	0	4.55
Hepatobiliary	Other: Right upper quadrant pain	22	1	1	1	4.55
disorders	Other: Hepatomegaly	22	2	2	0	9.09
	Bronchial infection	22	1	3	0	4.55

Table S45: Adverse events occurring in at least one patient. *(continued)*

Category	Toxicity	Exposed	Affected	Occurrences	Related	% Patients Affected
	Gallbladder infection	22	1	1	0	4.55
	Other: viral infection	22	1	1	0	4.55
Infections and	Wound infection	22	1	1	0	4.55
infestations	Upper respiratory infection	22	2	2	0	9.09
Injury, poisoning and procedural complications	Wrist fracture	22	1	1	0	4.55
	Blood corticotrophin decreased	22	1	1	0	4.55
	Other: Aspartate transaminase decreased	22	1	1	1	4.55
	Other: Bilirubin increased	22	1	1	0	4.55
	Other: Calcium decreased	22	1	1	1	4.55
	Other: CRP increased	22	1	1	0	4.55
	Other: estimated Glomerular Filtration Rate decreased	22	1	1	0	4.55
	Other: Ferritin increased	22	1	1	0	4.55
	Other: Haemoglobin decreased	22	1	2	0	4.55
	Other: Hypercholestraemia	22	1	1	0	4.55
	Other: Hypoalbuminemia	22	1	1	0	4.55
	Other: Indirect bilirubin increased	22	1	1	0	4.55
	Other: non significant raised QTC left ventricular hypertrophy	22	1	1	1	4.55
	Other: Phosphates decreased	22	1	1	0	4.55

Table S45: Adverse events occurring in at least one patient. *(continued)*

Category	Toxicity	Exposed	Affected	Occurrences	Related	% Patients Affected
	Other: Platelets increased	22	1	4	0	4.55
	Other: Reduced Ferritin levels	22	1	1	0	4.55
	Other: Sodium decreased	22	1	1	1	4.55
	Other: Mean cell volume increased	22	1	1	0	4.55
	Other: C-reactive protein increased	22	2	2	0	9.09
	Other: Urea increased	22	2	3	0	9.09
	Other: Basophils decreased	22	2	6	1	9.09
	Other: Mean cell haemoglobin increased	22	2	2	1	9.09
	Other: Red blood cells increased	22	2	4	0	9.09
	Other: White Blood Cells increased	22	2	7	5	9.09
	Other: Total Protein decreased	22	2	8	0	9.09
	Other: Neutrophils decreased	22	2	6	0	9.09
	Other: APTT decreased	22	3	4	0	13.64
	Other: Direct bilirubin increased	22	3	5	3	13.64
	Other: Mean cell volume decreased	22	3	4	0	13.64
	Other: Monocytes increased	22	4	10	0	18.18
	Other: Eosinophils decreased	22	4	25	21	18.18
	Other: INR decreased	22	4	5	1	18.18
	Other: Red blood cell count decreased	22	4	12	0	18.18
	Activated partial thromboplastin time prolonged	22	5	9	0	22.73
	Other: Mean cell haemoglobin decreased	22	5	6	1	22.73

Table S45: Adverse events occurring in at least one patient. *(continued)*

Category	Toxicity	Exposed	Affected	Occurrences	Related	% Patients Affected
	Other: Red blood cell distribution width increased	22	5	14	0	22.73
	Other: Eosinophils increased	22	6	26	0	27.27
	Other: White Blood Cells decreased	22	6	25	8	27.27
	Other: Urea decreased	22	7	21	0	31.82
	Platelet count decreased	22	8	18	2	36.36
	Other: Total Protein increased	22	10	19	0	45.45
	Other: Creatinine decreased	22	11	29	2	50.00
	Other: Neutrophils increased	22	12	30	10	54.55
	Other: Monocytes decreased	22	13	43	10	59.09
	Blood bilirubin increased	22	14	59	6	63.64
	Other: Red blood cells decreased	22	14	27	0	63.64
	Lymphocyte count decreased	22	16	92	28	72.73
	Other: Haematocrit decreased	22	17	44	3	77.27
	Alanine aminotransferase increased	22	21	59	1	95.45
	Aspartate aminotransferase increased	22	21	71	1	95.45
	Alkaline phosphatase increased	22	22	49	1	100.00
Investigations	GGT increased	22	22	50	1	100.00
	Hypercalcemia	22	1	4	0	4.55
	Hypernatremia	22	1	1	0	4.55
	Other: Vitamin D Deficiency	22	1	1	0	4.55
	Hyperglycemia	22	2	2	0	9.09

Table S45: Adverse events occurring in at least one patient. *(continued)*

Category	Toxicity	Exposed	Affected	Occurrences	Related	% Patients Affected
	Hypokalemia	22	3	8	0	13.64
	Hyponatremia	22	3	4	0	13.64
Metabolism and	Hypocalcemia	22	4	12	0	18.18
nutrition disorders	Hypoalbuminemia	22	5	37	7	22.73
	Arthralgia	22	1	1	0	4.55
	Chest wall pain	22	1	1	0	4.55
	Neck pain	22	1	2	0	4.55
	Other: Osteoarthritic nodes in fingers on of the right hand	22	1	1	0	4.55
	Other: Osteoathritis	22	1	1	0	4.55
	Other: Polyarthralgia	22	1	1	0	4.55
	Other: swelling of both hands	22	1	1	0	4.55
Musculoskeletal and	Other: Vertebral haemangioma	22	1	1	0	4.55
connective tissue	Other: worsening right knee pain	22	1	1	0	4.55
disorders	Back pain	22	5	8	3	22.73
	Dizziness	22	1	1	0	4.55
	Headache	22	1	1	0	4.55
Nervous system	Other: Diplopia in all directions	22	1	1	0	4.55
disorders	Presyncope	22	2	2	0	9.09
	Depression	22	1	1	0	4.55

Table S45: Adverse events occurring in at least one patient. *(continued)*

Category	Toxicity	Exposed	Affected	Occurrences	Related	% Patients Affected
Psychiatric disorders	Insomnia	22	1	1	0	4.55
Renal and urinary disorders	Urinary incontinence	22	1	1	0	4.55
	Other: Intermittent phlegm sitting in throat	22	1	1	0	4.55
	Other: mild inspiratory wheeze on right middle lobe chest	22	1	1	0	4.55
Respiratory, thoracic and mediastinal disorders	Other: Asthma	22	2	2	0	9.09
	Cough	22	4	6	0	18.18
	Sore throat	22	4	4	1	18.18
	Other: Chronic Venous eczema on both lower limbs	22	1	1	0	4.55
	Other: Creatinine decreased	22	1	1	0	4.55
	Other: Dry mouth	22	1	1	0	4.55
	Other: itchy chest	22	1	1	1	4.55
	Other: Itchy scalp	22	1	1	1	4.55
	Other: Mild foliculitis	22	1	1	0	4.55
	Other: psoriasis on legs and hands	22	1	1	0	4.55
	Other: Rash on forehead	22	1	1	0	4.55
	Other: Redness around umbilicus	22	1	1	0	4.55
	Other: Removal of Viral wart on left ankle	22	1	1	0	4.55

Table S45: Adverse events occurring in at least one patient. *(continued)*

Category	Toxicity	Exposed	Affected	Occurrences	Related	% Patients Affected
	Other: Right side of head above ear, insect bite with swelling and discharge	22	1	1	0	4.55
	Other: Sensitive skin over varicose vein on calves	22	1	1	0	4.55
	Other: Sunburn	22	1	1	0	4.55
	Other: vitiligo eczema	22	1	1	0	4.55
	Rash maculo-papular	22	1	1	0	4.55
Skin and subcutaneous	Other: Psoriasis	22	2	2	0	9.09
tissue disorders	Pruritus	22	10	14	0	45.45
Surgical and medical procedures	Other: Insertion of artificial urinary sphincter	22	1	1	0	4.55
	Hypotension	22	1	1	0	4.55
Vascular disorders	Hypertension	22	8	14	2	36.36

Note:

The following adverse events were categorised as 'other' within their respective categories and appeared multiple times (with slightly different word combinations, spellings and capitalisations). Work has been done to collapse these into a single row. The adverse events related to: monocytes (both an increase and decrease); basophils (both an increase and decrease); eosinophils (both an increase and decrease); INR decrease; mean cell haemoglobin (both an increase and decrease); red blood cells (both an increased and decreased, count decrease, distribution width increased); total protein (both an increase and decrease); neutrophils (both an increase and decrease); psoriasis; white blood cells (both an increase and decrease); haematocrit (both an increase and decrease); and mean cell volume (both an increase and decrease).

Table S46: Incidence of adverse events by CTCAE term and grade in the safety population.

		CTCAE Grade			
Category	**Toxicity**	**1**	**2**	**3**	**4**
	Anemia	42	2	0	0
Blood and lymphatic system disorders	Leukocytosis	6	0	0	0
	Other: Borderline prolonged OT interval	1	0	0	0
	Other: Borderline QTc on ECG	1	0	0	0
	Other: Hypotension	0	0	1	0
	Other: low grade hypertension	4	0	0	0
	Other: sinus rhythm - abnormal ECG	1	0	0	0
Cardiac disorders	Sinus bradycardia	2	0	0	0
	Hyperthyroidism	1	1	0	0
	Hypothyroidism	0	1	0	0
Endocrine disorders	Other: Type 1 diabetes	0	1	0	0
Eye disorders	Other: allergic retinitis	1	0	0	0
	Abdominal pain	7	0	0	0
	Anal pain	1	0	0	0
	Colitis	4	0	1	0
	Constipation	1	0	0	0
	Diarrhea	3	0	1	0
	Gastritis	1	0	0	0
	Gastrointestinal pain	1	0	0	0
	Nausea	3	0	0	0

Table S46: Incidence of adverse events by CTCAE term and grade in the safety population. *(continued)*

Category	Toxicity	1	2	3	4
	Other: 4 columns of varices seen. The columns of varix seem to become bigger at 35cm.Grade 3	0	0	1	0
	Other: Barrett's Oesophagus	0	1	0	0
	Other: Increased stool frequency due to pouchitis	1	0	0	0
	Other: intermittent tenesmus	1	0	0	0
	Other: Loose bloody stools x2	0	1	0	0
	Other: loss of appetite	1	0	0	0
	Other: Mouth ulcers	1	0	0	0
	Other: Oesophageal Candidiasis	0	1	0	0
	Other: Portal hypertensive gastropathy.	0	1	0	0
	Other: Spider naevi	1	0	0	0
	Other: Ulcerative colitis	1	0	0	0
Gastrointestinal disorders	Vomiting	0	1	0	0
	Chills	2	0	0	0
	Fatigue	12	7	1	0
	Flu like symptoms	3	0	0	0
	Infusion related reaction	0	0	2	0
	Irritability	1	0	0	0
	Localized edema	1	0	0	0
	Non-cardiac chest pain	0	1	0	0
	Other: Aching chest, right side of body	0	1	0	0
	Other: Bilateral rash to arms where cannula dressings were placed	2	0	0	0

Table S46: Incidence of adverse events by CTCAE term and grade in the safety population. *(continued)*

Category	Toxicity	1	2	3	4
	Other: Cold, cough and tickly throat	1	0	0	0
	Other: emotional	1	0	0	0
	Other: Hay fever	1	0	0	0
	Other: Infusion reaction	1	0	0	0
	Other: intermittent bursitis left shoulder	1	0	0	0
	Other: Intermittent pharyngeal fascitis	1	0	0	0
	Other: Left side groin pain during infusion	1	0	0	0
	Other: night sweats	1	0	0	0
	Other: pain in left shoulder / back / hip	0	1	0	0
	Other: Right shoulder pain.	0	1	0	0
General disorders and administration site conditions	Other: Sluggish/Aching	0	1	0	0
	Pain	2	1	1	0
	Other: Cholangitis	0	1	0	0
	Other: Chronic liver failure requiring pre-emptive liver transplantation	0	0	1	0
	Other: Hepatomegaly	2	0	0	0
	Other: mild hepatomegaly	1	0	0	0
Hepatobiliary disorders	Other: Right upper quadrant pain	1	0	0	0
	Bronchial infection	1	2	0	0
	Gallbladder infection	0	1	0	0
	Other: viral infection	0	1	0	0
	Upper respiratory infection	0	2	0	0
Infections and infestations	Wound infection	1	0	0	0

Table S46: Incidence of adverse events by CTCAE term and grade in the safety population. *(continued)*

Category	Toxicity	1	2	3	4
Injury, poisoning and procedural complications	Wrist fracture	0	1	0	0
	Activated partial thromboplastin time prolonged	9	0	0	0
	Alanine aminotransferase increased	35	15	8	1
	Alkaline phosphatase increased	20	21	8	0
	Aspartate aminotransferase increased	41	23	5	2
	Blood bilirubin increased	35	22	2	0
	Blood corticotrophin decreased	1	0	0	0
	GGT increased	8	15	19	8
	Lymphocyte count decreased	40	34	18	0
	Other: APTT decreased	4	0	0	0
	Other: Aspartate transaminase decreased	0	1	0	0
	Other: Basophils decreased	6	0	0	0
	Other: Bilirubin increased	0	1	0	0
	Other: C-reactive protein increased	2	0	0	0
	Other: Calcium decreased	1	0	0	0
	Other: Creatinine decreased	29	0	0	0
	Other: CRP increased	1	0	0	0
	Other: Direct bilirubin increased	5	0	0	0
	Other: Eosinophils decreased	24	0	1	0
	Other: Eosinophils increased	26	0	0	0
	Other: estimated Glomerular Filtration Rate decreased	1	0	0	0
	Other: Ferritin increased	1	0	0	0

Table S46: Incidence of adverse events by CTCAE term and grade in the safety population. *(continued)*

Category	Toxicity	1	2	3	4
	Other: Haematocrit decreased	44	0	0	0
	Other: Haemoglobin decreased	2	0	0	0
	Other: Hypercholestraemia	1	0	0	0
	Other: Hypoalbuminemia	1	0	0	0
	Other: Indirect bilirubin increased	1	0	0	0
	Other: INR decreased	5	0	0	0
	Other: Mean cell haemoglobin decreased	6	0	0	0
	Other: Mean cell haemoglobin increased	2	0	0	0
	Other: Mean cell volume decreased	4	0	0	0
	Other: Mean cell volume increased	1	0	0	0
	Other: Monocytes decreased	38	5	0	0
	Other: Monocytes increased	10	0	0	0
	Other: Neutrophils decreased	5	1	0	0
	Other: Neutrophils increased	30	0	0	0
	Other: non significant raised QTC left ventricular hypertrophy	1	0	0	0
	Other: Phosphates decreased	1	0	0	0
	Other: Platelets increased	4	0	0	0
	Other: Red blood cell count decreased	12	0	0	0
	Other: Red blood cell distribution width increased	14	0	0	0
	Other: Red blood cells decreased	27	0	0	0
	Other: Red blood cells increased	4	0	0	0
	Other: Reduced Ferritin levels	1	0	0	0

Table S46: Incidence of adverse events by CTCAE term and grade in the safety population. *(continued)*

Category	Toxicity	1	2	3	4
	Other: Sodium decreased	1	0	0	0
	Other: Total Protein decreased	8	0	0	0
	Other: Total Protein increased	19	0	0	0
	Other: Urea decreased	21	0	0	0
	Other: Urea increased	3	0	0	0
	Other: White Blood Cells decreased	17	8	0	0
	Other: White Blood Cells increased	7	0	0	0
Investigations	Platelet count decreased	14	4	0	0
	Hypercalcemia	4	0	0	0
	Hyperglycemia	2	0	0	0
	Hypernatremia	1	0	0	0
	Hypoalbuminemia	26	11	0	0
	Hypocalcemia	9	3	0	0
	Hypokalemia	8	0	0	0
	Hyponatremia	4	0	0	0
Metabolism and nutrition disorders	Other: Vitamin D Deficiency	1	0	0	0
	Arthralgia	1	0	0	0
	Back pain	4	4	0	0
	Chest wall pain	0	1	0	0
	Neck pain	0	2	0	0
	Other: Osteoarthritic nodes in fingers on of the right hand	1	0	0	0
	Other: Osteoathritis	0	1	0	0

Table S46: Incidence of adverse events by CTCAE term and grade in the safety population. *(continued)*

Category	Toxicity	1	2	3	4
	Other: Polyarthralgia	1	0	0	0
	Other: swelling of both hands	1	0	0	0
Musculoskeletal and connective tissue	Other: Vertebral haemangioma	1	0	0	0
disorders	Other: worsening right knee pain	0	1	0	0
	Dizziness	1	0	0	0
	Headache	0	1	0	0
	Other: Diplopia in all directions	1	0	0	0
Nervous system disorders	Presyncope	1	1	0	0
	Depression	1	0	0	0
Psychiatric disorders	Insomnia	1	0	0	0
Renal and urinary disorders	Urinary incontinence	0	1	0	0
	Cough	4	1	1	0
	Other: Asthma	2	0	0	0
	Other: Intermittent phlegm sitting in throat	1	0	0	0
	Other: mild inspiratory wheeze on right middle lobe	1	0	0	0
Respiratory, thoracic and mediastinal	chest				
disorders	Sore throat	3	1	0	0
	Other: Chronic Venous eczema on both lower limbs	1	0	0	0
	Other: Creatinine decreased	1	0	0	0
	Other: Dry mouth	1	0	0	0
	Other: itchy chest	1	0	0	0
	Other: Itchy scalp	1	0	0	0

Table S46: Incidence of adverse events by CTCAE term and grade in the safety population. *(continued)*

Category	Toxicity	1	2	3	4
	Other: Mild foliculitis	1	0	0	0
	Other: Psoriasis	2	0	0	0
	Other: psoriasis on legs and hands	1	0	0	0
	Other: Rash on forehead	1	0	0	0
	Other: Redness around umbilicus	1	0	0	0
	Other: Removal of Viral wart on left ankle	1	0	0	0
	Other: Right side of head above ear, insect bite with swelling and discharge	0	1	0	0
	Other: Sensitive skin over varicose vein on calves	0	1	0	0
	Other: Sunburn	1	0	0	0
	Other: vitiligo eczema	1	0	0	0
	Pruritus	7	6	1	0
Skin and subcutaneous tissue disorders	Rash maculo-papular	1	0	0	0
Surgical and medical procedures	Other: Insertion of artificial urinary sphincter	1	0	0	0
	Hypertension	8	4	2	0
Vascular disorders	Hypotension	1	0	0	0

Note:

The following adverse events were categorised as 'other' within their respective categories and appeared multiple times (with slightly different word combinations, spellings and capitalisations). Work has been done to collapse these into a single row. The adverse events related to: monocytes (both an increase and decrease); basophils (both an increase and decrease); eosinophils (both an increase and decrease); INR decrease; mean cell haemoglobin (both an increase and decrease); red blood cells (both an increased and decreased, count decrease, distribution width increased); total protein (both an increase and decrease); neutrophils (both an increase and decrease); psoriasis; white blood cells (both an increase and decrease); haematocrit (both an increase and decrease); and mean cell volume (both an increase and decrease).

Table S47: Patient-level incidence of adverse events by CTCAE term and grade in the safety population.

		CTCAE Grade			
Category	**Toxicity**	**1**	**2**	**3**	**4**
	Anemia	17/22	2/22	0/22	0/22
Blood and lymphatic system disorders	Leukocytosis	2/22	0/22	0/22	0/22
	Other: Borderline prolonged OT interval	1/22	0/22	0/22	0/22
	Other: Borderline QTc on ECG	1/22	0/22	0/22	0/22
	Other: Hypotension	0/22	0/22	1/22	0/22
	Other: low grade hypertension	1/22	0/22	0/22	0/22
	Other: sinus rhythm - abnormal ECG	1/22	0/22	0/22	0/22
Cardiac disorders	Sinus bradycardia	2/22	0/22	0/22	0/22
	Hyperthyroidism	1/22	1/22	0/22	0/22
	Hypothyroidism	0/22	1/22	0/22	0/22
Endocrine disorders	Other: Type 1 diabetes	0/22	1/22	0/22	0/22
Eye disorders	Other: allergic retinitis	1/22	0/22	0/22	0/22
	Abdominal pain	5/22	0/22	0/22	0/22
	Anal pain	1/22	0/22	0/22	0/22
	Colitis	4/22	0/22	1/22	0/22
	Constipation	1/22	0/22	0/22	0/22
	Diarrhea	3/22	0/22	1/22	0/22
	Gastritis	1/22	0/22	0/22	0/22
	Gastrointestinal pain	1/22	0/22	0/22	0/22
	Nausea	3/22	0/22	0/22	0/22

Table S47: Patient-level incidence of adverse events by CTCAE term and grade in the safety population. *(continued)*

Category	Toxicity	1	2	3	4
	Other: 4 columns of varices seen. The columns of varix seem to become bigger at 35cm.Grade 3	0/22	0/22	1/22	0/22
	Other: Barrett's Oesophagus	0/22	1/22	0/22	0/22
	Other: Increased stool frequency due to pouchitis	1/22	0/22	0/22	0/22
	Other: intermittent tenesmus	1/22	0/22	0/22	0/22
	Other: Loose bloody stools x2	0/22	1/22	0/22	0/22
	Other: loss of appetite	1/22	0/22	0/22	0/22
	Other: Mouth ulcers	1/22	0/22	0/22	0/22
	Other: Oesophageal Candidiasis	0/22	1/22	0/22	0/22
	Other: Portal hypertensive gastropathy.	0/22	1/22	0/22	0/22
	Other: Spider naevi	1/22	0/22	0/22	0/22
	Other: Ulcerative colitis	1/22	0/22	0/22	0/22
Gastrointestinal disorders	Vomiting	0/22	1/22	0/22	0/22
	Chills	2/22	0/22	0/22	0/22
	Fatigue	7/22	5/22	1/22	0/22
	Flu like symptoms	2/22	0/22	0/22	0/22
	Infusion related reaction	0/22	0/22	2/22	0/22
	Irritability	1/22	0/22	0/22	0/22
	Localized edema	1/22	0/22	0/22	0/22
	Non-cardiac chest pain	0/22	1/22	0/22	0/22
	Other: Aching chest, right side of body	0/22	1/22	0/22	0/22
	Other: Bilateral rash to arms where cannula dressings were placed	1/22	0/22	0/22	0/22

Table S47: Patient-level incidence of adverse events by CTCAE term and grade in the safety population. *(continued)*

Category	Toxicity	1	2	3	4
	Other: Cold, cough and tickly throat	1/22	0/22	0/22	0/22
	Other: emotional	1/22	0/22	0/22	0/22
	Other: Hay fever	1/22	0/22	0/22	0/22
	Other: Infusion reaction	1/22	0/22	0/22	0/22
	Other: intermittent bursitis left shoulder	1/22	0/22	0/22	0/22
	Other: Intermittent pharyngeal fascitis	1/22	0/22	0/22	0/22
	Other: Left side groin pain during infusion	1/22	0/22	0/22	0/22
	Other: night sweats	1/22	0/22	0/22	0/22
	Other: pain in left shoulder / back / hip	0/22	1/22	0/22	0/22
	Other: Right shoulder pain.	0/22	1/22	0/22	0/22
General disorders and administration site conditions	Other: Sluggish/Aching	0/22	1/22	0/22	0/22
	Pain	2/22	1/22	1/22	0/22
	Other: Cholangitis	0/22	1/22	0/22	0/22
	Other: Chronic liver failure requiring pre-emptive liver transplantation	0/22	0/22	1/22	0/22
	Other: Hepatomegaly	2/22	0/22	0/22	0/22
	Other: mild hepatomegaly	1/22	0/22	0/22	0/22
Hepatobiliary disorders	Other: Right upper quadrant pain	1/22	0/22	0/22	0/22
	Bronchial infection	1/22	1/22	0/22	0/22
	Gallbladder infection	0/22	1/22	0/22	0/22
	Other: viral infection	0/22	1/22	0/22	0/22
	Upper respiratory infection	0/22	2/22	0/22	0/22
Infections and infestations	Wound infection	1/22	0/22	0/22	0/22

Table S47: Patient-level incidence of adverse events by CTCAE term and grade in the safety population. *(continued)*

Category	Toxicity	1	2	3	4
Injury, poisoning and procedural complications	Wrist fracture	0/22	1/22	0/22	0/22
	Activated partial thromboplastin time prolonged	5/22	0/22	0/22	0/22
	Alanine aminotransferase increased	19/22	8/22	3/22	1/22
	Alkaline phosphatase increased	13/22	12/22	6/22	0/22
	Aspartate aminotransferase increased	20/22	9/22	2/22	1/22
	Blood bilirubin increased	13/22	8/22	1/22	0/22
	Blood corticotrophin decreased	1/22	0/22	0/22	0/22
	GGT increased	5/22	8/22	14/22	7/22
	Lymphocyte count decreased	13/22	10/22	3/22	0/22
	Other: APTT decreased	3/22	0/22	0/22	0/22
	Other: Aspartate transaminase decreased	0/22	1/22	0/22	0/22
	Other: Basophils decreased	2/22	0/22	0/22	0/22
	Other: Bilirubin increased	0/22	1/22	0/22	0/22
	Other: C-reactive protein increased	2/22	0/22	0/22	0/22
	Other: Calcium decreased	1/22	0/22	0/22	0/22
	Other: Creatinine decreased	11/22	0/22	0/22	0/22
	Other: CRP increased	1/22	0/22	0/22	0/22
	Other: Direct bilirubin increased	3/22	0/22	0/22	0/22
	Other: Eosinophils decreased	4/22	0/22	1/22	0/22
	Other: Eosinophils increased	6/22	0/22	0/22	0/22
	Other: estimated Glomerular Filtration Rate decreased	1/22	0/22	0/22	0/22
	Other: Ferritin increased	1/22	0/22	0/22	0/22

Table S47: Patient-level incidence of adverse events by CTCAE term and grade in the safety population. *(continued)*

Category	Toxicity	1	2	3	4
	Other: Haematocrit decreased	17/22	0/22	0/22	0/22
	Other: Haemoglobin decreased	1/22	0/22	0/22	0/22
	Other: Hypercholestraemia	1/22	0/22	0/22	0/22
	Other: Hypoalbuminemia	1/22	0/22	0/22	0/22
	Other: Indirect bilirubin increased	1/22	0/22	0/22	0/22
	Other: INR decreased	4/22	0/22	0/22	0/22
	Other: Mean cell haemoglobin decreased	5/22	0/22	0/22	0/22
	Other: Mean cell haemoglobin increased	2/22	0/22	0/22	0/22
	Other: Mean cell volume decreased	3/22	0/22	0/22	0/22
	Other: Mean cell volume increased	1/22	0/22	0/22	0/22
	Other: Monocytes decreased	13/22	1/22	0/22	0/22
	Other: Monocytes increased	4/22	0/22	0/22	0/22
	Other: Neutrophils decreased	2/22	1/22	0/22	0/22
	Other: Neutrophils increased	12/22	0/22	0/22	0/22
	Other: non significant raised QTC left ventricular hypertrophy	1/22	0/22	0/22	0/22
	Other: Phosphates decreased	1/22	0/22	0/22	0/22
	Other: Platelets increased	1/22	0/22	0/22	0/22
	Other: Red blood cell count decreased	4/22	0/22	0/22	0/22
	Other: Red blood cell distribution width increased	5/22	0/22	0/22	0/22
	Other: Red blood cells decreased	14/22	0/22	0/22	0/22
	Other: Red blood cells increased	2/22	0/22	0/22	0/22
	Other: Reduced Ferritin levels	1/22	0/22	0/22	0/22

Table S47: Patient-level incidence of adverse events by CTCAE term and grade in the safety population. *(continued)*

Category	Toxicity	1	2	3	4
	Other: Sodium decreased	1/22	0/22	0/22	0/22
	Other: Total Protein decreased	2/22	0/22	0/22	0/22
	Other: Total Protein increased	10/22	0/22	0/22	0/22
	Other: Urea decreased	7/22	0/22	0/22	0/22
	Other: Urea increased	2/22	0/22	0/22	0/22
	Other: White Blood Cells decreased	6/22	2/22	0/22	0/22
	Other: White Blood Cells increased	2/22	0/22	0/22	0/22
Investigations	Platelet count decreased	8/22	2/22	0/22	0/22
	Hypercalcemia	1/22	0/22	0/22	0/22
	Hyperglycemia	2/22	0/22	0/22	0/22
	Hypernatremia	1/22	0/22	0/22	0/22
	Hypoalbuminemia	5/22	2/22	0/22	0/22
	Hypocalcemia	4/22	2/22	0/22	0/22
	Hypokalemia	3/22	0/22	0/22	0/22
	Hyponatremia	3/22	0/22	0/22	0/22
Metabolism and nutrition disorders	Other: Vitamin D Deficiency	1/22	0/22	0/22	0/22
	Arthralgia	1/22	0/22	0/22	0/22
	Back pain	2/22	3/22	0/22	0/22
	Chest wall pain	0/22	1/22	0/22	0/22
	Neck pain	0/22	1/22	0/22	0/22
	Other: Osteoarthritic nodes in fingers on of the right hand	1/22	0/22	0/22	0/22
	Other: Osteoathritis	0/22	1/22	0/22	0/22

Table S47: Patient-level incidence of adverse events by CTCAE term and grade in the safety population. *(continued)*

Category	Toxicity	1	2	3	4
	Other: Polyarthralgia	1/22	0/22	0/22	0/22
	Other: swelling of both hands	1/22	0/22	0/22	0/22
Musculoskeletal and connective tissue	Other: Vertebral haemangioma	1/22	0/22	0/22	0/22
disorders	Other: worsening right knee pain	0/22	1/22	0/22	0/22
	Dizziness	1/22	0/22	0/22	0/22
	Headache	0/22	1/22	0/22	0/22
	Other: Diplopia in all directions	1/22	0/22	0/22	0/22
Nervous system disorders	Presyncope	1/22	1/22	0/22	0/22
	Depression	1/22	0/22	0/22	0/22
Psychiatric disorders	Insomnia	1/22	0/22	0/22	0/22
Renal and urinary disorders	Urinary incontinence	0/22	1/22	0/22	0/22
	Cough	3/22	1/22	1/22	0/22
	Other: Asthma	2/22	0/22	0/22	0/22
	Other: Intermittent phlegm sitting in throat	1/22	0/22	0/22	0/22
	Other: mild inspiratory wheeze on right middle lobe	1/22	0/22	0/22	0/22
Respiratory, thoracic and mediastinal	chest				
disorders	Sore throat	3/22	1/22	0/22	0/22
	Other: Chronic Venous eczema on both lower limbs	1/22	0/22	0/22	0/22
	Other: Creatinine decreased	1/22	0/22	0/22	0/22
	Other: Dry mouth	1/22	0/22	0/22	0/22
	Other: itchy chest	1/22	0/22	0/22	0/22
	Other: Itchy scalp	1/22	0/22	0/22	0/22

Table S47: Patient-level incidence of adverse events by CTCAE term and grade in the safety population. *(continued)*

Category	Toxicity	1	2	3	4
	Other: Mild foliculitis	1/22	0/22	0/22	0/22
	Other: Psoriasis	2/22	0/22	0/22	0/22
	Other: psoriasis on legs and hands	1/22	0/22	0/22	0/22
	Other: Rash on forehead	1/22	0/22	0/22	0/22
	Other: Redness around umbilicus	1/22	0/22	0/22	0/22
	Other: Removal of Viral wart on left ankle	1/22	0/22	0/22	0/22
	Other: Right side of head above ear, insect bite with swelling and discharge	0/22	1/22	0/22	0/22
	Other: Sensitive skin over varicose vein on calves	0/22	1/22	0/22	0/22
	Other: Sunburn	1/22	0/22	0/22	0/22
	Other: vitiligo eczema	1/22	0/22	0/22	0/22
	Pruritus	7/22	4/22	1/22	0/22
Skin and subcutaneous tissue disorders	Rash maculo-papular	1/22	0/22	0/22	0/22
Surgical and medical procedures	Other: Insertion of artificial urinary sphincter	1/22	0/22	0/22	0/22
	Hypertension	7/22	1/22	2/22	0/22
Vascular disorders	Hypotension	1/22	0/22	0/22	0/22

Note:

The following adverse events were categorised as 'other' within their respective categories and appeared multiple times (with slightly different word combinations, spellings and capitalisations). Work has been done to collapse these into a single row. The adverse events related to: monocytes (both an increase and decrease); basophils (both an increase and decrease); eosinophils (both an increase and decrease); INR decrease; mean cell haemoglobin (both an increase and decrease); red blood cells (both an increased and decreased, count decrease, distribution width increased); total protein (both an increase and decrease); neutrophils (both an increase and decrease); psoriasis; white blood cells (both an increase and decrease); haematocrit (both an increase and decrease); and mean cell volume (both an increase and decrease).

Table S48: Number of adverse events by relatedness to BTT1023 and treatment visit.

Visit	1-Unrelated	2-Unlikely to be related	3-Possibly related	4-Probably related	5-Definitely related	Total
Pre-screening	42 (3.70%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	42 (3.70%)
Screening visit 1	175 (15.43%)	5 (0.44%)	1 (0.09%)	0 (0.00%)	0 (0.00%)	181 (15.96%)
Screening visit 2	43 (3.79%)	3 (0.26%)	2 (0.18%)	0 (0.00%)	0 (0.00%)	48 (4.23%)
Visit 3	93 (8.20%)	17 (1.50%)	9 (0.79%)	3 (0.26%)	7 (0.62%)	129 (11.38%)
Visit 4	83 (7.32%)	10 (0.88%)	7 (0.62%)	3 (0.26%)	1 (0.09%)	104 (9.17%)
Visit 5	97 (8.55%)	17 (1.50%)	15 (1.32%)	3 (0.26%)	0 (0.00%)	132 (11.64%)
Visit 6	55 (4.85%)	8 (0.71%)	12 (1.06%)	4 (0.35%)	1 (0.09%)	80 (7.05%)
Visit 7	70 (6.17%)	14 (1.23%)	11 (0.97%)	4 (0.35%)	1 (0.09%)	100 (8.82%)
Visit 8	61 (5.38%)	17 (1.50%)	18 (1.59%)	4 (0.35%)	2 (0.18%)	102 (8.99%)
Visit 9	58 (5.11%)	14 (1.23%)	16 (1.41%)	3 (0.26%)	0 (0.00%)	91 (8.02%)
Follow up visit 10	43 (3.79%)	19 (1.68%)	13 (1.15%)	0 (0.00%)	0 (0.00%)	75 (6.61%)
Follow up visit 11	36 (3.17%)	2 (0.18%)	4 (0.35%)	0 (0.00%)	0 (0.00%)	42 (3.70%)
Other	8 (0.71%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	8 (0.71%)
Total	**864 (76.19%)**	**126 (11.11%)**	**108 (9.52%)**	**24 (2.12%)**	**12 (1.06%)**	**1134 (100.00%)**

Table S49: Adverse events graded 3, 4, or 5 and deemed at least possibly related.

Patient	Visit	Toxicity	AE Grade	Relatedness
2	Visit 3	Infusion related reaction	3	5-Definitely related
5	Visit 3	Infusion related reaction	3	5-Definitely related
17	Follow up visit 10	Aspartate aminotransferase increased	4	3-Possibly related
17	Follow up visit 10	Alanine aminotransferase increased	3	3-Possibly related
17	Follow up visit 10	GGT increased	3	3-Possibly related
17	Follow up visit 10	Blood bilirubin increased	3	3-Possibly related
17	Follow up visit 10	Alkaline phosphatase increased	3	3-Possibly related
22	Visit 3	Lymphocyte count decreased	3	3-Possibly related
22	Visit 4	Lymphocyte count decreased	3	3-Possibly related
22	Visit 5	Lymphocyte count decreased	3	3-Possibly related
22	Visit 6	Lymphocyte count decreased	3	3-Possibly related
22	Visit 7	Other: Eosinophil count decreased	3	3-Possibly related
22	Visit 7	Lymphocyte count decreased	3	3-Possibly related
22	Visit 8	Lymphocyte count decreased	3	3-Possibly related
22	Visit 9	Lymphocyte count decreased	3	3-Possibly related

Table S50: Number of adverse events (all grades) per visit and CTC category.

CTC Category	Pre-screening	Screening visit 1	Screening visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Follow up visit 10	Follow up visit 11	Other	Total
Blood and lymphatic system disorders	0 (0.00%)	11 (0.97%)	3 (0.26%)	12 (1.06%)	6 (0.53%)	7 (0.62%)	4 (0.35%)	3 (0.26%)	7 (0.62%)	5 (0.44%)	3 (0.26%)	1 (0.09%)	0 (0.00%)	**62 (5.47%)**
Cardiac disorders	0 (0.00%)	1 (0.09%)	0 (0.00%)	3 (0.26%)	1 (0.09%)	2 (0.18%)	1 (0.09%)	1 (0.09%)	1 (0.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	**10 (0.88%)**
Endocrine disorders	3 (0.26%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (0.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	**4 (0.35%)**
Eye disorders	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (0.09%)	0 (0.00%)	0 (0.00%)	**1 (0.09%)**
Gastrointestinal disorders	5 (0.44%)	0 (0.00%)	1 (0.09%)	3 (0.26%)	5 (0.44%)	5 (0.44%)	1 (0.09%)	1 (0.09%)	1 (0.09%)	2 (0.18%)	8 (0.71%)	1 (0.09%)	2 (0.18%)	**35 (3.09%)**
General disorders and administration site conditions	5 (0.44%)	1 (0.09%)	1 (0.09%)	9 (0.79%)	3 (0.26%)	8 (0.71%)	2 (0.18%)	5 (0.44%)	4 (0.35%)	4 (0.35%)	3 (0.26%)	2 (0.18%)	1 (0.09%)	**48 (4.23%)**
Hepatobiliary disorders	0 (0.00%)	2 (0.18%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (0.09%)	1 (0.09%)	0 (0.00%)	0 (0.00%)	2 (0.18%)	0 (0.00%)	0 (0.00%)	**6 (0.53%)**
Infections and infestations	0 (0.00%)	2 (0.18%)	0 (0.00%)	1 (0.09%)	0 (0.00%)	1 (0.09%)	1 (0.09%)	1 (0.09%)	1 (0.09%)	0 (0.00%)	1 (0.09%)	0 (0.00%)	0 (0.00%)	**8 (0.71%)**
Injury, poisoning and procedural complications	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (0.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	**1 (0.09%)**
Investigations	11 (0.97%)	151 (13.32%)	40 (3.53%)	80 (7.05%)	75 (6.61%)	86 (7.58%)	64 (5.64%)	73 (6.44%)	74 (6.53%)	67 (5.91%)	48 (4.23%)	33 (2.91%)	0 (0.00%)	**802 (70.72%)**
Metabolism and nutrition disorders	1 (0.09%)	4 (0.35%)	1 (0.09%)	10 (0.88%)	8 (0.71%)	10 (0.88%)	3 (0.26%)	7 (0.62%)	10 (0.88%)	8 (0.71%)	5 (0.44%)	3 (0.26%)	0 (0.00%)	**70 (6.17%)**
Musculoskeletal and connective tissue disorders	3 (0.26%)	0 (0.00%)	0 (0.00%)	2 (0.18%)	2 (0.18%)	4 (0.35%)	2 (0.18%)	2 (0.18%)	2 (0.18%)	1 (0.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	**18 (1.59%)**
Nervous system disorders	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (0.18%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (0.09%)	0 (0.00%)	0 (0.00%)	1 (0.09%)	0 (0.00%)	1 (0.09%)	**5 (0.44%)**
Psychiatric disorders	1 (0.09%)	1 (0.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	**2 (0.18%)**
Renal and urinary disorders	1 (0.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	**1 (0.09%)**
Respiratory, thoracic and mediastinal disorders	3 (0.26%)	1 (0.09%)	0 (0.00%)	2 (0.18%)	0 (0.00%)	2 (0.18%)	0 (0.00%)	2 (0.18%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	4 (0.35%)	**14 (1.23%)**
Skin and subcutaneous tissue disorders	7 (0.62%)	4 (0.35%)	1 (0.09%)	3 (0.26%)	3 (0.26%)	5 (0.44%)	1 (0.09%)	2 (0.18%)	1 (0.09%)	2 (0.18%)	1 (0.09%)	1 (0.09%)	0 (0.00%)	**31 (2.73%)**
Surgical and medical procedures	1 (0.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	**1 (0.09%)**
Vascular disorders	1 (0.09%)	3 (0.26%)	1 (0.09%)	2 (0.18%)	1 (0.09%)	1 (0.09%)	0 (0.00%)	1 (0.09%)	1 (0.09%)	1 (0.09%)	2 (0.18%)	1 (0.09%)	0 (0.00%)	**15 (1.32%)**
Total	**42 (3.70%)**	**181 (15.96%)**	**48 (4.23%)**	**129 (11.38%)**	**104 (9.17%)**	**132 (11.64%)**	**80 (7.05%)**	**100 (8.82%)**	**102 (8.99%)**	**91 (8.02%)**	**75 (6.61%)**	**42 (3.70%)**	**8 (0.71%)**	**1134 (100.00%)**

Table S51: Duration (days) of adverse events by CTCAE grade.

	CTCAE Grade				
	1	**2**	**3**	**4**	**Overall**
N	828	221	74	11	1134
Mean	22.44	21.47	20.38	90	22.36
Median	14	14	14	74	14
Range	(0,2411)	(0,152)	(0,98)	(35,161)	(0,2411)
IQR	(3,21)	(5,28)	(10,21)	(54.5,117.5)	(4.5,21.5)
Missing					271

Table S52: Number of ongoing adverse events by visit.

Ongoing	Pre-screening	Screening visit 1	Screening visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Follow up visit 10	Follow up visit 11	Other	Total
No	10 (0.88%)	107 (9.44%)	39 (3.44%)	121 (10.67%)	97 (8.55%)	120 (10.58%)	72 (6.35%)	92 (8.11%)	94 (8.29%)	73 (6.44%)	23 (2.03%)	2 (0.18%)	8 (0.71%)	858 (75.66%)
Yes	32 (2.82%)	74 (6.53%)	9 (0.79%)	7 (0.62%)	6 (0.53%)	11 (0.97%)	7 (0.62%)	8 (0.71%)	7 (0.62%)	18 (1.59%)	52 (4.59%)	40 (3.53%)	0 (0.00%)	271 (23.90%)
	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (0.09%)	1 (0.09%)	1 (0.09%)	1 (0.09%)	0 (0.00%)	1 (0.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	5 (0.44%)
Total	**42 (3.70%)**	**181 (15.96%)**	**48 (4.23%)**	**129 (11.38%)**	**104 (9.17%)**	**132 (11.64%)**	**80 (7.05%)**	**100 (8.82%)**	**102 (8.99%)**	**91 (8.02%)**	**75 (6.61%)**	**42 (3.70%)**	**8 (0.71%)**	**1134 (100.00%)**

Table S53: Adverse event outcome by visit.

Resolution	Pre-screening	Screening visit 1	Screening visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Follow up visit 10	Follow up visit 11	Other	Total
Resolved – no sequelae	10 (0.88%)	110 (9.70%)	39 (3.44%)	122 (10.76%)	98 (8.64%)	122 (10.76%)	73 (6.44%)	92 (8.11%)	95 (8.38%)	72 (6.35%)	25 (2.20%)	4 (0.35%)	8 (0.71%)	870 (76.72%)
Resolved with sequelae	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (0.09%)	0 (0.00%)	0 (0.00%)	1 (0.09%)
Unresolved	32 (2.82%)	71 (6.26%)	9 (0.79%)	7 (0.62%)	6 (0.53%)	10 (0.88%)	7 (0.62%)	8 (0.71%)	7 (0.62%)	19 (1.68%)	49 (4.32%)	38 (3.35%)	0 (0.00%)	263 (23.19%)
Total	**42 (3.70%)**	**181 (15.96%)**	**48 (4.23%)**	**129 (11.38%)**	**104 (9.17%)**	**132 (11.64%)**	**80 (7.05%)**	**100 (8.82%)**	**102 (8.99%)**	**91 (8.02%)**	**75 (6.61%)**	**42 (3.70%)**	**8 (0.71%)**	**1134 (100.00%)**

D.9.3 Serious Adverse Events

Table S54: Summary of serious adverse events.

Category	Toxicity	Number of Patients Exposed	Number of Patients Affected	Occurrences	Fatal	Number of Events Related to BTT1023	Related & Fatal
Gastrointestinal disorders	Colitis	22	1	1	0	0	0
	Diarrhea	22	1	1	0	0	0

Table S54: Summary of serious adverse events. *(continued)*

Category	Toxicity	Number of Patients Exposed	Number of Patients Affected	Occurrences	Fatal	Number of Events Related to BTT1023	Related & Fatal
General disorders and administration site conditions	Infusion related reaction	22	1	1	0	1	0
Investigations	Blood bilirubin increased	22	1	1	0	1	0

D.9.4 Secondary Outcomes

D.9.5 Tolerability and Treatment Compliance

Table S55: Proportion of patients recruited to each phase of the trial.

Trial Phase Recruited To	
Dose Confirmatory Phase	7 (31.82%)
Phase II expansion	15 (68.18%)
Total	**22 (100.00%)**

Table S56: Proportion of patients who complied with visits per protocol.

Attended All Trial Visits	
FALSE	3 (13.64%)
TRUE	19 (86.36%)
Total	**22 (100%)**

Table S57: Summary of number of visits attended.

Number of Trial Visits Attended	
N	22
Mean	10.64
Median	11
Range	(5,11)
IQR	(11,11)

Table S58: Length of time on treatment by patient.

Patient	Treatment Start Date	Date of Last Treatment	Length of Treatment (days)
1	09-Sep-2015	26-Nov-2015	77
2	09-Dec-2015	09-Dec-2015	1
3	13-Jan-2016	30-Mar-2016	78
4	18-Jan-2016	03-Apr-2016	77
5	11-Feb-2016	27-Apr-2016	77
6	22-May-2016	10-Aug-2016	80
7	14-Jun-2016	30-Aug-2016	77
8	07-Mar-2017	22-May-2017	77
9	08-Mar-2017	23-May-2017	77
11	09-May-2017	12-Jul-2017	64
12	15-May-2017	31-Jul-2017	77
13	11-May-2017	26-Jul-2017	76
14	05-Jun-2017	21-Aug-2017	77
15	20-Aug-2017	09-Nov-2017	80
16	07-Sep-2017	23-Nov-2017	76
17	27-Sep-2017	14-Dec-2017	77
18	11-Dec-2017	26-Feb-2018	77
19	05-Jan-2018	22-Mar-2018	76
20	26-Feb-2018	13-May-2018	77
21	08-Mar-2018	23-May-2018	77
22	23-May-2018	08-Aug-2018	77
23	25-Jun-2018	10-Sep-2018	77

Table S59: Summary of length of time from first until final trial visit.

Length of Treatment (days)	
N	22
Mean	73.14
Median	77
Range	(1,80)
IQR	(77,77)

Table S60: Proportion of patients allocated each dose of BTT1023.

Dose Allocated	
8 mg/kg	22 (100.00%)
Total	**22 (100.00%)**

Table S61: Target and received dose of BTT1023 by treatment patient and treatment visit.

	Visit 3			Visit 4			Visit 5			Visit 6			Visit 7			Visit 8			Visit 9		
Patient	Weight (kg)	Target Dose (mg)	Dose Received (mg)	Weight (kg)	Target Dose (mg)	Dose Received (mg)	Weight (kg)	Target Dose (mg)	Dose Received (mg)	Weight (kg)	Target Dose (mg)	Dose Received (mg)	Weight (kg)	Target Dose (mg)	Dose Received (mg)	Weight (kg)	Target Dose (mg)	Dose Received (mg)	Weight (kg)	Target Dose (mg)	Dose Received (mg)
1	88.4	707.2	740	89.2	713.6	704	87.1	696.8	704	87.2	697.6	704	87.2	697.6	704	88	704	704	87.7	701.6	704
2	71.2	569.6	584																		
3	59.2	473.6	480	59.8	478.4	480	60.4	483.2	480	60.1	480.8	480	60.7	485.6	480	60.6	484.8	480	60.9	487.2	480
4	76.7	613.6	600	75.5	604	600	78.4	627.2	600	75.5	604	600	77.4	619.2	600	77.7	621.6	600	78.7	629.6	600
5	87.7	701.6	712	89.1	712.8	712	87.5	700	712	89.3	714.4	712	88.5	708	712	86.7	693.6	712	87.2	697.6	712
6	87.0	696.0	696	87	696	696	88.2	705.6	696	87.3	698.4	696	85.7	685.6	696	84.6	676.8	696	83.7	669.6	696
7	71.0	568.0	568	71.9	575.2	568	73	584	568	70.3	562.4	568	71.8	574.4	568	72	576	568	72.8	582.4	568
8	69.4	555.2	568	69.8	558.4	568	71	568	568	71.1	568.8	568	71.1	568.8	568	70.7	565.6	568	70.7	565.6	568
9	91.0	728.0	744	91.8	734.4	744	92.3	738.4	744	92.3	738.4	744	91.1	728.8	744	91.4	731.2	744	93.5	748	744
11	72.2	577.6	608	77.1	616.8	608	77.8	622.4	608	76.3	610.4	608	75.4	603.2	608						
12	66.0	528.0	552	67.2	537.6	552	67.8	542.4	552	67.4	539.2	552	66.4	531.2	552	67.2	537.6	552	66.4	531.2	552
13	50.0	400.0	400	50	400	400	49	392	400	50	400	400	49.5	396	400	48.5	388	400	49	392	400
14	80.8	646.4	648	81.4	651.2	648	81.7	653.6	648	81.8	654.4	648	81.5	652	648	82.6	660.8	648	81.6	652.8	648
15	82.6	660.8	664	82.3	658.4	666	80.8	646.4	664	81.5	652	664				82.1	656.8	664	81.7	653.6	664
16	85.5	684.0	688	86	688	688	86	688	688	87	696	688	88	704	688	87	696	688	86	688	688
17	71.3	570.4	568	71.2	569.6	568	71.6	572.8	568	70.3	562.4	568	70.4	563.2	568	69.4	555.2	568	70.8	566.4	568
18	71.5	572.0	576	71.5	572	576	73	584	576	71.5	572	584	70	560	576	71	568	560	71.5	572	568
19	91.0	728.0	736	92	736	728	94	752	736	94	752	752	95	760	752	94	752	760	96	768	752
20	94.7	757.6	760	92.6	740.8	760	92.5	740	760	93.3	746.4	760	94	752	760	92.8	742.4	760	93.5	748	760
21	95.1	760.8	784	97.1	776.8	784	97.1	776.8	784	97.5	780	784	97.3	778.4	784	97.3	778.4	784	94.6	756.8	784

Table S61: Target and received dose of BTT1023 by treatment patient and treatment visit. *(continued)*

Patient	Weight (kg)	Target Dose (mg)	Dose Received (mg)	Weight (kg)	Target Dose (mg)	Dose Received (mg)	Weight (kg)	Target Dose (mg)	Dose Received (mg)	Weight (kg)	Target Dose (mg)	Dose Received (mg)	Weight (kg)	Target Dose (mg)	Dose Received (mg)	Weight (kg)	Target Dose (mg)	Dose Received (mg)	Weight (kg)	Target Dose (mg)	Dose Received (mg)
22	82.1	656.8	648	82.9	663.2	648	82.8	662.4	648	82.1	656.8	644	82.6	660.8	644	81.7	653.6	644	81.5	652	644
23	85.4	683.2	680	83.4	667.2	680	84.1	672.8	680	85.1	680.8	680	84.9	679.2	680	85.1	680.8	680	86.1	688.8	680

Note:

All patients were allocated the same dose of BTT1023, 8mg/kg.

Table S62: Amount dose of BTT1023 received deviated from target dose by patient and treatment visit.

	Dose deviation (mg, percentage difference).						
Patient	**Visit 3**	**Visit 4**	**Visit 5**	**Visit 6**	**Visit 7**	**Visit 8**	**Visit 9**
1	32.8 (4.64 %)	-9.6 (-1.35 %)	7.2 (1.03 %)	6.4 (0.92 %)	6.4 (0.92 %)	0 (0 %)	2.4 (0.34 %)
2	14.4 (2.53 %)						
3	6.4 (1.35 %)	1.6 (0.33 %)	-3.2 (-0.66 %)	-0.8 (-0.17 %)	-5.6 (-1.15 %)	-4.8 (-0.99 %)	-7.2 (-1.48 %)
4	-13.6 (-2.22 %)	-4 (-0.66 %)	-27.2 (-4.34 %)	-4 (-0.66 %)	-19.2 (-3.1 %)	-21.6 (-3.47 %)	-29.6 (-4.7 %)
5	10.4 (1.48 %)	-0.8 (-0.11 %)	12 (1.71 %)	-2.4 (-0.34 %)	4 (0.56 %)	18.4 (2.65 %)	14.4 (2.06 %)
6	0 (0 %)	0 (0 %)	-9.6 (-1.36 %)	-2.4 (-0.34 %)	10.4 (1.52 %)	19.2 (2.84 %)	26.4 (3.94 %)
7	0 (0 %)	-7.2 (-1.25 %)	-16 (-2.74 %)	5.6 (1 %)	-6.4 (-1.11 %)	-8 (-1.39 %)	-14.4 (-2.47 %)
8	12.8 (2.31 %)	9.6 (1.72 %)	0 (0 %)	-0.8 (-0.14 %)	-0.8 (-0.14 %)	2.4 (0.42 %)	2.4 (0.42 %)
9	16 (2.2 %)	9.6 (1.31 %)	5.6 (0.76 %)	5.6 (0.76 %)	15.2 (2.09 %)	12.8 (1.75 %)	-4 (-0.53 %)
11	30.4 (5.26 %)	-8.8 (-1.43 %)	-14.4 (-2.31 %)	-2.4 (-0.39 %)	4.8 (0.8 %)		
12	24 (4.55 %)	14.4 (2.68 %)	9.6 (1.77 %)	12.8 (2.37 %)	20.8 (3.92 %)	14.4 (2.68 %)	20.8 (3.92 %)
13	0 (0 %)	0 (0 %)	8 (2.04 %)	0 (0 %)	4 (1.01 %)	12 (3.09 %)	8 (2.04 %)
14	1.6 (0.25 %)	-3.2 (-0.49 %)	-5.6 (-0.86 %)	-6.4 (-0.98 %)	-4 (-0.61 %)	-12.8 (-1.94 %)	-4.8 (-0.74 %)
15	3.2 (0.48 %)	7.6 (1.15 %)	17.6 (2.72 %)	12 (1.84 %)		7.2 (1.1 %)	10.4 (1.59 %)

Table S62: Amount dose of BTT1023 received deviated from target dose by patient and treatment visit. *(continued)*

Patient	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9
16	4 (0.58 %)	0 (0 %)	0 (0 %)	-8 (-1.15 %)	-16 (-2.27 %)	-8 (-1.15 %)	0 (0 %)
17	-2.4 (-0.42 %)	-1.6 (-0.28 %)	-4.8 (-0.84 %)	5.6 (1 %)	4.8 (0.85 %)	12.8 (2.31 %)	1.6 (0.28 %)
18	4 (0.7 %)	4 (0.7 %)	-8 (-1.37 %)	12 (2.1 %)	16 (2.86 %)	-8 (-1.41 %)	-4 (-0.7 %)
19	8 (1.1 %)	-8 (-1.09 %)	-16 (-2.13 %)	0 (0 %)	-8 (-1.05 %)	8 (1.06 %)	-16 (-2.08 %)
20	2.4 (0.32 %)	19.2 (2.59 %)	20 (2.7 %)	13.6 (1.82 %)	8 (1.06 %)	17.6 (2.37 %)	12 (1.6 %)
21	23.2 (3.05 %)	7.2 (0.93 %)	7.2 (0.93 %)	4 (0.51 %)	5.6 (0.72 %)	5.6 (0.72 %)	27.2 (3.59 %)
22	-8.8 (-1.34 %)	-15.2 (-2.29 %)	-14.4 (-2.17 %)	-12.8 (-1.95 %)	-16.8 (-2.54 %)	-9.6 (-1.47 %)	-8 (-1.23 %)
23	-3.2 (-0.47 %)	12.8 (1.92 %)	7.2 (1.07 %)	-0.8 (-0.12 %)	0.8 (0.12 %)	-0.8 (-0.12 %)	-8.8 (-1.28 %)

Note:

In the above calculation of deviation between target dose and actual dose received, the target dose was used as the reference category.

Therefore, a positive number represents the target/actual dose exceeded.

Table S63: Per patient treatment compliance information.

Patient	Infusions	Mean Dose	Total Dose	Number of Dose Delays	Number of Dose Inter-ruptions	Number of Dose Changes	Infusion-Related Reasons	Infusion-Related Comments
1	7	709.14	4964	0	0	0		
2	1	584.00	584	0	0	0		
3	7	480.00	3360	0	0	0		
4	7	600.00	4200	1	0	0	Delay in drug being delivered by pharmacy	Delay in drug being delivered by pharmacy Infusion took 5 minutes extra as cannula needed an extra flush. Pump alarmed as occluded, which was fixed after cannula was flushed.
5	7	712.00	4984	0	0	0	infusion was given at 19.8ml/hr rather than 40.2ml/hr due to previous infusion reaction	hydrocortisone 100mg given IV 20 minutes before infusion started.
6	7	696.00	4872	1	0	0	Dose was administered on 18-July-2016 instead of 14 July 2016 due to malfunctioned Pharmacy fridge. Please see protocol deviation report for details.	
7	7	568.00	3976	1	0	0	Infusion started 20 minutes after the 2 hour post pre-med time limit as cannula had to be replaced.	

Table S63: Per patient treatment compliance information. *(continued)*

Patient	Infusions	Mean Dose	Total Dose	Number of Dose Delays	Number of Dose Inter-ruptions	Number of Dose Changes	Infusion-Related Reasons	Infusion-Related Comments
8	7	568.00	3976	2	0	0	Delivery of infusion from pharmacy was late Delayed due to pharmacy delays	
9	7	744.00	5208	0	0	0		
11	5	608.00	3040	0	0	0		
12	7	552.00	3864	0	0	0		
13	7	400.00	2800	0	0	0		
14	7	648.00	4536	0	0	0		
15	6	664.33	3986	1	1	1	dose amended to 48ml as only 8 vials of BTT1023 available Difficulty in cannulating so unable to start dose within two hours.	Patient complained of tingling numb fingers, infusion was stopped, and restarted slowly. See deviation form for more details

Table S63: Per patient treatment compliance information. *(continued)*

Patient	Infusions	Mean Dose	Total Dose	Number of Dose Delays	Number of Dose Inter-ruptions	Number of Dose Changes	Infusion-Related Reasons	Infusion-Related Comments
16	7	688.00	4816	0	1	0	AT 12.05 infusion pump alarmed "occlusion" - no position change by patient. site around cannula looked puffy, although not tender, ? tissued. Drug disconnected, cannula not flushed. New Cannula placed in R ACF and infusion re-commenced at 12.20pm. Original cannula removed and no hardness or redness at original site.	As noted above, infusion was interrupted.
17	7	568.00	3976	0	0	0		50mg hydrocortizone given rather than 100mg due to high Blood sugar post visit 3 infusion
18	7	573.71	4016	0	0	0		
19	7	745.14	5216	0	0	0		
20	7	760.00	5320	0	1	0	10 minutes spent re-cannulating due to tissued cannula	
21	7	784.00	5488	0	0	0		
22	7	645.71	4520	0	0	0		

Table S63: Per patient treatment compliance information. *(continued)*

Patient	Infusions	Mean Dose	Total Dose	Number of Dose Delays	Number of Dose Inter-ruptions	Number of Dose Changes	Infusion-Related Reasons	Infusion-Related Comments
23	7	680.00	4760	0	0	0		

D.9.6 EQ-5D-5L Health Questionnaire

Table S64: Summary of EQ-5D 5L Index Scores between screening and follow-up.

	EQ-5D 5L Index Scores		
	Visit 3	Follow-up Visit 10	Difference
N	21	22	21
Mean	0.94	0.86	-0.04
Median	1	1	0
Range	(0.77,1)	(0.229,1)	(-0.481,0.171)
IQR	(0.887,1)	(0.8465,1)	(-0.084,0)

Table S65: Patient level change in EQ-5D 5L index scores.

	EQ-5D 5L Index Score			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
7	0.812	0.33	0.48	-59.24
15	0.77	0.32	0.45	-58.7
6	0.829	0.73	0.1	-11.94
22	1	0.89	0.11	-11.3
20	0.922	0.83	0.09	-9.65
1	1	0.92	0.08	-8.4
23	0.829	0.82	0.01	-1.57
2	1	1.00	0	0
3	1	1.00	0	0
8	1	1.00	0	0
9	1	1.00	0	0
11	1	1.00	0	0
14	1	1.00	0	0
16	1	1.00	0	0
18	1	1.00	0	0
21	1	1.00	0	0
17	0.95	1.00	0.05	5.26
19	0.887	0.94	0.05	5.64
4	0.937	1.00	0.06	6.72
5	0.937	1.00	0.06	6.72
13	0.829	1.00	0.17	20.63
12		0.23		

Table S66: Average Difference in EQ-5D 5L index score.

Absolute Difference	
N	21
Mean	0.08
Median	0.05
Range	(0,0.481)
IQR	(0,0.089)
Percentage Change	
N	21
Mean	-5.52
Median	0
Range	(-59.24,20.63)
IQR	(-8.4,0)



Figure S6: Repeated measures plot of EQ-5D-5L index score for all evaluable patients in the mITT population. A mean loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Table S67: Summary of EQ-VAS scores between screening and follow-up.

	EQ-VAS Score		
	Visit 3	Follow-up Visit 10	Difference
N	21	22	21
Mean	82.19	77.95	-3.38
Median	83	82.5	0
Range	(40,100)	(36,100)	(-40,15)
IQR	(75,95)	(64.5,90)	(-10,5)

Table S68: Patient level change in EQ-VAS scores.

	EQ-VAS Index Score			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
7	61	36	25	-40.98
22	100	60	40	-40
11	85	60	25	-29.41
16	75	61	14	-18.67
14	90	75	15	-16.67
2	95	85	10	-10.53
1	95	90	5	-5.26
20	100	95	5	-5
15	40	40	0	0
17	75	75	0	0
21	100	100	0	0
23	75	75	0	0
13	95	97	2	2.11
19	75	77	2	2.67
4	90	95	5	5.56
3	85	90	5	5.88
5	83	90	7	8.43
18	83	90	7	8.43
8	80	90	10	12.5
9	79	94	15	18.99
6	65	80	15	23.08
12		60		

Table S69: Average Difference in EQ-VAS score.

Absolute Difference	
N	21
Mean	9.86
Median	7
Range	(0,40)
IQR	(2,15)
Percentage Change	
N	21
Mean	-3.76
Median	0
Range	(-40.98,23.08)
IQR	(-10.53,5.88)



Figure S7: Repeated measures plot of EQ-5D VAS score for all evaluable patients in the mITT population. A mean loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

D.10.7 Fatigue Severity Scale (FSS)

Table S70: Summary of total FSS score between screening and follow-up.

	Total FSS Score		
	Visit 3	Follow-up Visit 10	Difference
N	21	22	21
Mean	34.05	34.45	-0.67
Median	34	38	-1
Range	(9,59)	(9,58)	(-10,10)
IQR	(24,46)	(20.25,49.25)	(-4,3)

Table S71: Patient level change in total FSS scores.

	Total FSS Score			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
18	24	14	10	-41.67
20	31	23	8	-25.81
9	47	37	10	-21.28
1	21	17	4	-19.05
21	24	20	4	-16.67
2	10	9	1	-10
5	40	36	4	-10
17	43	39	4	-9.3
8	23	21	2	-8.7
19	50	47	3	-6
6	43	42	1	-2.33
15	59	58	1	-1.69
4	25	25	0	0
14	9	9	0	0
23	51	52	1	1.96
16	51	56	5	9.8
7	46	52	6	13.04
22	44	50	6	13.64
13	34	41	7	20.59
11	31	41	10	32.26
3	9	12	3	33.33
12		57		

Table S72: Average Difference in total FSS score.

Absolute Difference	
N	21
Mean	4.29
Median	4
Range	(0,10)
IQR	(1,6)
Percentage Change	
N	21
Mean	-2.28
Median	-2.33
Range	(-41.67,33.33)
IQR	(-10,9.8)



Figure S8: Repeated measures plot of FSS score for all evaluable patients in the mITT population. A mean loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

D.10.8 Pruritus Visual Analogue Scale (VAS)

Table S73: Summary of total Pruritus VAS score between screening and follow-up.

	Pruritus VAS Score		
	Visit 3	**Follow-up Visit 10**	**Difference**
N	21	21	20
Mean	31.95	27.24	-5.2
Median	29	24	-9
Range	(2,92)	(1,78)	(-53,51)
IQR	(12,38)	(13,30)	(-14.25,4.25)

Table S74: Patient level change in Pruritus VAS scores.

	Pruritus VAS Score			
Patient Number	**Visit 3**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
1	54	1	53	-98.15
3	12	3	9	-75
9	15	4	11	-73.33
19	38	13	25	-65.79
5	52	23	29	-55.77
21	30	15	15	-50
23	54	30	24	-44.44
2	38	24	14	-36.84
8	27	18	9	-33.33
22	5	4	1	-20
6	90	76	14	-15.56
15	92	78	14	-15.22
20	33	30	3	-9.09
4	11	12	1	9.09
16	21	25	4	19.05
13	30	37	7	23.33
18	8	13	5	62.5
7	29	64	35	120.69
14	11	25	14	127.27
11	2	53	51	2550
12		24		
17	19			

Table S75: Average Difference in Pruritus VAS score.

Absolute Difference	
N	20
Mean	16.9
Median	14
Range	(1,53)
IQR	(6.5,24.25)
Percentage Change	
N	20
Mean	115.97
Median	-17.78
Range	(-98.15,2550)
IQR	(-51.44,20.12)



Figure S9: Repeated measures plot of pruritus VAS score for all evaluable patients in the mITT population. A mean loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

D.10.9 Inflammatory Bowel Disease (IBD) Diaroes

Number of Stools

Table S76: Summary of median number of stools per day at screening and follow-up.

	Median Number of Stools Per Day		
	Visit 2 (screening)	**Visit 10 (follow-up)**	**Difference**
N	14	13	13
Mean	2.5	3.62	1.23
Median	2	3	0
Range	(0,7)	(1,10)	(-1,10)
IQR	(1,3)	(1,3)	(0,1)

Table S77: Average Difference in Median Number of Stools (per day).

Absolute Difference	
N	13
Mean	1.38
Median	0
Range	(0,10)
IQR	(0,1)
Percentage Change	
N	13
Mean	Inf
Median	0
Range	(-33.33,Inf)
IQR	(0,50)

Table S78: Average Difference in Median Number of Stools (per day).

Absolute Difference	
N	12
Mean	0.67
Median	0
Range	(0,3)
IQR	(0,1)
Percentage Change	
N	12
Mean	25.79
Median	0
Range	(-33.33,200)
IQR	(0,44.6428)

Note:
The above table excludes any participants who reported a median average of 0 stools per day at screening.



Figure S10: Repeated measures plot of median number of stools per day for all evaluable patients with IBD in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Frequency of Blood in Stool

Table S79: Summary of median frequency of blood in stools per day at screening and follow-up.

	Median Frequency of Blood in Stools Per Day		
	Visit 2 (screening)	**Visit 10 (follow-up)**	**Difference**
N	14	13	13
Mean	0	0	0
Median	0	0	0
Range	(0,0)	(0,0)	(0,0)
IQR	(0,0)	(0,0)	(0,0)

Table S80: Average Difference in Median Frequency of Blood in Stools (per day).

Absolute Difference	
N	13
Mean	0
Median	0
Range	(0,0)
IQR	(0,0)
Percentage Change	
N	0
Mean	NaN
Median	NA
Range	(NA,NA)
IQR	(NA,NA)



Figure S11: Repeated measures plot of median frequency of blood in stools per day for all evaluable patients with IBD in the mITT population.

Abdominal Pain/Cramp

Table S81: Summary of median average abdominal pain in the weeks preceding visit 2 and visit 10.

	Median Average Abdominal Pain		
	Visit 2 (screening)	**Visit 10 (follow-up)**	**Difference**
N	14	13	13
Mean	0.21	0.31	0.08
Median	0	0	0
Range	(0,2)	(0,2)	(-1,1)
IQR	(0,0)	(0,0)	(0,0)

Table S82: Average Difference in median average abdominal pain in the weeks preceding visit 2 and visit 10.

Absolute Difference	
N	13
Mean	0.23
Median	0
Range	(0,1)
IQR	(0,0)
Percentage Change	
N	4
Mean	Inf
Median	Inf
Range	(-100,Inf)
IQR	(-25,Inf)



Figure S12: Repeated measures plot of median abdominal pain in the week before trial visit for all evaluable patients with IBD in the mITT population.

General Wellbeing

Table S83: Summary of median average general wellbeing in the weeks preceding visit 2 and visit 10.

	Median Average General Wellbeing		
	Visit 2 (screening)	**Visit 10 (follow-up)**	**Difference**
N	14	13	13
Mean	0.79	0.77	0
Median	1	1	0
Range	(0,3)	(0,3)	(-1,1)
IQR	(0,1)	(0,1)	(0,0)

Table S84: Average difference in median average general wellbeing in the weeks preceding visit 2 and visit 10.

Absolute Difference	
N	13
Mean	0.31
Median	0
Range	(0,1)
IQR	(0,1)
Percentage Change	
N	8
Mean	Inf
Median	0
Range	(-100,Inf)
IQR	(-12.5,25)



Figure S13: Repeated measures plot of median general wellbeing in the week before trial visit for all evaluable patients with IBD in the mITT population.

D.10.10 Enhanced Liver Fibrosis (ELF)

ELF Score

Table S85: Summary of ELF score at visit 3 and follow-up visit 10.

	ELF Score		
	Visit 3	**Visit 10**	**Difference**
N	17	17	17
Mean	10.27	10.34	0.07
Median	10.16	10.41	0.13
Range	(8.61,12.32)	(8.58,12.69)	(-1.42,0.88)
IQR	(9.73,10.89)	(9.78,11.02)	(-0.21,0.46)

Table S86: Patient level change in ELF Score

	ELF Score			
Patient Number	**Visit 3 Pre-Infusion**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
1	10.22	8.80	1.42	-13.89
15	11.62	10.72	0.90	-7.75
5	9.96	9.69	0.27	-2.71
3	10.09	9.82	0.27	-2.68
9	11.63	11.42	0.21	-1.81
21	10.83	10.76	0.07	-0.65
7	8.61	8.58	0.03	-0.35
20	9.81	9.78	0.03	-0.31
14	10.89	11.02	0.13	1.19
17	10.98	11.17	0.19	1.73
19	10.16	10.41	0.25	2.46
4	12.32	12.69	0.37	3.00
18	8.67	9.13	0.46	5.31
2	10.61	11.28	0.67	6.31
8	9.73	10.48	0.75	7.71
12	9.30	10.02	0.72	7.74
6	9.09	9.97	0.88	9.68

Table S87: Average difference in ELF score.

Absolute Difference	
N	17
Mean	0.45
Median	0.27
Range	(0.03,1.42)
IQR	(0.19,0.72)
Percentage Change	
N	17
Mean	0.88
Median	1.19
Range	(-13.89,9.68)
IQR	(-1.81,5.31)



Figure S14: Repeated measures plot of ELF score in the mITT population over all time points. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

ELF Category

Table S88: Summary of ELF Category at trial visits in the mITT.

ELF Category	Visit 3 (pre-infusion)	Visit 10 (follow-up)
None - Mild	0 (0.00%)	0 (0.00%)
Moderate	5 (29.41%)	5 (29.41%)
Severe	12 (70.59%)	12 (70.59%)
Total	**17 (100.00%)**	**17 (100.00%)**

Table S89: Patient line listing of ELF Category at visit 3 and visit 10 (follow-up)

Patient Number	ELF Category	
	Visit 3	Follow-up Visit 10
1	Severe	Moderate
2	Severe	Severe
3	Severe	Severe
4	Severe	Severe
5	Severe	Moderate
6	Moderate	Severe
7	Moderate	Moderate
8	Moderate	Severe
9	Severe	Severe
12	Moderate	Severe
14	Severe	Severe
15	Severe	Severe
17	Severe	Severe
18	Moderate	Moderate
19	Severe	Severe
20	Severe	Moderate
21	Severe	Severe



Figure S15: Repeated measures plot of ELF Category in the mITT population.

ELF Components

ELF score is the composite of hyaluronic acid (HA), procollagen III amino terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP-1). Table S90 shows summary statistics of the component parts of ELF, while table S91 shows the average difference.

Table S90: Summary of ELF score component parts at visits 3 (pre-infusion) and 10 (follow-up).

	Visit 3	Visit 10	Difference
HA			
N	17	17	17
Mean	128.46	141.81	13.34
Median	103.47	107.41	1.24
Range	(20.55,422.92)	(24.08,557.65)	(-113.35,134.73)
IQR	(55.45,131.47)	(54.32,153.96)	(-15.52,46.19)
PIIINP			
N	17	17	17
Mean	13.52	13.09	-0.43
Median	12.16	10.23	0.25
Range	(4.14,29.23)	(5.04,30.53)	(-11.54,5.52)
IQR	(9.77,15.22)	(9.44,15.78)	(-1.82,1.3)
TIMP-1			
N	17	17	17
Mean	303.96	326.51	22.54
Median	296.6	304.5	12.8
Range	(186.2,417.8)	(203.4,518.5)	(-45.8,120.8)
IQR	(219,371.5)	(274.8,395.8)	(-2.4,32.4)

Table S91: Summary differences in ELF component parts between visit 3 and visit 10.

	HA	PIIINP	TIMP-1
Absolute Difference			
N	17	17	17
Mean	52.69	2.44	32.84
Median	43.58	1.75	18.5
Range	(0.32,134.73)	(0.1,11.54)	(1,120.8)
IQR	(15.52,88.25)	(0.92,2.3)	(7.9,39.6)
Percentage Change			
N	17	17	17
Mean	24.75	-0.51	7.71
Median	2.41	2.15	4.19
Range	(-78.56,135.18)	(-46.18,34.59)	(-12.54,47.24)
IQR	(-18.92,78.59)	(-15.87,13.82)	(-0.85,11.34)

Tables S92, S93, and S94 shows the patient level changes in HA, PIINP, and TIMP-1 respectively.

Hyaluronic acid (HA)

Table S92: Patient level changes in ELF score component part HA.

	HA			
Patient Number	Visit 3 (pre-infusion)	Follow-up Visit 10	Absolute Difference	Percentage change (%)
1	112.33	24.08	88.25	-78.56
15	223.88	141.45	82.43	-36.82
9	356.08	242.73	113.35	-31.83
7	40.24	32.45	7.79	-19.36
3	82.01	66.49	15.52	-18.92
14	131.47	107.41	24.06	-18.30
20	57.34	54.32	3.02	-5.27
21	127.69	128.01	0.32	0.25
5	51.41	52.65	1.24	2.41
17	122.69	139.24	16.55	13.49
4	422.92	557.65	134.73	31.86
19	101.12	153.96	52.84	52.25
12	55.45	99.03	43.58	78.59
2	141.03	253.27	112.24	79.59
18	20.55	43.06	22.51	109.54
8	103.47	234.55	131.08	126.68
6	34.17	80.36	46.19	135.18

Procollagen III amino terminal peptide (PIIINP)

Table S93: Patient level changes in ELF score component part PIIINP

	PIIINP			
Patient Number	Visit 3 (pre-infusion)	Follow-up Visit 10	Absolute Difference	Percentage change (%)
15	24.99	13.45	11.54	-46.18
5	14.22	9.44	4.78	-33.61
1	11.94	9.64	2.30	-19.26
18	9.77	7.95	1.82	-18.63
19	12.16	10.23	1.93	-15.87
3	11.08	10.00	1.08	-9.75
21	15.22	14.30	0.92	-6.04
8	5.44	5.54	0.10	1.84
20	11.62	11.87	0.25	2.15
4	29.23	30.53	1.30	4.45
17	20.72	21.98	1.26	6.08
12	7.42	8.14	0.72	9.70
9	14.83	16.88	2.05	13.82
6	8.45	10.20	1.75	20.71
7	4.14	5.04	0.90	21.74
2	12.57	15.78	3.21	25.54
14	15.96	21.48	5.52	34.59

Tissue inhibitor of metalloproteinase 1 (TIMP-1)

Table S94: Patient level changes in ELF score component part TIMP-1

Patient Number	TIMP-1		Absolute Difference	Percentage change (%)
	Visit 3 (pre-infusion)	Follow-up Visit 10		
15	365.3	319.5	45.8	-12.54
21	417.8	399.3	18.5	-4.43
3	307.4	294.3	13.1	-4.26
18	211.1	203.4	7.7	-3.65
2	282.8	280.4	2.4	-0.85
7	219.0	220.0	1.0	0.46
20	296.6	300.1	3.5	1.18
6	266.9	274.8	7.9	2.96
5	379.9	395.8	15.9	4.19
9	363.8	383.8	20.0	5.50
19	193.6	206.4	12.8	6.61
17	371.5	411.1	39.6	10.66
8	285.6	318.0	32.4	11.34
1	186.2	212.1	25.9	13.91
14	415.4	508.6	93.2	22.44
4	397.7	518.5	120.8	30.37
12	206.8	304.5	97.7	47.24

Figure S16 shows a repeated measures plot of component parts of ELF score in the mITT with a loess smoother trend line to help evaluate any potential trend in scores.



Figure S16: Repeated measures plot of component part of ELF score in the mITT population, presented by component part. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

D.10.11 Fibroscan

kPa

Table S95: Patient level change in Fibroscan kPa Measurement.

Patient Number	Fibroscan kPa		Absolute Difference	Percentage change (%)
	Screening Visit 2	Follow-up Visit 10		
15	22.1	10.0	12.1	-54.75
9	31.6	16.6	15.0	-47.47
11	19.4	14.1	5.3	-27.32
2	18.0	13.4	4.6	-25.56
4	35.8	30.5	5.3	-14.80
22	38.0	32.4	5.6	-14.74
14	12.2	12.0	0.2	-1.64
8	14.8	14.6	0.2	-1.35
3	8.8	8.8	0.0	0.00
20	7.5	7.5	0.0	0.00
17	17.4	17.6	0.2	1.15
18	7.8	8.0	0.2	2.56
13	17.1	19.0	1.9	11.11
21	15.7	17.8	2.1	13.38
23	24.3	28.7	4.4	18.11
1	7.0	8.6	1.6	22.86
19	8.5	12.1	3.6	42.35
16	12.3	18.1	5.8	47.15
12	7.8	13.0	5.2	66.67
5	7.1	11.9	4.8	67.61
7	5.1	8.7	3.6	70.59
6	3.5	7.8	4.3	122.86

Table S96: Average Difference in Fibroscan kPa Measurement.

Absolute Difference	
N	22
Mean	3.91
Median	3.95
Range	(0,15)
IQR	(0.55,5.275)
Percentage Change	
N	22
Mean	13.58
Median	1.86
Range	(-54.7511,122.8571)
IQR	(-11.4624,37.4789)



Figure S17: Repeated measures plot of Fibroscan measurement kpa for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

IQR

Table S97: Summary of Fibroscan IQR Measurement.

	Fibroscan IQR		
	Screening Visit 2	Follow-up Visit 10	Difference
N	22	22	22
Mean	1.84	2.41	0.58
Median	1.4	1.6	0
Range	(0.5,5.6)	(0.5,8.3)	(-1.7,6.5)
IQR	(0.825,2.025)	(1.1,3.3)	(-0.3,1.075)

Table S98: Patient level change in Fibroscan IQR Measurement.

	Fibroscan IQR			
Patient Number	Screening Visit 2	Follow-up Visit 10	Absolute Difference	Percentage change (%)
5	1.5	0.7	0.8	-53.33
17	3.0	1.7	1.3	-43.33
11	2.1	1.2	0.9	-42.86
18	0.9	0.6	0.3	-33.33
9	5.6	3.9	1.7	-30.36
2	3.8	2.9	0.9	-23.68
1	1.4	1.1	0.3	-21.43
15	1.5	1.2	0.3	-20.00
13	4.8	4.6	0.2	-4.17
8	0.5	0.5	0.0	0.00
14	0.6	0.6	0.0	0.00
21	1.1	1.1	0.0	0.00
20	1.2	1.3	0.1	8.33
16	1.7	1.9	0.2	11.76
22	4.0	6.6	2.6	65.00
19	0.8	1.5	0.7	87.50
7	0.5	1.1	0.6	120.00
12	1.4	3.4	2.0	142.86
3	0.5	1.7	1.2	240.00
23	1.1	4.2	3.1	281.82
4	1.8	8.3	6.5	361.11
6	0.6	3.0	2.4	400.00

Table S99: Average Difference in Fibroscan IQR Measurement.

Absolute Difference	
N	22
Mean	1.19
Median	0.75
Range	(0,6.5)
IQR	(0.225,1.6)
Percentage Change	
N	22
Mean	65.72
Median	0
Range	(-53.3333,400)
IQR	(-23.1203,111.875)



Figure S18: Repeated measures plot of Fibroscan measurement IQR for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

D.10.12 Liver Function Tests

Table S100: Liver Function Tests: Post-infusion Results.

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11
AST (IU/L)											
N	21	22	20	18	20	19	18	19	18	20	19
Mean	99.24	87.77	84.85	72.56	71.9	68.89	75.11	80.79	75.67	78.25	181.53
Median	79	74	68.5	59.5	68.5	55	66	63	67	73.5	82
Range	(18,357)	(24,249)	(31,226)	(27,146)	(19,135)	(27,132)	(20,164)	(28,201)	(21,203)	(23,230)	(25,1732)
IQR	(56,124)	(45.5,104)	(48.75,112.75)	(46,92.75)	(44,92.75)	(43,101.5)	(41.75,101.5)	(46,110)	(44,100)	(47.75,94.5)	(49.5,129.5)
ALT (IU/L)											
N	22	22	21	19	20	20	20	20	20	21	22
Mean	109.77	94.68	93.14	89.32	78.4	74.55	79.25	84.8	83.9	93.33	130.86
Median	84	73.5	79	72	72	66.5	70.5	74.5	76.5	72	84
Range	(32,303)	(33,265)	(28,243)	(26,222)	(28,169)	(26,212)	(22,213)	(24,230)	(21,191)	(29,249)	(19,841)
IQR	(70.25,135.5)	(56,107.75)	(57,120)	(56.5,96.5)	(49.75,105.75)	(46.75,88.5)	(54.75,92.25)	(60,97.75)	(56.75,95.25)	(53,123)	(58.25,112.75)
ALP (IU/L)											
N	22	22	22	20	21	20	20	20	20	22	22
Mean	477.64	450.77	434.64	412.35	401.48	394.95	405.65	444.25	440.95	456.18	479
Median	406.5	346.5	340.5	321.5	342	329.5	315.5	335.5	312.5	354.5	335.5
Range	(199,1318)	(215,1075)	(216,1069)	(222,1002)	(196,874)	(209,874)	(202,946)	(198,1035)	(180,1152)	(142,1407)	(172,2046)
IQR	(295.5,528)	(311.25,565.75)	(287.5,544)	(268,486.75)	(275,455)	(272,442)	(269.75,441.25)	(281.25,517.75)	(258.75,533.75)	(273.25,495.75)	(264.5,516)
GGT (IU/L)											
N	20	21	21	19	21	19	20	19	18	21	21

Table S100: Liver Function Tests: Post-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11
Mean	732.85	643.24	622.52	583.37	636.14	563.89	472.05	534	579.44	583.76	630.1
Median	447.5	398	465	393	324	371	338	333	329.5	342	356
Range	(77,2857)	(69,1918)	(76,1651)	(75,1708)	(53,2838)	(62,1891)	(63,1304)	(103,1877)	(77,2666)	(86,2032)	(74,2242)
IQR	(297.25,1096.75)	(249,1079)	(242,1010)	(217.5,761)	(231,872)	(237.5,849.5)	(203.75,662.75)	(203.5,742.5)	(192.75,682.75)	(213,924)	(180,872)
Albumin (g/L)											
N	22	22	22	21	21	20	20	20	20	22	22
Mean	41.32	41.59	39.27	39.33	38.57	38.2	38.15	38.7	37.6	40.45	40.05
Median	43	43	41	41	40	40	39.5	40.5	39	42	41.5
Range	(29,50)	(31,48)	(28,46)	(28,50)	(26,46)	(29,44)	(28,45)	(28,47)	(25,44)	(29,47)	(28,48)
IQR	(37,44)	(38,46)	(36.5,42)	(36,43)	(36,42)	(36,41.25)	(35.75,41)	(35.5,42)	(34.75,41)	(36.25,43)	(36.5,44)
Direct Biliru-bin (umol/l)											
N	19	19	19	16	18	17	17	16	18	21	20
Mean	12.89	15.11	11.42	11.62	12.94	12.88	12.59	13.25	11.39	13.62	19.55
Median	13	12	5	7	10.5	8	6	8.5	8.5	8	12
Range	(2,38)	(2,44)	(2,29)	(2,28)	(2,37)	(2,35)	(2,38)	(2,36)	(2,29)	(3,47)	(3,136)
IQR	(5.5,16.5)	(6.5,21)	(4,21)	(3,20.5)	(6,19.5)	(5,20)	(4,18)	(5.5,20.5)	(5,16.5)	(5,17)	(4,21.5)
Indirect Biliru-bin (umol/l)											

Table S100: Liver Function Tests: Post-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11
N	18	17	18	15	17	16	16	14	16	19	19
Mean	7.5	9.76	7.89	10.6	7.82	8.75	9.44	9.5	7.88	8.26	8.63
Median	6.5	8	6	10	6	8	8.5	9	6	7	8
Range	(2,19)	(1,25)	(2,21)	(4,25)	(2,15)	(1,26)	(2,19)	(3,19)	(2,24)	(1,19)	(3,19)
IQR	(5,9.75)	(6,11)	(4,10)	(8,13)	(6,10)	(5.5,9.25)	(5,14)	(5,13.5)	(5,9.5)	(5,11.5)	(4,12.5)
INR											
N	22	22	21	21	20	19	20	19	19	22	20
Mean	1	1.01	1.01	1	1	1.02	1.02	1.01	1.03	1	1.02
Median	1	1	1	1	1	1	1	1	1	1	1
Range	(0.9,1.1)	(0.9,1.2)	(0.9,1.2)	(0.9,1.2)	(0.9,1.2)	(0.9,1.2)	(0.9,1.1)	(0.9,1.2)	(0.9,1.2)	(0.8,1.2)	(0.9,1.2)
IQR	(1,1)	(1,1.075)	(1,1)	(1,1)	(1,1)	(1,1)	(1,1.1)	(1,1)	(1,1)	(1,1.075)	(1,1.025)



Figure S19: Repeated measures plot of liver function tests at all trial visits in the mITT population, presented by liver function test. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.



Figure S20: Repeated measures plot of liver function tests at pre-BTT1023 infusion in the mITT population, presented by liver function test. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.



Figure S21: Repeated measures plot of liver function tests at post-BTT1023 infusion in the mITT population, presented by liver function test.A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

AST

Table S101: Summary of AST (IU/L) between baseline and follow-up.

	AST (IU/L)		
	Visit 3 (pre-infusion)	Follow-up Visit 10	Difference
N	22	20	20
Mean	87.45	78.25	-5.55
Median	71	73.5	-10
Range	(26,250)	(23,230)	(-37,44)
IQR	(48.25,102.25)	(47.75,94.5)	(-18.5,3.25)

Table S102: Patient level change in AST (IU/L).

	AST (IU/L)			
Patient Number	Visit 3 (pre-infusion)	Follow-up Visit 10	Absolute Difference	Percentage change (%)
19	38	23	15	-39.47
12	43	28	15	-34.88
2	131	94	37	-28.24
16	133	96	37	-27.82
20	66	48	18	-27.27
22	103	77	26	-25.24
3	90	74	16	-17.78
9	91	75	16	-17.58
13	141	118	23	-16.31
11	52	47	5	-9.62
15	53	48	5	-9.43
17	250	230	20	-8
21	75	73	2	-2.67
6	55	55	0	0
7	26	28	2	7.69
1	46	53	7	15.22
23	100	121	21	21
18	37	47	10	27.03
4	99	143	44	44.44
8	47	87	40	85.11
5	67			
14	181			

Table S103: Average Difference in AST (IU/L).

Absolute Difference	
N	20
Mean	17.95
Median	16
Range	(0,44)
IQR	(6.5,23.75)
Percentage Change	
N	20
Mean	-3.19
Median	-9.52
Range	(-39.4737,85.1064)
IQR	(-25.75,9.57)

From figure S20, there is only negligible evidence that AST varies in time, therefore it would be inappropriate to do a repeated measures analysis.

ALT

Table S104: Summary of ALT (IU/L) between baseline and follow-up.

	ALT (IU/L)		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	22	21	21
Mean	95.14	93.33	-0.76
Median	71	72	-11
Range	(27,255)	(29,249)	(-36,126)
IQR	(60.5,118.5)	(53,123)	(-25,5)

Table S105: Patient level change in ALT.

Patient Number	ALT (IU/L) Visit 3 (pre-infusion)	ALT (IU/L) Follow-up Visit 10	Absolute Difference	Percentage change (%)
19	56	31	25	-44.64
12	67	39	28	-41.79
15	46	29	17	-36.96
5	119	85	34	-28.57
20	107	82	25	-23.36
16	68	53	15	-22.06
2	166	130	36	-21.69
9	78	62	16	-20.51
21	88	77	11	-12.5
13	255	226	29	-11.37
6	62	57	5	-8.06
17	227	215	12	-5.29
22	74	71	3	-4.05
11	54	52	2	-3.7
23	125	123	2	-1.6
1	65	72	7	10.77
7	27	32	5	18.52
18	43	60	17	39.53
4	60	89	29	48.33
8	66	126	60	90.91
14	123	249	126	102.44
3	117			

Table S106: Average Difference in ALT (IU/L).

Absolute Difference	
N	21
Mean	24
Median	17
Range	(2,126)
IQR	(7,29)
Percentage Change	
N	21
Mean	1.16
Median	-8.06
Range	(-44.64,102.44)
IQR	(-22.06,10.77)

From figure S20, there is only negligible evidence that ALT varies in time, therefore it would be inappropriate to

do a repeated measures analysis.

ALP

Table S107: Summary of ALP (IU/L) between baseline and follow-up.

	ALP (IU/L)		
	Visit 3 (pre-infusion)	Follow-up Visit 10	Difference
N	22	22	22
Mean	443	456.18	13.18
Median	345	354.5	-12
Range	(180,1069)	(142,1407)	(-124,452)
IQR	(288.25,549.25)	(273.25,495.75)	(-48.75,23.25)

Table S108: Patient level change in ALP (IU/L).

	ALP (IU/L)			
Patient Number	Visit 3 (pre-infusion)	Follow-up Visit 10	Absolute Difference	Percentage change (%)
18	249	142	107	-42.97
6	574	450	124	-21.60
3	431	356	75	-17.40
12	295	245	50	-16.95
13	597	511	86	-14.41
16	350	305	45	-12.86
5	925	812	113	-12.22
20	335	296	39	-11.64
19	262	232	30	-11.45
11	312	292	20	-6.41
15	429	417	12	-2.80
2	685	673	12	-1.75
23	271	268	3	-1.11
8	286	289	3	1.05
21	424	437	13	3.07
22	180	198	18	10.00
9	219	244	25	11.42
4	475	531	56	11.79
7	340	386	46	13.53
1	298	353	55	18.46
17	1069	1407	338	31.62
14	740	1192	452	61.08

Table S109: Average Difference in ALP (IU/L).

Absolute Difference	
N	22
Mean	78.27
Median	45.5
Range	(3,452)
IQR	(18.5,83.25)
Percentage Change	
N	22
Mean	-0.53
Median	-2.27
Range	(-42.97,61.08)
IQR	(-12.7,11.06)

From figure S20 and the trend line, there was such a negligible effect of ALP changing in time that it would be futile to do repeated measures analysis.

GGT

Table S110: Summary of GGT (IU/L) between baseline and follow-up.

	GGT (IU/L)		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	22	21	21
Mean	609.45	583.76	16.14
Median	460	342	-8
Range	(76,1773)	(86,2032)	(-138,259)
IQR	(245,984.75)	(213,924)	(-39,99)

Table S111: Patient level change in GGT (IU/L)

Patient Number	GGT (IU/L) Visit 3 (pre-infusion)	GGT (IU/L) Follow-up Visit 10	Absolute Difference	Percentage change (%)
12	470	332	138	-29.36
5	493	359	134	-27.18
22	257	192	65	-25.29
16	450	342	108	-24
11	194	155	39	-20.1
6	497	401	96	-19.32
9	152	134	18	-11.84
20	241	213	28	-11.62
1	286	259	27	-9.44
3	361	338	23	-6.37
18	137	129	8	-5.84
8	909	924	15	1.65
7	235	243	8	3.4
13	1010	1081	71	7.03
21	1278	1391	113	8.84
19	76	86	10	13.16
17	1053	1195	142	13.49
15	1773	2032	259	14.61
2	1179	1367	188	15.95
23	551	650	99	17.97
4	318	436	118	37.11
14	1488			

Table S112: Average Difference in GGT (IU/L).

Absolute Difference	
N	21
Mean	81.29
Median	71
Range	(8,259)
IQR	(23,118)
Percentage Change	
N	21
Mean	-2.72
Median	-5.84
Range	(-29.36,37.11)
IQR	(-19.32,13.16)

From figure S20 and the trend line, there was such a negligible effect of ALP changing in time that it would be

futile to perform repeated measures analysis.

Albumin

Table S113: Summary of Albumin (g/L) between baseline and follow-up.

	Albumin (g/L)		
	Visit 3 (pre-infusion)	Follow-up Visit 10	Difference
N	22	22	22
Mean	40.45	40.45	0
Median	42	42	0
Range	(30,49)	(29,47)	(-4,7)
IQR	(36.75,43.75)	(36.25,43)	(-2.75,1.75)

Table S114: Patient level change in Albumin (g/L).

	Albumin (g/L)			
Patient Number	Visit 3 (pre-infusion)	Follow-up Visit 10	Absolute Difference	Percentage change (%)
17	42	38	4	-9.52
18	39	36	3	-7.69
11	45	42	3	-6.67
15	46	43	3	-6.52
20	48	45	3	-6.25
3	49	46	3	-6.12
16	36	34	2	-5.56
12	43	41	2	-4.65
5	44	42	2	-4.55
13	30	29	1	-3.33
2	43	43	0	0.00
9	35	35	0	0.00
1	43	44	1	2.33
7	42	43	1	2.38
21	41	42	1	2.44
19	34	35	1	2.94
8	45	47	2	4.44
6	41	43	2	4.88
14	43	46	3	6.98
23	39	43	4	10.26
22	32	36	4	12.50
4	30	37	7	23.33

Table S115: Average Difference in Albumin (g/L).

Absolute Difference	
N	22
Mean	2.36
Median	2
Range	(0,7)
IQR	(1,3)
Percentage Change	
N	22
Mean	0.53
Median	0
Range	(-9.52,23.33)
IQR	(-5.98,4.07)

Figure S20 showed no discernible trend in the trend line, therefore any repeated measures analysis would be futile.

Direct Bilirubin

Table S116: Summary of direct Bilirubin (*µmol/l*) between baseline and follow-up.

	Direct Bilirubin (*µmol/l*)		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	20	21	19
Mean	13.9	13.62	1.11
Median	8.5	8	0
Range	(2,35)	(3,47)	(-11,27)
IQR	(5,24.5)	(5,17)	(-2,3)

Table S117: Patient level change in direct Bilirubin.

Patient Number	Direct Bilirubin (*µmol/l*) Visit 3 (pre-infusion)	Direct Bilirubin (*µmol/l*) Follow-up Visit 10	Absolute Difference	Percentage change (%)
15	26	15	11	-42.31
19	5	3	2	-40
13	26	17	9	-34.62
3	7	5	2	-28.57
16	35	27	8	-22.86
20	5	4	1	-20
18	6	5	1	-16.67
2	27	23	4	-14.81
21	9	8	1	-11.11
5	17	17	0	0
12	3	3	0	0
4	31	35	4	12.9
22	5	6	1	20
23	12	16	4	33.33
7	2	3	1	50
9	8	12	4	50
1	3	5	2	66.67
17	20	47	27	135
11	7	24	17	242.86
6		4		
8		7		
14	24			

Table S118: Average Difference in Direct Bilirubin (*µmol/l*).

Absolute Difference	
N	19
Mean	5.21
Median	2
Range	(0,27)
IQR	(1,6)
Percentage Change	
N	19
Mean	19.99
Median	0
Range	(-42.31,242.86)
IQR	(-21.43,41.67)

Figure S20 showed no discernible trend in the trend line, therefore any repeated measures analysis would be

futile.

Indirect Bilirubin

Table S119: Summary of indirect Bilirubin (*µmol/l*) between baseline and follow-up.

	Indirect Bilirubin (*µmol/l*)		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	19	19	17
Mean	8.16	8.26	-0.29
Median	7	7	-1
Range	(2,23)	(1,19)	(-6,7)
IQR	(5,10.5)	(5,11.5)	(-3,3)

Table S120: Patient level change in indirect Bilirubin.

	Indirect Bilirubin (*µmol/l*)			
Patient Number	**Visit 3 (pre-infusion)**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
12	7	3	4	-57.14
7	2	1	1	-50
1	13	7	6	-46.15
19	5	3	2	-40
20	5	3	2	-40
18	8	5	3	-37.5
4	14	9	5	-35.71
5	10	8	2	-20
9	23	19	4	-17.39
16	14	13	1	-7.14
11	11	14	3	27.27
13	9	12	3	33.33
3	5	7	2	40
21	3	5	2	66.67
22	9	16	7	77.78
17	6	11	5	83.33
2	3	6	3	100
6		10		
8				
14	5	5		
15	3			
23				

Table S121: Average Difference in Indirect Bilirubin (*µmol/l*).

Absolute Difference	
N	17
Mean	3.24
Median	3
Range	(1,7)
IQR	(2,4)
Percentage Change	
N	17
Mean	4.55
Median	-17.39
Range	(-57.14,100)
IQR	(-40,40)

Figure S20 showed no discernible trend in the trend line, therefore any repeated measures analysis would be inappropriate.

INR

Table S122: Summary of INR between baseline and follow-up.

	INR		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	22	22	22
Mean	1.01	1	0
Median	1	1	0
Range	(0.9,1.2)	(0.8,1.2)	(-0.1,0.1)
IQR	(1,1)	(1,1.075)	(0,0)

Table S123: Patient level change in INR.

Patient Number	INR		Absolute Difference	Percentage change (%)
	Visit 3 (pre-infusion)	Follow-up Visit 10		
15	0.9	0.8	0.1	-11.11
3	1.0	0.9	0.1	-10.00
6	1.0	0.9	0.1	-10.00
18	1.0	0.9	0.1	-10.00
1	1.1	1.1	0.0	0.00
2	1.0	1.0	0.0	0.00
4	1.1	1.1	0.0	0.00
5	1.0	1.0	0.0	0.00
8	1.0	1.0	0.0	0.00
9	1.2	1.2	0.0	0.00
11	1.0	1.0	0.0	0.00
12	1.1	1.1	0.0	0.00
13	1.0	1.0	0.0	0.00
16	1.0	1.0	0.0	0.00
19	0.9	0.9	0.0	0.00
20	1.0	1.0	0.0	0.00
21	1.0	1.0	0.0	0.00
22	1.1	1.1	0.0	0.00
23	1.0	1.0	0.0	0.00
7	1.0	1.1	0.1	10.00
14	0.9	1.0	0.1	11.11
17	0.9	1.0	0.1	11.11

Table S124: Average Difference of INR.

Absolute Difference	
N	22
Mean	0.03
Median	0
Range	(0,0.1)
IQR	(0,0.1)
Percentage Change	
N	22
Mean	-0.4
Median	0
Range	(-11.11,11.11)
IQR	(0,0)

Figure S20 showed no discernible trend in the trend line, therefore any repeated measures analysis would be

futile.

D.10.13 Model for End Stage Liver Disease (MELD)

Table S125: Summary of MELD score between screening and follow-up.

	MELD Score		
	Screening Visit 2	Follow-up Visit 10	Difference
N	22	21	21
Mean	8.05	7.81	-0.24
Median	7	7	0
Range	(6,12)	(5,11)	(-3,5)
IQR	(6,10)	(6,8)	(-1,0)

Table S126: Patient level change in MELD Score.

	MELD Score			
Patient Number	Screening Visit 2	Follow-up Visit 10	Absolute Difference	Percentage change (%)
15	10	7	3	-30
2	10	8	2	-20
5	10	8	2	-20
3	6	5	1	-16.67
6	7	6	1	-14.29
13	9	8	1	-11.11
23	9	8	1	-11.11
4	12	11	1	-8.33
1	7	7	0	0
8	6	6	0	0
9	11	11	0	0
12	7	7	0	0
16	10	10	0	0
17	11	11	0	0
18	6	6	0	0
19	6	6	0	0
20	6	6	0	0
21	7	7	0	0
22	7	8	1	14.29
7	6	7	1	16.67
11	6	11	5	83.33
14	8			

Table S127: Average Difference in MELD score.

Absolute Difference	
N	21
Mean	0.9
Median	1
Range	(0,5)
IQR	(0,1)
Percentage Change	
N	21
Mean	-0.82
Median	0
Range	(-30,83.33)
IQR	(-11.11,0)



Figure S22: Repeated measures plot of Model for End Stage Liver Disease (MELD) score for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

D.10.14 Mayo PSC Risk Score

Table S128: Patient level change in Mayo Score.

Patient Number	Mayo Score		Absolute Difference	Percentage change (%)
	Screening Visit 2	Follow-up Visit 10		
19	0.06	0.3088	0.25	390.16
17	0.68	1.0723	0.4	58.58
8	0.24	0.3036	0.06	23.92
20	1.08	1.3158	0.24	22.16
22	0.82	0.9582	0.13	16.17
9	2.68	2.836	0.16	5.86
12	0.64	0.6473	0.01	1.76
13	1.68	1.5989	0.08	-4.83
7	1.16	1.0997	0.06	-5.44
4	1.53	1.3712	0.16	-10.34
16	1.33	1.1811	0.15	-11.26
1	1.31	1.0682	0.24	-18.45
23	0.71	0.5402	0.17	-24.3
21	0.84	0.5462	0.3	-35.13
2	1.02	0.5971	0.42	-41.49
18	0.24	0.1203	0.12	-50.37
3	0.20	0.0645	0.13	-67.04
11	0.79	0.2049	0.58	-74.01
15	0.16	0.0356	0.12	-77.03
6	0.28	0.0239	0.25	-91.38
5	0.03			
14	0.59			

Table S129: Average Difference in Mayo PSC score.

Absolute Difference	
N	20
Mean	0.2
Median	0.16
Range	(0.01,0.58)
IQR	(0.12,0.25)
Percentage Change	
N	20
Mean	0.38
Median	-10.8
Range	(-91.38,390.16)
IQR	(-43.71,8.44)



Figure S23: Repeated measures plot of Mayo PSC risk score for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

D.10.15 PK Data

Trough BTT1023

Figure S24 shows a repeated measures plot of circulating BTT1023 levels in the mITT population over all time points where blood serum was collected. Figures S25 and S26 then subset this to just samples taken pre-infusion and at the end of infusion respectively.



Figure S24: Repeated measures plot of circulating BTT1023 levels in the mITT population over all time points. A loess smoother trend line has been added to aid the evaluation of any potential trend.



Figure S25: Repeated measures plot of circulating BTT1023 levels in the mITT population pre-infusion. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by shaded grey region.



Figure S26: Repeated measures plot of circulating BTT1023 levels in the mITT population at the end of infusion. A mean loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Table S130 presents descriptive statistics of the circulating BTT1023 levels (μg/mL) recorded at each treatment visit. The laboratory test has a lower limit of quantification (LLOQ = 104ng/mL = 0.104μg/mL) with results below this having thus been set to zero. Moreover, the laboratory test also has an upper limit of

quantification (ULQ). Results above the limit of quantification (ALQ) have been treated as missing.

Table S130: Descriptive statistics of circulating BTT1023 (μg/mL) across all treatment visits in the whole mITT population.

	Circulating BTT1023 (μg/mL)								
	Visit 3	**Visit 4**	**Visit 5**	**Visit 6**	**Visit 7**	**Visit 8**	**Visit 9**	**Visit 10**	**Visit 11**
N	11	10	10	10	10	8	9	8	8
Mean	0	6.22	5.39	8.81	9.22	26.84	31.08	5.02	0
Median	0	6.82	3.45	6.89	10.4	20.4	28.3	1.79	0
Range	(0,0)	(0.83,14.8)	(0,19.7)	(0,26)	(0,23.6)	(12.6,46.9)	(10.8,64.5)	(0,21)	(0,0)
IQR	(0,0)	(2.07,8.47)	(1.65,6.53)	(4.36,10.06)	(0,13.1)	(18.8,35.2)	(17.95,40.03)	(0.15,5.45)	(0,0)
ALQ (n)	1	3	0	0	1	1	1	0	0

Note:

ALQ(n) indicates the number of patients whose circulating BTT1023 levels were above the level of quantification.

Table S131 shows descriptive analyses of the trough BTT1023 levels at visit 3 (pre-infusion) and follow-up visit 10. Table S132 shows patient level changes and table S133 shows the average difference in trough BTT1023.

Table S131: Summary of circulating BTT1023 (μg/mL) at visit 3 (pre-infusion) and follow-up visit 10.

	Circulating BTT1023 (μg/mL)		
	Visit 3	**Visit 10**	**Difference**
N	11	8	7
Mean	0	5.02	5.53
Median	0	1.79	2.12
Range	(0,0)	(0,21)	(0,21)
IQR	(0,0)	(0.15,5.45)	(0.1005,7.7)
ALQ (n)	1	0	

Note:

ALQ(n) indicates the number of patients whose circulating BTT1023 levels were above the level of quantification.

Table S132: Patient level change in trough BTT1023 (μg/mL)

	Circulating BTT1023 (μg/mL)			
Patient Number	**Visit 3 (pre-infusion)**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
1	0	3.2	3.2	Inf
3	0	12.2	12.2	Inf
4	0	0.201	0.201	Inf
5	0	2.12	2.12	Inf
7	0	21	21	Inf
6		1.46		
8	0			
9	0			
13	0			
2	0	0	0	
11	0	0	0	

Table S133: Average difference in trough BTT1023 (μg/mL) .

Absolute Difference	
N	7
Mean	5.53
Median	2.12
Range	(0,21)
IQR	(0.1005,7.7)

Anti-Drug Antibodies

The Anti-Drug Antibodies (ADA) are categorised as either:

- negative,
- non-specific, or
- specific.

Table S134 shows a descriptive summary of the ADA, while table S135 gives a patient line listing of ADA category at each trial visit.

Table S134: Summary of Anti-Drug Antibodies (ADA) at trial visits in the mITT.

Result	**Visit 3; Pre-infusion**	**Visit 7; Pre-infusion**	**Visit 9; Pre-infusion**	**Visit 10; Follow-up**	**Visit 11; Follow-up**
Negative	20 (90.91%)	21 (100.00%)	20 (100.00%)	20 (90.91%)	15 (68.18%)
Non-specific	1 (4.55%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Specific	1 (4.55%)	0 (0.00%)	0 (0.00%)	2 (9.09%)	7 (31.82%)
Total	**22 (100.00%)**	**21 (100.00%)**	**20 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**

Table S135: Patient line listing of Anti-Drug Antibodies (ADA) at visit 3 (pre-infusion) and visit 11 (follow-up)

	ADA	
Patient Number	**Visit 3 (pre-infusion)**	**Follow-up Visit 10**
1	Negative	Negative
2	Non-specific	Specific
3	Specific	Negative
4	Negative	Specific
5	Negative	Negative
6	Negative	Negative
7	Negative	Negative
8	Negative	Negative
9	Negative	Negative
11	Negative	Negative
12	Negative	Negative
13	Negative	Negative
14	Negative	Negative
15	Negative	Negative
16	Negative	Negative
17	Negative	Negative
18	Negative	Negative
19	Negative	Negative
20	Negative	Negative
21	Negative	Negative
22	Negative	Negative
23	Negative	Negative

Figure S27 presents a repeated measures plot of the ADA category.



Figure S27: Repeated measures plot of Anti-Drug Antibodies (ADA)s in the mITT population with loess smoother trend line.

Due to the categorical nature of the ADA results, no repeated measures analyses have been performed.

PD: sVAP-1 as an protein

Table S136 presents descriptive statistics of pharmacodynamic (PD) sVAP-1 levels (ng/mL) recorded at each

treatment visit. The laboratory test has a lower limit of quantification (LLOQ = 0.5ng/mL) with results below this having thus been set to zero. Moreover, the laboratory test also has an upper limit of quantification. Results above the limit of quantification (ALQ) have been treated as missing.

Table S136: Descriptive statistics of sVAP-1 (ng/mL) pre-infusion across all treatment visits in the whole mITT population.

	sVAP-1 (ng/mL)								
	Visit 3	**Visit 4**	**Visit 5**	**Visit 6**	**Visit 7**	**Visit 8**	**Visit 9**	**Visit 10**	**Visit 11**
N	22	20	21	21	21	20	20	22	21
Mean	348.84	1.49	5.83	5.53	1.1	6.96	0.78	25.47	114.02
Median	350	1.26	1.56	1.14	0.5	0.5	0.5	0.75	103
Range	(0.5,582)	(0.5,6.41)	(0.5,33.6)	(0.5,76.7)	(0.5,6.56)	(0.5,117)	(0.5,5.44)	(0.5,287)	(52.4,301)
IQR	(293.5,406.75)	(0.88,1.44)	(1.09,2.87)	(0.5,1.73)	(0.5,1.07)	(0.5,1.15)	(0.5,0.5)	(0.5,5.88)	(74.3,124)
ALQ (n)	0	0	0	0	0	0	0	0	0

Note:

ALQ(n) indicates the number of patients whose sVAP-1 levels were above the level of quantification.

Table S137 shows descriptive analyses of sVAP-1 levels at visit 3 (pre-infusion) and follow-up visit 10. Table S138 shows patient level changes and table S139 shows the average difference in sVAP-1.

Table S137: Summary of sVAP-1 (ng/mL) at visit 3 (pre-infusion) and follow-up visit 10.

	sVAP-1 (ng/mL)		
	Visit 3	**Visit 10**	**Difference**
N	22	22	22
Mean	348.84	25.47	-323.37
Median	350	0.75	-336
Range	(0.5,582)	(0.5,287)	(-581.5,0.91)
IQR	(293.5,406.75)	(0.5,5.88)	(-382.875,-253.325)
ALQ (n)	0	0	

Note:

ALQ(n) indicates the number of patients whose sVAP-1 levels were above the level of quantification.

Table S138: Patient level change in sVAP-1 (ng/mL)

Patient Number	sVAP-1 (ng/mL) Visit 3 (pre-infusion)	sVAP-1 (ng/mL) Follow-up Visit 10	Absolute Difference	Percentage change (%)
23	582.0	0.50	581.50	-99.91
19	413.0	0.50	412.50	-99.88
9	388.0	0.50	387.50	-99.87
21	358.0	0.50	357.50	-99.86
8	342.0	0.50	341.50	-99.85
3	331.0	0.50	330.50	-99.85
18	295.0	0.50	294.50	-99.83
20	293.0	0.50	292.50	-99.83
1	246.0	0.50	245.50	-99.80
5	219.0	0.50	218.50	-99.77
7	215.0	0.50	214.50	-99.77
15	370.0	1.00	369.00	-99.73
17	511.0	1.42	509.58	-99.72
14	310.0	1.01	308.99	-99.67
12	363.0	1.34	361.66	-99.63
16	556.0	7.36	548.64	-98.68
11	309.0	32.20	276.80	-89.58
4	420.0	63.00	357.00	-85.00
13	261.0	46.20	214.80	-82.30
22	517.0	113.00	404.00	-78.14
2	375.0	287.00	88.00	-23.47
6	0.5	1.41	0.91	182.00

Table S139: Average Difference in sVAP-1 (ng/mL).

Absolute Difference	
N	22
Mean	323.45
Median	336
Range	(0.91,581.5)
IQR	(253.325,382.875)
Percentage Change	
N	22
Mean	-80.55
Median	-99.75
Range	(-99.9141,182)
IQR	(-99.8443,-91.8536)

Figure S28 shows a repeated measures plot of sVAP-1 levels in the mITT population pre-infusion.



Figure S28: Repeated measures plot of sVAP-1 (ng/mL) in the mITT population at the end of infusion.

D.10.13 Liver MultiScan MRI Data

The raw Liver MultiScan MRI data was sent to Perspectum Diagnostics, with them forwarding the results of the completed CRF back to CRCTU. Patients had a scan pre-therapy (at screening visit 1) and post-therapy (at follow up visit 11).

The following variables are derived from the Liver MultiScan MRI are analysed:

- $T2^*$ (ms, informs about the iron status),
- Estimated Liver Iron (mg/g),
- cT1 (ms, informs about fibrosis and/or inflammation),
- T1 (ms),
- Fat percentage (%),
- LIF.

For each variable derived from the Liver MultiScan MRI test as described above, μ, the following calculations are made: The difference is calculated as

$$\text{Difference} = \mu_{\text{Follow-up Visit 11}} - \mu_{\text{Screening Visit 1}} \tag{24}$$

and the percentage change is calculated as

$$\text{Percentage change} = \frac{\mu_{\text{Follow-up Visit 11}} - \mu_{\text{Screening Visit 1}}}{\mu_{\text{Screening Visit 1}}} \tag{25}$$

In total 12 patients had Liver MultiScan tests.

All tests were performed using a 'Verio' scanner manufactured by SIEMENS of Magnetic Field Strength 3. All Molli software was the same (Siemens_561_3T). The Liver MultiScan was the same for all but one of the scans performed (23 scans used release-LMS-Discover-4.1.4, and one used release-LMS-Discover-4.2.1).

Since Liver MultiScan was only completed at screening visit 1 and follow-up visit 11, any repeated measures analysis would be inappropriate, and therefore has not been completed for any of the derived variables.

D.10.14 ROI Analysis: $T2^*$

The following analysis is applicable to the region of interest (ROI), the liver. For ROI analyses for T2* for all patients at all time points, 3 ROI's were pooled together. All had the same ROI size of 168 mm^2 and same diameter of 15mm.

ROI pooled median (ms)

Table S140 presents descriptive analyses of the pooled T2* median in the ROI at screening visit 1, follow-up visit 11, and the difference between them. Table S141 then shows the patient level absolute difference and percentage change in the pooled T2* median in the ROI; table S142 shows summary measures pooled across the whole mITT population.

Table S140: Summary of Liver MultiScan T2* Measurement: pooled median (ms).

	Pooled T2* median (ms)		
	Screening Visit 1	Follow-up Visit 11	Difference
N	12	12	12
Mean	24.57	25.35	0.78
Median	24.24	26.62	-0.12
Range	(14.67,35.98)	(15.07,35.91)	(-3.81,8.34)
IQR	(21.79,26.83)	(22.6,27.72)	(-1.05,2.52)

Table S141: Patient level changes in T2* pooled median (ms).

	Pooled T2* median (ms)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
7	23.34	19.53	3.81	-16.34
20	21.83	18.84	2.98	-13.67
1	26.53	25.20	1.32	-4.99
15	28.46	27.51	0.96	-3.37
8	26.67	26.11	0.56	-2.11
2	27.30	27.14	0.16	-0.60
5	35.98	35.91	0.07	-0.20
3	14.67	15.07	0.40	2.72
21	21.66	23.63	1.97	9.09
17	25.15	29.48	4.33	17.23
4	23.23	27.39	4.16	17.93
14	20.01	28.36	8.34	41.69

Table S142: Average Difference in Pooled T2* Median (ms).

Absolute Difference	
N	12
Mean	2.42
Median	1.65
Range	(0.07,8.34)
IQR	(0.52,3.9)
Percentage Change	
N	12
Mean	4
Median	-0.5
Range	(-16,42)
IQR	(-3.5,11)

Figure S29 shows a repeated measures plot of the Liver MultiScan T2* pooled median measurement with loess smoother trend line to help evaluate any potential trend in scores.



Figure S29: Repeated measures plot of Liver MultiScan measurement pooled T2* median (ms) for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Quantile 1

Table S143 presents descriptive analyses of the pooled T2* lower quantile (25%) in the ROI at screening visit 1, follow-up visit 11, and the difference between them. Table S144 then shows the patient level absolute

difference and percentage change in the pooled T2* at quantile 1 in the ROI; table S145 shows summary measures pooled across the whole mITT population.

Table S143: Summary of Liver MultiScan T2* Measurement: pooled Q1 (ms).

	Pooled T2* Q1 (ms)		
	Screening Visit 1	Follow-up Visit 11	Difference
N	12	12	12
Mean	22.82	23.43	0.6
Median	22.76	24.8	0.25
Range	(13.15,34.44)	(13.54,32.6)	(-3.51,6.86)
IQR	(20.35,25.27)	(20.91,25.87)	(-1.89,2.52)

Table S144: Patient level changes in T2* pooled Q1 (ms).

	Pooled T2* Q1 (ms)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
20	20.58	17.21	3.37	-16.36
7	22.06	18.55	3.51	-15.90
1	25.22	23.18	2.05	-8.11
5	34.44	32.60	1.83	-5.33
15	26.48	25.85	0.63	-2.38
2	25.42	25.53	0.11	0.42
3	13.15	13.54	0.39	2.96
8	23.64	24.76	1.12	4.74
21	19.67	21.69	2.02	10.28
17	23.47	27.49	4.02	17.11
4	20.71	24.83	4.12	19.91
14	19.05	25.91	6.86	36.02

Table S145: Average Difference in Pooled T2* Q1 (ms).

Absolute Difference	
N	12
Mean	2.5
Median	2.03
Range	(0.11,6.86)
IQR	(1,3.63)
Percentage Change	
N	12
Mean	3.67
Median	1.5
Range	(-16,36)
IQR	(-5.75,11.75)

Quantile 3

Table S146 presents descriptive analyses of the pooled T2* upper quantile (75%) in the ROI at screening visit 1, follow-up visit 11, and the difference between them. Table S147 then shows the patient level absolute difference and percentage change in the pooled T2* at quantile 3 in the ROI; table S148 shows summary measures pooled across the whole mITT population.

Table S146: Summary of Liver MultiScan T2* Measurement: pooled Q3 (ms).

	Pooled T2* Q3 (ms)		
	Screening Visit 1	Follow-up Visit 11	Difference
N	12	12	12
Mean	26.62	27.36	0.74
Median	26.79	28.35	-0.16
Range	(16.51,38.38)	(16.44,38.62)	(-3.61,9.67)
IQR	(24.05,29.09)	(24.31,30.39)	(-1.34,1.45)

Table S147: Patient level changes in T2* pooled Q3 (ms).

	Pooled T2* Q3 (ms)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
7	24.29	20.68	3.61	-14.86
20	23.31	20.66	2.65	-11.38
1	28.33	26.83	1.51	-5.32
8	29.16	27.88	1.28	-4.40
15	30.39	29.85	0.54	-1.77
2	29.06	28.81	0.25	-0.86
3	16.51	16.44	0.07	-0.42
5	38.38	38.62	0.23	0.61
21	24.63	25.51	0.89	3.60
17	28.42	31.56	3.13	11.03
4	25.24	30.05	4.81	19.04
14	21.73	31.40	9.67	44.50

Table S148: Average Difference in Pooled T2* Q3 (ms).

Absolute Difference	
N	12
Mean	2.39
Median	1.4
Range	(0.07,9.67)
IQR	(0.47,3.25)
Percentage Change	
N	12
Mean	3.42
Median	-0.5
Range	(-15,44)
IQR	(-4.25,5.75)

Figure S30 shows a repeated measures plot of the Liver MultiScan T2* pooled median measurement with error bars depicting quantile 1 to quantile 3.



Figure S30: Repeated measures plot of Liver MultiScan measurement pooled T2* median (ms) with error bars showing quantile 1 to quantile 3.

D.10.15 ROI Analysis: Estimated Liver Iron

The following analysis is applicable to the ROI, the liver. The normal range of estimate liver iron is <1.8mg/g.

ROI pooled median (mg/g)

Table S149 presents descriptive analyses of the pooled estimated liver iron median in the ROI at screening visit 1, follow-up visit 11, and the difference between them. Table S150 then shows the patient level absolute difference and percentage change in the pooled estimated liver iron median in the ROI; table S151 shows summary measures pooled across the whole mITT population.

Table S149: Summary of Liver MultiScan Estimated Liver Iron Measurement: pooled median (mg/g).

	Pooled Estimated Liver Iron median (mg/g)		
	Screening Visit 1	**Follow-up Visit 11**	**Difference**
N	12	12	12
Mean	1.19	1.17	-0.01
Median	1.17	1.12	0
Range	(1,1.51)	(1,1.49)	(-0.19,0.11)
IQR	(1.12,1.23)	(1.1,1.21)	(-0.06,0.02)

Table S150: Patient level changes in estimated liver iron pooled median (mg/g).

	Pooled Estimated Liver Iron median (mg/g)			
Patient Number	**Screening Visit 1**	**Follow-up Visit 11**	**Absolute Difference**	**Percentage change (%)**
14	1.28	1.09	0.19	-14.58
4	1.19	1.11	0.08	-6.97
17	1.15	1.08	0.07	-6.45
21	1.23	1.18	0.05	-3.96
3	1.51	1.49	0.02	-1.52
5	1.00	1.00	0.00	0.07
2	1.11	1.11	0.00	0.25
8	1.12	1.13	0.01	0.92
15	1.09	1.11	0.02	1.42
1	1.13	1.15	0.03	2.24
20	1.23	1.32	0.09	7.50
7	1.19	1.30	0.11	8.93

Table S151: Average Difference in Pooled Estimated Liver Iron Median (mg/g).

Absolute Difference	
N	12
Mean	0.06
Median	0.04
Range	(0,0.19)
IQR	(0.01,0.09)
Percentage Change	
N	12
Mean	-1.17
Median	0
Range	(-15,9)
IQR	(-4.5,1.25)

Figure S31 shows a repeated measures plot of the Liver MultiScan estimated liver iron pooled median measurement with loess smoother trend line to help evaluate any potential trend in scores.



Figure S31: Repeated measures plot of Liver MultiScan measurement pooled estimated liver iron* median (mg/g) for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Quantile 1 (mg/g)

Table S152 presents descriptive analyses of the pooled estimated liver iron lower quantile (25%) in the ROI at screening visit 1, follow-up visit 11, and the difference between them. Table S153 then shows the patient

level absolute difference and percentage change in the pooled T1 at quantile 1 in the ROI; table S154 shows summary measures pooled across the whole mITT population.

Table S152: Summary of Liver MultiScan Estimated Liver Iron Measurement: pooled Q1 (mg/g).

	Pooled Estimated Liver Iron Q1 (mg/g)		
	Screening Visit 1	Follow-up Visit 11	Difference
N	12	12	12
Mean	1.14	1.13	-0.01
Median	1.12	1.09	0
Range	(0.98,1.42)	(0.98,1.42)	(-0.18,0.09)
IQR	(1.08,1.17)	(1.06,1.17)	(-0.02,0.02)

Table S153: Patient level changes in estimated liver iron pooled Q1 (mg/g).

	Pooled estimated liver iron Q1 (mg/g)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
14	1.23	1.05	0.18	-14.62
4	1.15	1.07	0.08	-7.00
17	1.09	1.05	0.04	-4.06
21	1.16	1.14	0.02	-1.54
5	0.98	0.98	0.00	-0.21
3	1.42	1.42	0.00	0.23
2	1.08	1.09	0.00	0.35
15	1.06	1.07	0.01	0.71
8	1.08	1.10	0.02	1.85
1	1.09	1.12	0.03	2.30
20	1.19	1.26	0.07	5.87
7	1.17	1.26	0.09	7.81

Table S154: Average Difference in Pooled Estimated Liver Iron Q1 (mg/g).

Absolute Difference	
N	12
Mean	0.05
Median	0.02
Range	(0,0.18)
IQR	(0.01,0.07)
Percentage Change	
N	12
Mean	-0.75
Median	0
Range	(-15,8)
IQR	(-2.5,2)

Quantile 3

Table S155 presents descriptive analyses of the pooled estimated liver iron upper quantile (75%) in the ROI at screening visit 1, follow-up visit 11, and the difference between them. Table S156 then shows the patient level absolute difference and percentage change in the pooled T1 at quantile 3 in the ROI; table S157 shows summary measures pooled across the whole mITT population.

Table S155: Summary of Liver MultiScan Estimated Liver Iron Measurement: pooled Q3 (mg/g).

	Pooled Estimated Liver Iron Q3 (mg/g)		
	Screening Visit 1	Follow-up Visit 11	Difference
N	12	12	12
Mean	1.23	1.22	-0.01
Median	1.2	1.16	-0.01
Range	(1.02,1.61)	(1.04,1.58)	(-0.18,0.12)
IQR	(1.15,1.27)	(1.14,1.26)	(-0.06,0.03)

Table S156: Patient level changes in estimated liver iron pooled Q3 (mg/g).

	Pooled Estimated Liver Iron Q3 (mg/g)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
14	1.31	1.14	0.18	-13.44
4	1.26	1.16	0.10	-8.08
17	1.19	1.11	0.08	-6.66
21	1.29	1.23	0.06	-4.66
8	1.18	1.16	0.02	-2.05
3	1.61	1.58	0.03	-1.72
2	1.15	1.14	0.00	-0.18
15	1.13	1.14	0.01	1.04
5	1.02	1.04	0.02	2.04
1	1.15	1.19	0.04	3.86
7	1.22	1.33	0.11	8.90
20	1.26	1.38	0.12	9.55

Table S157: Average Difference in Pooled Estimated Liver Iron Q3 (mg/g).

Absolute Difference	
N	12
Mean	0.06
Median	0.05
Range	(0,0.18)
IQR	(0.02,0.1)
Percentage Change	
N	12
Mean	-0.92
Median	-1
Range	(-13,10)
IQR	(-5.5,2.5)

Figure S32 shows a repeated measures plot of the Liver MultiScan Estimated Liver Iron pooled median measurement with error bars depicting quantile 1 to quantile 3.



Figure S32: Repeated measures plot of Liver MultiScan measurement pooled Estimated Liver Iron median (mg/g) with error bars showing quantile 1 to quantile 3.

D.10.16 ROI Analysis: cT1

The following analysis is applicable to the ROI, the liver.

ROI pooled mean (ms)

Table S158 presents descriptive analyses of the pooled cT1 mean in the ROI at screening visit 1, follow-up visit 11, and the difference between them. Table S159 then shows the patient level absolute difference and percentage change in the pooled cT1 mean in the ROI; table S160 shows summary measures pooled across the whole mITT population.

Table S158: Summary of Liver MultiScan cT1 Measurement: pooled mean (ms).

	Pooled cT1 mean (ms)		
	Screening Visit 1	**Follow-up Visit 11**	**Difference**
N	12	12	11
Mean	809.3	835.8	18.15
Median	810.14	780.9	25.07
Range	(610.45,1095.32)	(720.78,1105.15)	(-150.48,140.37)
IQR	(733.41,855.84)	(749.17,896.79)	(-13.54,75.07)

Table S159: Patient level changes in cT1 pooled mean (ms).

	Pooled cT1 mean (ms)			
Patient Number	**Screening Visit 1**	**Follow-up Visit 11**	**Absolute Difference**	**Percentage change (%)**
8	921.40	770.92	150.48	-16.33
1	827.31	747.52	79.79	-9.64
20	757.69	720.78	36.91	-4.87
4	1095.32	1105.15	9.83	0.9
5	930.95	941.2	10.25	1.1
21	823.21	848.28	25.07	3.05
15	738.73	780.9	42.17	5.71
17	833.98	907.48	73.5	8.81
7	797.07	886.1	89.03	11.17
3	658.05	734.7	76.65	11.65
14	610.45	750.82	140.37	23
2	717.47			

Table S160: Average Difference in Pooled cT1 Mean (ms).

Absolute Difference	
N	11
Mean	66.73
Median	73.49
Range	(9.83,150.48)
IQR	(30.99,84.41)
Percentage Change	
N	11
Mean	3.18
Median	3
Range	(-16,23)
IQR	(-2,10)

Figure S33 shows a repeated measures plot of the Liver MultiScan cT1 pooled mean measurement with loess smoother trend line to help evaluate any potential trend in scores.



Figure S33: Repeated measures plot of Liver MultiScan measurement cT1 pooled mean (ms) for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Standard deviation (ms)

Table S161 presents descriptive analyses of the pooled cT1 standard deviation in the ROI at screening visit 1, follow-up visit 11, and the difference between them. Table S162 then shows the patient level absolute

difference and percentage change in the pooled cT1 standard deviation in the ROI; table S163 shows summary measures pooled across the whole mITT population.

Table S161: Summary of Liver MultiScan cT1 Measurement: pooled standard deviation (ms).

	Pooled cT1 standard deviation (ms)		
	Screening Visit 1	Follow-up Visit 11	Difference
N	12	12	11
Mean	49.96	44.93	-6.66
Median	38.31	32.26	-3.82
Range	(28.26,138.77)	(28.83,134.87)	(-36.18,7.24)
IQR	(33.9,54.5)	(29.66,36.64)	(-8.4,0.18)

Table S162: Patient level changes in cT1 pooled standard deviation (ms).

	Pooled cT1 standard deviation (ms)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
3	65.05	28.87	36.18	-55.62
8	50.98	33.69	17.29	-33.92
15	38.37	29.38	8.99	-23.44
1	38.25	30.44	7.81	-20.41
14	33.77	29.95	3.82	-11.3
5	35.88	32.26	3.62	-10.09
17	138.77	134.87	3.9	-2.81
20	38.77	38.55	0.22	-0.56
7	28.26	28.83	0.57	2.02
21	33.95	34.73	0.78	2.3
4	65.39	72.64	7.25	11.08
2	32.08			

Table S163: Average Difference in Pooled cT1 standard deviation (ms).

Absolute Difference	
N	11
Mean	8.22
Median	3.9
Range	(0.21,36.18)
IQR	(2.2,8.4)
Percentage Change	
N	11
Mean	-13
Median	-10
Range	(-56,11)
IQR	(-21.5,0.5)

Figure S34 shows a repeated measures plot of the Liver MultiScan cT1 pooled mean measurement with error bars depicting ± 1 standard deviation.



Figure S34: Repeated measures plot of Liver MultiScan measurement pooled cT1 mean (ms) with error bars showing ± 1 standard deviation.

D.10.20 ROI Analysis: T1

The following analysis is applicable to the ROI, the liver.

ROI pooled mean (ms)

Table S164 presents descriptive analyses of the pooled T1 mean in the ROI at screening visit 1, follow-up visit 11, and the difference between them. Table S165 then shows the patient level absolute difference and percentage change in the pooled T1 mean in the ROI; table S166 shows summary measures pooled across the whole mITT population.

Table S164: Summary of Liver MultiScan T1 Measurement: pooled mean (ms).

	Pooled T1 mean (ms)		
	Screening Visit 1	Follow-up Visit 11	Difference
N	12	12	11
Mean	807.72	831.74	15.85
Median	810.37	781.14	25.06
Range	(610.95,1095.53)	(691.67,1105.35)	(-150.45,140.11)
IQR	(733.68,856.09)	(749.41,897.02)	(-15.52,64.49)

Table S165: Patient level changes in T1 pooled mean (ms).

	Pooled T1 mean (ms)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
8	921.62	771.17	150.45	-16.32
1	827.52	747.77	79.75	-9.64
20	757.94	717.08	40.86	-5.39
4	1095.53	1105.35	9.82	0.9
5	931.16	941.42	10.26	1.1
21	823.43	848.49	25.06	3.04
15	738.99	781.14	42.15	5.7
3	636.15	691.67	55.52	8.73
17	834.25	907.71	73.46	8.81
7	797.31	886.33	89.02	11.17
14	610.95	751.06	140.11	22.93
2	717.75			

Table S166: Average Difference in Pooled T1 Mean (ms).

Absolute Difference	
N	11
Mean	65.13
Median	55.52
Range	(9.82,150.45)
IQR	(32.96,84.39)
Percentage Change	
N	11
Mean	2.91
Median	3
Range	(-16,23)
IQR	(-2,9)

Figure S35 shows a repeated measures plot of the Liver MultiScan T1 pooled mean measurement with loess smoother trend line to help evaluate any potential trend in scores.



Figure S35: Repeated measures plot of Liver MultiScan measurement pooled T1 mean (ms) for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Standard deviation (ms)

Table S167 presents descriptive analyses of the pooled T1 standard deviation in the ROI at screening visit 1, follow-up visit 11, and the difference between them. Table S168 then shows the patient level absolute

difference and percentage change in the pooled T1 standard deviation in the ROI; table S169 shows summary measures pooled across the whole mITT population.

Table S167: Summary of Liver MultiScan T1 Measurement: pooled standard deviation (ms).

	Pooled T1 standard deviation (ms)		
	Screening Visit 1	Follow-up Visit 11	Difference
N	12	12	11
Mean	48.29	44.5	-5.27
Median	38.28	32.27	-3.82
Range	(28.25,138.71)	(25.27,134.86)	(-19.94,7.25)
IQR	(33.89,46.66)	(29.65,36.08)	(-8.39,-0.36)

Table S168: Patient level changes in T1 pooled standard deviation (ms).

	Pooled T1 standard deviation (ms)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
3	45.22	25.27	19.95	-44.12
8	50.97	33.68	17.29	-33.93
15	38.33	29.36	8.97	-23.4
1	38.23	30.43	7.8	-20.41
14	33.76	29.95	3.81	-11.3
5	35.87	32.27	3.6	-10.04
20	38.75	37.45	1.3	-3.36
17	138.71	134.86	3.85	-2.78
7	28.25	28.83	0.58	2.07
21	33.93	34.72	0.79	2.32
4	65.41	72.65	7.24	11.07
2	32.03			

Table S169: Average Difference in Pooled T1 standard deviation (ms).

Absolute Difference	
N	11
Mean	6.84
Median	3.85
Range	(0.58,19.94)
IQR	(2.46,8.39)
Percentage Change	
N	11
Mean	-12.09
Median	-10
Range	(-44,11)
IQR	(-21.5,-0.5)

Figure S36 shows a repeated measures plot of the Liver MultiScan T1 pooled mean measurement with error bars depicting ± 1 standard deviation.



Figure S36: Repeated measures plot of Liver MultiScan measurement pooled T1 mean (ms) with error bars showing ± 1 standard deviation.

D.10.21 ROI Analysis: Fat Percentage

The following analysis is applicable to the ROI, the liver. The normal range of fat percentage <5.6%. For each patient at both timepoints, the forthcoming analysis represents the pool of 3 ROIs. Table S170 shows the size (mm^2) of the ROI for fat percentage analysis, while figure S37 shows a plot of the fat percentage ROI size (mm^2) over both time points. For all patients, at both time points the ROI had diameter 15mm.

Table S170: Patient level fat percentage ROI sizes (mm^2).

	fat percentage ROI size (mm^2)	
Patient Number	**Screening Visit 1**	**Follow-up Visit 11**
1	105.79	117.19
2	99.28	119.63
3	114.75	117.19
4	126.95	108.24
5	146.48	133.46
7	106.61	144.04
8	113.12	109.86
14	117.19	99.28
15	168.46	168.46
17	135.09	109.86
20	130.21	135.90
21	109.05	106.61



Figure S37: Repeated measures plot of Liver MultiScan fat percentage ROI size (mm^2).

ROI pooled mean (%)

Table S171 presents descriptive analyses of the fat percentage pooled mean in the ROI at screening visit 1, follow-up visit 11, and the difference between them. Table S172 then shows the patient level absolute difference and percentage change in the fat percentage pooled mean in the ROI; table S173 shows summary measures

pooled across the whole mITT population.

Table S171: Summary of Liver MultiScan Fat Percentage Measurement: pooled mean (%).

	Fat percentage pooled mean (%)		
	Screening Visit 1	Follow-up Visit 11	Difference
N	12	12	12
Mean	1.76	1.58	-0.18
Median	1.71	1.26	-0.24
Range	(0.96,3.14)	(0.69,4.93)	(-1.35,1.79)
IQR	(1.36,2.04)	(0.99,1.78)	(-0.64,0.03)

Table S172: Patient level changes in fat percentage pooled mean (%).

	Fat percentage pooled mean (%)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
17	2.04	0.69	1.35	-66.26
14	1.57	0.80	0.77	-49.06
3	2.07	1.09	0.98	-47.21
8	1.47	0.88	0.60	-40.62
20	2.27	1.82	0.45	-19.65
4	1.86	1.56	0.29	-15.83
5	1.38	1.18	0.20	-14.19
2	1.12	1.03	0.09	-7.99
21	1.98	1.87	0.11	-5.66
1	1.29	1.76	0.47	36.61
7	0.96	1.34	0.39	40.43
15	3.14	4.93	1.79	57.06

Table S173: Average Difference in Fat Percentage Pooled Mean (%).

Absolute Difference	
N	12
Mean	0.62
Median	0.46
Range	(0.09,1.79)
IQR	(0.27,0.82)
Percentage Change	
N	12
Mean	-11.08
Median	-15
Range	(-66,57)
IQR	(-42.5,4.75)

Figure S38 shows a repeated measures plot of the Liver MultiScan fat percentage pooled mean measurement with loess smoother trend line to help evaluate any potential trend in scores.



Figure S38: Repeated measures plot of Liver MultiScan measurement fat percentage pooled mean (%) for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Standard deviation (%)

Table S174 presents descriptive analyses of the fat percentage pooled standard deviation in the ROI at screening visit 1, follow-up visit 11, and the difference between them. Table S175 then shows the patient level absolute difference and percentage change in the fat percentage pooled standard deviation in the ROI; table S176 shows summary measures pooled across the whole mITT population.

Table S174: Summary of Liver MultiScan Fat Percentage Measurement: pooled standard deviation (%).

	Fat percentage pooled standard deviation (%)		
	Screening Visit 1	**Follow-up Visit 11**	**Difference**
N	12	12	12
Mean	1.05	0.9	-0.15
Median	1.12	0.75	0
Range	(0.52,1.59)	(0.45,1.41)	(-1.02,0.55)
IQR	(0.8,1.26)	(0.58,1.28)	(-0.49,0.16)

Table S175: Patient level changes in fat percentage pooled standard deviation (%).

	Fat percentage pooled standard deviation (%)			
Patient Number	**Screening Visit 1**	**Follow-up Visit 11**	**Absolute Difference**	**Percentage change (%)**
17	1.47	0.45	1.02	-69.40
3	1.29	0.59	0.71	-54.71
14	1.13	0.57	0.56	-49.68
8	0.99	0.52	0.47	-47.66
20	1.59	1.31	0.28	-17.55
2	0.67	0.66	0.01	-1.53
4	1.10	1.10	0.01	0.51
21	1.13	1.26	0.13	11.35
15	1.25	1.41	0.16	12.65
5	0.60	0.76	0.16	25.96
7	0.52	0.74	0.22	41.17
1	0.84	1.39	0.55	64.98

Table S176: Average Difference in Fat Percentage Pooled standard deviation (%).

Absolute Difference	
N	12
Mean	0.36
Median	0.25
Range	(0.01,1.02)
IQR	(0.15,0.55)
Percentage Change	
N	12
Mean	-7.08
Median	-0.5
Range	(-69,65)
IQR	(-48.5,16.25)

Figure S39 shows a repeated measures plot of the Liver MultiScan fat percentage pooled mean measurement with error bars depicting ± 1 standard deviation.



Figure S39: Repeated measures plot of Liver MultiScan measurement fat percentage pooled mean (%) with error bars showing ±1 standard deviation.

D.10.22 ROI Analysis: LIF

The following analysis is applicable to the ROI, the liver.

ROI LIF

Table S177 presents descriptive analyses of LIF in the ROI at screening visit 1, follow-up visit 11, and the difference between them. Table S178 then shows the patient level absolute difference and percentage change in the LIF in the ROI; table S179 shows summary measures pooled across the whole mITT population.

Table S177: Summary of Liver MultiScan ROI LIF.

	ROI LIF		
	Screening Visit 1	Follow-up Visit 11	Difference
N	12	12	12
Mean	1.31	1.72	0.41
Median	1.14	1.26	0.31
Range	(0,3.42)	(0.47,4)	(-1.81,3.55)
IQR	(0.56,1.74)	(0.67,2.55)	(-0.04,0.75)

Table S178: Patient level changes in the ROI LIF.

	ROI LIF			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
8	2.62	0.81	1.81	-69.22
1	1.36	0.65	0.71	-52.34
20	0.72	0.47	0.25	-34.27
4	3.42	3.44	0.03	0.82
5	2.75	2.88	0.14	4.98
21	1.31	1.64	0.33	25.53
15	0.59	0.87	0.28	47.53
17	1.45	2.43	0.98	67.43
7	0.98	2.15	1.17	119.08
2	0.45	4.00	3.55	789.32
3	0.05	0.56	0.51	952.64
14	0.00	0.67	0.67	Inf

Table S179: Average Difference in ROI LIF.

Absolute Difference	
N	12
Mean	0.87
Median	0.59
Range	(0.03,3.55)
IQR	(0.27,1.03)
Percentage Change	
N	12
Mean	Inf
Median	37
Range	(-69,Inf)
IQR	(-7.75,286.5)

Figure S40 shows a repeated measures plot of the Liver MultiScan LIF in the ROI with loess smoother trend line to help evaluate any potential trend in scores.



Figure S40: Repeated measures plot of Liver MultiScan measurement pooled T1 mean (ms) for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

D.10.23 Whole Analysis: cT1

Whole sample mode (ms)

Table S180 presents descriptive analyses of the cT1 mode for the whole sample at screening visit 1, follow-up visit 11, and the difference between them. Table S181 then shows the patient level absolute difference and percentage change in the cT1 mode in the whole sample; table S182 shows summary measures pooled across the whole mITT population.

Table S180: Summary of Liver MultiScan cT1 Measurement: whole sample mode (ms).

	cT1 mode (ms)		
	Screening Visit 1	**Follow-up Visit 11**	**Difference**
N	12	12	12
Mean	775.67	793.92	18.25
Median	764.5	762.5	21.5
Range	(619,1045)	(683,1027)	(-73,102)
IQR	(688.25,824.5)	(719,849.75)	(-20.75,48.5)

Table S181: Patient level changes in cT1 whole sample mode (ms).

	cT1 mode (ms)			
Patient Number	**Screening Visit 1**	**Follow-up Visit 11**	**Absolute Difference**	**Percentage change (%)**
8	844	771	73	-8.65
1	802	738	64	-7.98
20	741	712	29	-3.91
4	1045	1027	18	-1.72
5	899	913	14	1.56
2	697	719	22	3.16
17	662	683	21	3.17
21	818	846	28	3.42
15	745	784	39	5.23
7	784	861	77	9.82
14	652	754	102	15.64
3	619	719	100	16.16

Table S182: Average Difference in cT1 Whole Sample Mode (ms).

Absolute Difference	
N	12
Mean	48.92
Median	34
Range	(14,102)
IQR	(21.75,74)
Percentage Change	
N	12
Mean	2.92
Median	3
Range	(-9,16)
IQR	(-2.5,6.25)

Figure S41 shows a repeated measures plot of the Liver MultiScan cT1 whole sample mode measurement with loess smoother trend line to help evaluate any potential trend in scores.



Figure S41: Repeated measures plot of Liver MultiScan measurement cT1 whole sample mode (ms) for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Whole sample mean (ms)

Table S183 presents descriptive analyses of the cT1 mean for the whole sample at screening visit 1, follow-up visit 11, and the difference between them. Table S184 then shows the patient level absolute difference and

percentage change in the cT1 mean in the whole sample; table S185 shows summary measures pooled across the whole mITT population.

Table S183: Summary of Liver MultiScan cT1 Measurement: whole sample mean (ms).

	cT1 mean (ms)		
	Screening Visit 1	Follow-up Visit 11	Difference
N	12	12	12
Mean	876.14	908.58	32.44
Median	859.39	879.83	29.64
Range	(746.3,1162.48)	(798.81,1163.81)	(-60.89,115.91)
IQR	(809.14,917.62)	(849.25,932.33)	(-3.34,71.86)

Table S184: Patient level changes in cT1 whole sample mean (ms).

	cT1 mean (ms)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
1	920.81	859.92	60.89	-6.61
8	916.56	895.00	21.56	-2.35
20	842.34	833.00	9.33	-1.11
2	800.16	798.81	1.34	-0.17
4	1162.48	1163.81	1.33	0.11
5	981.58	1001.61	20.03	2.04
21	887.35	926.59	39.25	4.42
15	817.21	864.67	47.45	5.81
7	876.45	945.16	68.70	7.84
3	750.29	831.63	81.33	10.84
17	812.14	928.05	115.91	14.27
14	746.30	854.67	108.37	14.52

Table S185: Average Difference in cT1 Whole Sample Mean (ms).

Absolute Difference	
N	12
Mean	47.96
Median	43.35
Range	(1.33,115.91)
IQR	(17.36,71.86)
Percentage Change	
N	12
Mean	4.17
Median	3
Range	(-7,15)
IQR	(-0.25,8.75)

Figure S42 shows a repeated measures plot of the Liver MultiScan cT1 whole sample mean measurement with loess smoother trend line to help evaluate any potential trend in scores.



Figure S42: Repeated measures plot of Liver MultiScan measurement cT1 whole sample mean (ms) for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Whole sample median (ms)

Table S186 presents descriptive analyses of the cT1 median for the whole sample at screening visit 1, follow-up visit 11, and the difference between them. Table S187 then shows the patient level absolute difference and percentage change in the cT1 median in the whole sample; table S188 shows summary measures pooled across the whole mITT population.

Table S186: Summary of Liver MultiScan cT1 Measurement: whole sample median (ms).

	cT1 median (ms)		
	Screening Visit 1	**Follow-up Visit 11**	**Difference**
N	12	12	12
Mean	811.54	838.43	26.9
Median	792.76	816.76	24.5
Range	(669,1092.3)	(741.25,1101.3)	(-60.01,110.26)
IQR	(722.5,849.78)	(771.9,877.54)	(0.4,52.25)

Table S187: Patient level changes in cT1 whole sample median (ms).

	cT1 median (ms)			
Patient Number	**Screening Visit 1**	**Follow-up Visit 11**	**Absolute Difference**	**Percentage change (%)**
1	842.28	782.27	60.01	-7.12
8	863.29	817.26	46.03	-5.33
20	775.26	749.84	25.42	-3.28
4	1092.30	1101.30	9.00	0.82
5	926.29	944.29	18.00	1.94
2	723.25	741.25	18.00	2.49
21	845.28	876.29	31.01	3.67
15	770.27	816.26	45.99	5.97
3	700.72	744.63	43.91	6.27
7	810.27	881.29	71.02	8.77
17	720.25	827.27	107.02	14.86
14	669.00	779.26	110.26	16.48

Table S188: Average Difference in cT1 Whole Sample Median (ms).

Absolute Difference	
N	12
Mean	48.81
Median	44.95
Range	(9,110.26)
IQR	(23.56,62.76)
Percentage Change	
N	12
Mean	3.83
Median	3
Range	(-7,16)
IQR	(0,6.75)

Figure S43 shows a repeated measures plot of the Liver MultiScan cT1 whole sample median measurement with loess smoother trend line to help evaluate any potential trend in scores.



Figure S43: Repeated measures plot of Liver MultiScan measurement cT1 whole sample median (ms) for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Whole sample Q1 (ms)

Table S189 presents descriptive analyses of the cT1 whole sample lower quantile (25%) at screening visit 1, follow-up visit 11, and the difference between them. Table S190 then shows the patient level absolute difference

and percentage change in the cT1 Q1 in the whole sample; table S191 shows summary measures pooled across the whole mITT population.

Table S189: Summary of Liver MultiScan cT1 Measurement: whole sample Q1 (ms).

	cT1 Q1 (ms)		
	Screening Visit 1	Follow-up Visit 11	Difference
N	12	12	12
Mean	760.18	787.13	26.95
Median	755.76	752.75	23.63
Range	(604,1012.3)	(700.25,1015.3)	(-62.01,115.26)
IQR	(675,806.51)	(720.15,835.28)	(-3.6,64.94)

Table S190: Patient level changes in cT1 whole sample Q1 (ms).

	cT1 Q1 (ms)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
1	800.26	738.25	62.01	-7.75
8	813.27	761.25	52.02	-6.40
20	731.26	707.84	23.42	-3.20
4	1012.30	1015.30	3.00	0.30
5	887.28	901.28	14.00	1.58
2	680.00	700.25	20.25	2.98
21	804.26	831.28	27.02	3.36
15	720.25	770.27	50.02	6.94
7	780.27	847.28	67.01	8.59
17	660.00	724.25	64.25	9.73
3	604.00	704.03	100.03	16.56
14	629.00	744.26	115.26	18.32

Table S191: Average Difference in cT1 Whole Sample Q1 (ms).

Absolute Difference	
N	12
Mean	49.86
Median	51.02
Range	(3,115.26)
IQR	(22.63,64.94)
Percentage Change	
N	12
Mean	4.33
Median	3
Range	(-8,18)
IQR	(-0.75,9.25)

Whole sample Q3 (ms)

Table S192 presents descriptive analyses of the cT1 whole sample upper quantile (75%) at screening visit 1, follow-up visit 11, and the difference between them. Table S193 then shows the patient level absolute difference and percentage change in the cT1 Q3 in the whole sample; table S194 shows summary measures pooled across the whole mITT population.

Table S192: Summary of Liver MultiScan cT1 Measurement: whole sample Q3 (ms).

	cT1 Q3 (ms)		
	Screening Visit 1	**Follow-up Visit 11**	**Difference**
N	12	12	12
Mean	898.04	932.8	34.76
Median	875.78	906.78	30
Range	(742.26,1194.3)	(819.26,1211.3)	(-61,149.01)
IQR	(832.78,942.04)	(852.1,968.54)	(5.24,59.68)

Table S193: Patient level changes in cT1 whole sample Q3 (ms).

	cT1 Q3 (ms)			
Patient Number	**Screening Visit 1**	**Follow-up Visit 11**	**Absolute Difference**	**Percentage change (%)**
1	950.28	889.28	61.00	-6.42
20	869.28	848.51	20.77	-2.39
8	939.29	924.29	15.00	-1.60
4	1194.30	1211.30	17.00	1.42
2	807.27	819.26	11.99	1.49
5	991.30	1013.30	22.00	2.22
21	918.29	956.28	37.99	4.14
15	841.28	883.28	42.00	4.99
7	882.29	947.29	65.00	7.37
3	784.37	842.28	57.91	7.38
14	742.26	853.29	111.03	14.96
17	856.29	1005.30	149.01	17.40

Table S194: Average Difference in cT1 Whole Sample Q3 (ms).

Absolute Difference	
N	12
Mean	50.89
Median	40
Range	(11.99,149.01)
IQR	(19.83,62)
Percentage Change	
N	12
Mean	4.08
Median	3
Range	(-6,17)
IQR	(0.25,7)

Figure S44 shows a repeated measures plot of the Liver MultiScan cT1 median measurement in the whole sample with error bars depicting quantile 1 to quantile 3.



Figure S44: Repeated measures plot of Liver MultiScan measurement cT1 (ms) in the whole sample with error bars showing quantile 1 to quantile 3.

In previous data extracts provided by Perspectum Diagnostics, there included data on the percentage of cT1 in relation to the reference interval (645ms - 822ms). However, in the most recent this was omitted and replaced with LIF scores. Therefore, such analyses are not included in this report.

D.10.24 Whole Analysis: LIF

Whole LIF

Table S195 presents descriptive analyses of LIF for the whole sample at screening visit 1, follow-up visit 11, and the difference between them. Table S196 then shows the patient level absolute difference and percentage change in the cT1 mode in the whole sample; table S197 shows summary measures pooled across the whole mITT population.

Table S195: Summary of Liver MultiScan LIF: whole sample.

	LIF		
	Screening Visit 1	**Follow-up Visit 11**	**Difference**
N	12	12	12
Mean	1	1.14	0.14
Median	0.76	0.75	0.17
Range	(0,3.27)	(0.22,3.22)	(-0.78,0.92)
IQR	(0.25,1.33)	(0.46,1.66)	(-0.09,0.39)

Table S196: Patient level changes in whole sample LIF

	LIF			
Patient Number	**Screening Visit 1**	**Follow-up Visit 11**	**Absolute Difference**	**Percentage change (%)**
8	1.59	0.81	0.78	-49.16
1	1.03	0.59	0.44	-42.86
20	0.61	0.41	0.19	-31.87
4	3.27	3.22	0.05	-1.57
5	2.32	2.51	0.19	8.05
21	1.24	1.61	0.37	30.11
15	0.63	0.89	0.26	41.05
2	0.31	0.46	0.15	46.81
7	0.89	1.81	0.92	102.99
17	0.08	0.22	0.14	175.00
14	0.01	0.69	0.68	5100.13
3	0.00	0.46	0.46	Inf

Table S197: Average Difference in Whole Sample LIF.

Absolute Difference	
N	12
Mean	0.39
Median	0.32
Range	(0.05,0.92)
IQR	(0.18,0.52)
Percentage Change	
N	12
Mean	Inf
Median	35.5
Range	(-49,Inf)
IQR	(-9.5,121)

Figure S45 shows a repeated measures plot of the Liver MultiScan LIF whole sample measurement with loess smoother trend line to help evaluate any potential trend in scores.



Figure S45: Repeated measures plot of Liver MultiScan measurement LIF in the whole mode for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Whole LIF median

Table S198 presents descriptive analyses of LIF for the whole sample at screening visit 1, follow-up visit 11, and the difference between them. Table S199 then shows the patient level absolute difference and percentage change in the cT1 mode in the whole sample; table S200 shows summary measures pooled across the whole mITT population.

Table S198: Summary of Liver MultiScan LIF: whole sample median.

	LIF median		
	Screening Visit 1	**Follow-up Visit 11**	**Difference**
N	12	12	12
Mean	1.27	1.49	0.22
Median	0.99	1.22	0.27
Range	(0.13,3.41)	(0.61,3.43)	(-0.68,0.95)
IQR	(0.48,1.66)	(0.81,2.03)	(-0.02,0.5)

Table S199: Patient level changes in whole sample LIF median.

	LIF Median			
Patient Number	**Screening Visit 1**	**Follow-up Visit 11**	**Absolute Difference**	**Percentage change (%)**
1	1.56	0.88	0.68	-43.61
8	1.84	1.23	0.61	-33.29
20	0.84	0.67	0.17	-20.29
4	3.41	3.43	0.03	0.75
5	2.68	2.92	0.24	8.94
2	0.49	0.61	0.12	24.57
21	1.60	2.02	0.41	25.78
15	0.80	1.22	0.42	51.76
7	1.14	2.08	0.95	83.29
3	0.34	0.63	0.29	86.57
17	0.47	1.36	0.90	191.16
14	0.13	0.86	0.74	580.31

Table S200: Average Difference in Whole Sample LIF Median.

Absolute Difference	
N	12
Mean	0.46
Median	0.41
Range	(0.03,0.95)
IQR	(0.22,0.7)
Percentage Change	
N	12
Mean	79.75
Median	25.5
Range	(-44,580)
IQR	(-4.25,84)

Figure S46 shows a repeated measures plot of the Liver MultiScan whole sample LIF median measurement with loess smoother trend line to help evaluate any potential trend in scores.



Figure S46: Repeated measures plot of Liver MultiScan measurement LIF median in the whole mode for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Whole LIF mean

Table S201 presents descriptive analyses of LIF for the whole sample at screening visit 1, follow-up visit 11, and the difference between them. Table S202 then shows the patient level absolute difference and percentage

change in the cT1 mode in the whole sample; table S203 shows summary measures pooled across the whole mITT population.

Table S201: Summary of Liver MultiScan LIF: whole sample mean

	LIF mean		
	Screening Visit 1	Follow-up Visit 11	Difference
N	12	12	12
Mean	1.86	2.22	0.36
Median	1.79	2.06	0.29
Range	(0.64,3.61)	(0.99,3.61)	(-0.81,1.55)
IQR	(1.12,2.57)	(1.66,2.76)	(-0.04,0.79)

Table S202: Patient level changes in whole sample LIF median.

	LIF Median			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
1	2.61	1.80	0.81	-31.10
8	2.55	2.27	0.29	-11.26
20	1.56	1.44	0.12	-7.96
2	1.00	0.99	0.01	-1.00
4	3.61	3.61	0.00	0.11
5	3.09	3.15	0.06	1.85
21	2.16	2.69	0.52	24.17
7	2.02	2.94	0.92	45.36
15	1.23	1.86	0.63	51.46
3	0.67	1.42	0.75	112.63
17	1.16	2.71	1.55	133.02
14	0.64	1.73	1.09	169.30

Table S203: Average Difference in Whole Sample LIF Mean.

Absolute Difference	
N	12
Mean	0.56
Median	0.58
Range	(0,1.55)
IQR	(0.11,0.84)
Percentage Change	
N	12
Mean	40.5
Median	13
Range	(-31,169)
IQR	(-2.75,66.5)

Figure S47 shows a repeated measures plot of the Liver MultiScan whole sample LIF median measurement with loess smoother trend line to help evaluate any potential trend in scores.



Figure S47: Repeated measures plot of Liver MultiScan measurement LIF median in the whole mode for all evaluable patients in the mITT population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

LIF Reference Values

For cT1 analysis, the reference interval is 654ms - 822ms. Table S204 shows summary statistics of the percentage of LIF in the reference intervals given, while S205 shows the average difference in the percentage of LIF with relation to the reference interval.

Table S204: Percentage of LIF in reference interval.

	Screening Visit 1	Follow-up Visit 11	Difference
subLIF			
N	12	12	12
Mean	9.6	2.73	-6.87
Median	0.31	0.16	-0.02
Range	(0,43.42)	(0,15.13)	(-38.05,1.67)
IQR	(0.05,13.07)	(0.03,3.19)	(-5.12,0.08)
LIF 0-1 (%)			
N	12	12	12
Mean	35.08	36.31	1.23
Median	38.77	42.41	-0.04
Range	(0.03,63.62)	(0.03,64.3)	(-39.78,32.03)
IQR	(21.88,50.12)	(8.48,58.07)	(-10,17.94)
LIF 1-2 (%)			
N	12	12	12
Mean	18.71	19.3	0.59
Median	16.45	15.81	1.15
Range	(0.92,40.63)	(1.13,42.68)	(-20.3,15.1)
IQR	(8.12,31.98)	(11.03,25.58)	(-4.64,7.71)
LIF 2-3 (%)			
N	12	12	12
Mean	12.19	14.01	1.82

Table S204: Percentage of LIF in reference interval. *(continued)*

	Screening Visit 1	Follow-up Visit 11	Difference
Median	8.17	9.29	1.24
Range	(2.68,44.7)	(5.02,42.1)	(-10.58,19.3)
IQR	(5.05,14.53)	(6.63,14.5)	(-2.29,4.73)
LIF 3-4 (%)			
N	12	12	12
Mean	18.65	20.71	2.07
Median	11.39	13.52	2.14
Range	(6.21,76.08)	(8.64,74.73)	(-4.92,8.45)
IQR	(9.26,17.41)	(9.4,19.5)	(-1.53,5.3)
extraLIF (%)			
N	12	12	12
Mean	5.76	6.93	1.17
Median	5.11	5.92	1.13
Range	(2.49,14.87)	(3.46,15.96)	(-2.22,5.13)
IQR	(4.45,6.06)	(5.47,6.9)	(0.69,1.98)

Table S205: Average difference in percentage of LIF in the reference range.

	subLIF (%)	LIF 0-1 (%)	LIF 1-2 (%)	LIF 2-3 (%)	LIF 3-4 (%)	extraLIF (%)
Absolute Difference						
N	12	12	12	12	12	12
Mean	7.2	15.16	8.12	5.32	3.96	1.76
Median	0.78	15.04	6.34	4.38	2.83	1.51
Range	(0,38.05)	(0,39.78)	(0.21,20.3)	(0.05,19.3)	(1.35,8.45)	(0.62,5.13)
IQR	(0.06,5.12)	(3.88,21.95)	(3.04,13.09)	(1.95,6.01)	(2.08,5.47)	(1.02,2.16)
Percentage Change						
N	11	12	12	12	12	12
Mean	Inf	11.33	36.17	40.92	19.33	27
Median	-18	-0.5	23.5	32	25	23.5
Range	(-99,Inf)	(-92,128)	(-56,296)	(-49,188)	(-28,64)	(-36,86)
IQR	(-68,226)	(-25.75,44.5)	(-27.75,54.25)	(-11,76)	(-5.75,31.75)	(10.75,42.25)

Tables S206, S207, S208, S209, S210, and S211 show the patient level changes in percentage of subLIF, LIF between 0 and 1, 1 and 2, 2 and 3, 3 and 4, and extraLIF respectively.

subLIF (%)

Table S206: Patient level changes in percentage of LIF in the reference interval.

	subLIF (%)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
14	38.30	0.25	38.05	-99.3473
15	1.44	0.02	1.42	-98.6111
17	20.80	6.11	14.69	-70.625
3	43.42	15.13	28.29	-65.1543
5	0.07	0.03	0.04	-57.1429
2	10.49	8.56	1.93	-18.3985
21	0.06	0.13	0.07	116.6667
8	0.07	0.17	0.10	142.8571
20	0.54	2.21	1.67	309.2593
1	0.01	0.16	0.15	1500
4	0.00	0.01	0.01	Inf
7	0.00	0.00	0.00	

LIF 0-1 (%)

Table S207: Patient level changes in percentage of LIF between 0 and 1.

	LIF 0-1 (%)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
7	43.36	3.58	39.78	-91.74
21	22.83	10.11	12.72	-55.72
15	62.62	41.46	21.16	-33.79
5	0.35	0.27	0.08	-22.86
17	47.04	37.95	9.09	-19.32
2	63.62	62.89	0.73	-1.15
4	0.03	0.03	0.00	0.00
20	59.37	64.30	4.93	8.30
14	43.44	60.79	17.35	39.94
3	34.18	53.88	19.70	57.64
1	25.13	57.16	32.03	127.46
8	19.03	43.35	24.32	127.80

LIF 1-2 (%)

Table S208: Patient level changes in percentage of LIF between 1 and 2.

	LIF 1-2 (%)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
1	36.43	16.13	20.30	-55.72
5	17.60	11.14	6.46	-36.70
8	36.62	23.53	13.09	-35.75
20	16.29	12.26	4.03	-24.74
21	40.63	39.32	1.31	-3.22
4	0.92	1.13	0.21	22.83
2	8.59	10.69	2.10	24.45
7	30.49	42.68	12.19	39.98
3	6.70	10.05	3.35	50.00
17	9.27	15.49	6.22	67.10
15	16.62	31.72	15.10	90.85
14	4.42	17.51	13.09	296.15

LIF 2-3 (%)

Table S209: Patient level changes in percentage of LIF between 2 and 3.

	LIF 2-3 (%)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
8	21.67	11.09	10.58	-48.82
1	13.65	8.01	5.64	-41.32
20	8.24	6.06	2.18	-26.46
5	44.70	42.10	2.60	-5.82
4	8.10	8.15	0.05	0.62
2	4.11	5.33	1.22	29.68
3	3.76	5.02	1.26	33.51
21	17.17	24.30	7.13	41.53
15	6.61	11.23	4.62	69.89
17	5.37	10.44	5.07	94.41
14	2.68	6.82	4.14	154.48
7	10.26	29.56	19.30	188.11

LIF 3-4 (%)

Table S210: Patient level changes in percentage of LIF between 3 and 4.

	LIF 3-4 (%)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
1	17.58	12.66	4.92	-27.99
20	11.31	9.22	2.09	-18.48
8	17.36	14.37	2.99	-17.22
4	76.08	74.73	1.35	-1.77
2	7.08	8.64	1.56	22.03
15	9.87	12.11	2.24	22.70
5	31.29	39.74	8.45	27.01
3	7.43	9.46	2.03	27.32
21	16.82	21.51	4.69	27.88
14	6.21	8.88	2.67	43.00
7	11.27	18.41	7.14	63.35
17	11.46	18.83	7.37	64.31

extraLIF (%)

Table S211: Patient level changes in percentage of extraLIF.

	extraLIF (%)			
Patient Number	Screening Visit 1	Follow-up Visit 11	Absolute Difference	Percentage change (%)
2	6.11	3.89	2.22	-36.33
1	7.20	5.88	1.32	-18.33
4	14.87	15.96	1.09	7.33
5	5.99	6.71	0.72	12.02
14	4.95	5.75	0.80	16.16
15	2.84	3.46	0.62	21.83
7	4.62	5.78	1.16	25.11
20	4.25	5.95	1.70	40.00
8	5.26	7.49	2.23	42.40
3	4.51	6.44	1.93	42.79
17	6.05	11.18	5.13	84.79
21	2.49	4.63	2.14	85.94



Figure S48: Repeated measures plot of percentage LIF in the mITT population, presented in relation to the reference interval. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

D.10.25 sVAP-1/SSAO Liver Disease Activity Biomarker

SSAO

Table S212: Summary of SSAO Enzyme Activity (H_2O_2).

	SSAO Enzyme Activity (H_2O_2)		
	Visit 3	Follow-up Visit 10	Difference
N	14	14	14
Mean	0.26	0.17	-0.08
Median	0.23	0.1	-0.08
Range	(0.12,0.6)	(0.08,0.72)	(-0.18,0.12)
IQR	(0.16,0.28)	(0.09,0.17)	(-0.13,-0.06)

Table S213: Patient level changes in SSAO enzyme activity (H_2O_2).

	SSAO Enzyme Activity (H_2O_2)			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
19	0.25	0.08	0.16	-66.00
4	0.28	0.11	0.18	-62.44
9	0.25	0.11	0.14	-56.63
3	0.21	0.10	0.11	-52.17
1	0.17	0.09	0.08	-46.21
15	0.16	0.09	0.07	-45.70
8	0.16	0.10	0.07	-41.02
18	0.14	0.09	0.05	-38.55
7	0.12	0.08	0.04	-35.56
14	0.49	0.32	0.17	-34.53
6	0.18	0.13	0.05	-30.10
5	0.26	0.19	0.08	-28.61
12	0.32	0.24	0.08	-24.48
17	0.60	0.72	0.12	19.82

Table S214: Average Difference in SSAO Enzyme Activity (H_2O_2).

Absolute Difference	
N	14
Mean	0.1
Median	0.08
Range	(0.04,0.18)
IQR	(0.07,0.13)
Percentage Change	
N	14
Mean	-38.73
Median	-39.79
Range	(-66,19.82)
IQR	(-50.68,-31.21)



Figure S49: Repeated measures plot of SSAO enzyme activity at all trial visits in the mITT population. A line depicting the fixed effects from the repeated measures analysis has been added in black.



Figure S50: Repeated measures plot of SSAO enzyme activity as a percentage of the screening 1 value across all trial visits in the mITT population.

sVAP-1/SSAO



Figure S51: Repeated measures plot of ratio to sVAP-1 to SSAO (sVAP-1/SSAO) assessed pre-infusion (where applicable) at all trial visits in the mITT population for those samples which were rested before analysis. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Table S215: Summary of sVAP-1/SSAO Activity.

	sVAP-1/SSAO Activity		
	Visit 3	**Follow-up Visit 10**	**Difference**
N	13	6	5
Mean	1492.11	104.04	-1154.41
Median	1547.45	8.33	-888.92
Range	(634.6,2303.86)	(1.96,590.99)	(-2292.39,-631.44)
IQR	(1120.72,1769.55)	(3.74,11.4)	(-1115.24,-844.06)

Table S216: Patient level changes in sVAP-1/SSAO.

Patient Number	sVAP-1/SSAO		Absolute Difference	Percentage change (%)
	Visit 3	Follow-up Visit 10		
17	846.03	1.96	-844.06	-99.77
12	1120.72	5.48	-1115.24	-99.51
14	634.6	3.16	-631.44	-99.5
15	2303.86	11.47	-2292.39	-99.5
4	1479.92	590.99	-888.92	-60.07
1	1435.24			
3	1547.45			
5	832.07			
6		11.18		
7	1769.55			
8	2103.32			
9	1574.04			
18	2090.72			
19	1659.97			

Table S217: Average Difference in sVAP-1/SSAO Activity.

Absolute Difference	
N	5
Mean	-1154.41
Median	-888.92
Range	(-2292.39,-631.44)
IQR	(-1115.24,-844.06)
Percentage Change	
N	5
Mean	-91.67
Median	-99.5
Range	(-99.77,-60.07)
IQR	(-99.51,-99.5)

Immune Cell Populations as Assessed by Flow Cytometry

Flow cytometry was performed on serum and cells isolated from patients at all trial visits. During flow cytometry analysis the relative percentage of the each cell type in the blood was determined. The following cell types as assessed by flow cytometry are here presented:

- B Cells,

- CD3 Cells,
- CD3 Negative CD56 Positive NK Cells,
- CD4 Cells, CD8 Cells,
- Classical Monocytes,
- Delta 2 Cells,
- Intermediate Monocytes,
- NK Cells, NKT Cells,
- Non-Classical Monocytes,
- Th17 Cells, and
- Treg Cells.

Note: Note that not all patient samples were analysed, and that for the monocyte analyses (classical, intermediate and non-classical) there were two different analysis methods. Some patients had their sample defrosted and left to thaw overnight before analysis, while others were only left to defrost before analysis. These methods are respectively referred to as thawed and defrosted samples.

Akin to SSAO enzyme activity, for each cell type as assessed by flow cytometry, μ, the following calculations are made: The difference is calculated as

$$\text{Difference} = \mu_{\text{Follow-up Visit 10}} - \mu_{\text{Visit 3}} \tag{26}$$

and the percentage change is calculated as

$$\text{Percentage change} = \frac{\mu_{\text{Follow-up Visit 10}} - \mu_{\text{Visit 3}}}{\mu_{\text{Visit 3}}} \tag{27}$$

Table S218 shows summary information of all cell types as assessed by flow cytometry over all trial visits, while

figure S52 shows a repeated measures plot all immune cell populations.

The results for each cell population are shown separately. Tables are presented showing descriptive analyses of each measurement of flow cytometry at visit 3 (first treatment visit) and visit 10 (follow-up). Descriptive analyses regarding the differences in the SSAO cell populations are also shown. From figure S52, all cell populations showed a negligible trend in the smoother line with significant heterogeneity at all time points, repeated measures analysis would therefore be futile and thus has not been completed.

Table S218: Immune Cell Populations as Assessed by Flow Cytometry Over All Trial Visits.

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	Visit 11
B Cells											
N	12	12	12	11	11	11	11	11	11	12	12
Mean	46.01	41.72	49.37	50.8	46.7	48.23	46.29	49.63	49.75	53.14	51.41
Median	43	44.1	53.05	54.5	57.9	51.9	48.5	49.9	54.9	57	54.65
Range	(13.6,80)	(9.72,72)	(14.8,75.1)	(23.1,71.5)	(14.3,76.1)	(23.3,74.2)	(18.6,72.2)	(20.5,70.8)	(20.3,69)	(21.8,66.2)	(18,82.3)
IQR	(34.38,57.25)	(25.53,58.97)	(45.22,59.25)	(39.9,61.5)	(27.2,63.25)	(28.9,60.15)	(30.65,61.7)	(43.15,60.3)	(39.5,64)	(48.45,62.42)	(39.62,61.17)
CD3 Cells											
N	12	12	12	11	11	11	11	11	11	12	12
Mean	46.59	45.67	45.8	45.13	48.59	45.66	46.44	46.05	49.27	48.27	49.77
Median	44.15	44.9	43.05	43.4	54.4	53	49	40.3	51.4	43.1	48.25
Range	(24.6,83.3)	(6.78,81.3)	(20.4,80)	(16.8,77.9)	(17.3,87)	(21.8,71.6)	(19.8,92.7)	(17.2,85.1)	(18.3,89.6)	(17.4,87)	(21.7,86.5)
IQR	(33.27,58.2)	(38.95,55.38)	(28.85,64.58)	(28.2,62.95)	(27.85,64.65)	(27.25,60.35)	(29.5,55.75)	(33.55,54.85)	(29.3,61.85)	(35.4,61.3)	(35.95,60.2)
CD3 Negative CD56 Positive Cells											
N	10	10	10	10	10	10	10	10	10	10	10
Mean	14.46	18.15	15.61	14.57	13.77	16.27	16.54	14.26	13.7	15.03	12.54
Median	10.07	13.15	11.02	11.25	9.8	12.62	11.04	13.45	10.57	10.5	4.84
Range	(0.25,51.7)	(0.49,59.3)	(1.29,50.6)	(0.28,45.2)	(0.18,53)	(0.13,49.5)	(0.21,54.2)	(0.18,52)	(0,50.1)	(0.17,54.1)	(0.38,51.2)
IQR	(6.01,19.27)	(4.33,26.57)	(5.37,20)	(4.58,22.3)	(3.36,17.48)	(7.83,19.12)	(8.18,16.05)	(4.48,17.5)	(7.05,14.73)	(4.13,19.48)	(2.57,18.05)
CD4 Cells											
N	12	12	12	11	11	11	11	11	11	12	12
Mean	69.5	67.22	68.22	67.63	65.04	67.67	68.78	68.56	70.96	73.54	72.38

Table S218: Immune Cell Populations as Assessed by Flow Cytometry Over All Trial Visits. *(continued)*

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	Visit 11
Median	72.5	63.95	70.55	71.8	71	70	71.5	74.5	74	73.45	75.6
Range	(32.6,85.1)	(48,84.7)	(36.4,85.6)	(41.2,85.3)	(21.4,86.3)	(32.5,86)	(36.1,84.7)	(14.6,82.4)	(42.9,82.7)	(60.3,86.2)	(49.1,85.7)
IQR	(62.15,82.53)	(59.18,79.33)	(62.1,78.27)	(59.75,74.3)	(61.7,77.05)	(62.7,75.9)	(69.05,78.1)	(66.1,79.95)	(66.65,78.8)	(66.8,81.45)	(64.05,81.02)
CD8 Cells											
N	12	12	12	11	11	11	11	11	11	12	12
Mean	22.05	22.4	20.92	21.11	20.56	20.68	20.38	21.01	20.52	19.48	19.24
Median	18.4	25.55	17.4	19	19.3	20.3	20.5	17.5	17.8	15.6	16
Range	(9.24,62.8)	(9.46,34.9)	(9.1,39.7)	(9.93,42.6)	(8.49,38)	(7.47,40)	(8.34,37)	(10.7,41.5)	(10.7,35.7)	(11,37.5)	(8.58,36)
IQR	(11.92,24.98)	(14.78,27.82)	(14.53,27.75)	(15.85,24.35)	(14.35,24.9)	(13.5,25.85)	(13.85,26.05)	(13.3,24.95)	(12.95,27)	(13.5,24.65)	(13.05,24.75)
Classical Monocytes											
N	12	12	12	11	11	11	11	11	11	12	12
Mean	44.78	38.46	38.24	41.14	43.69	41.35	45.55	40.16	41.89	36.89	39.74
Median	31.45	33.6	33.7	33	32.6	35.9	38.5	32.4	32.9	25.05	31.2
Range	(16.4,100)	(10.1,72.7)	(11.6,85.4)	(13.5,89.7)	(15,90.1)	(17.2,84.6)	(16.3,94)	(11.1,97.2)	(12.1,99.5)	(12.5,96.3)	(10.9,89.3)
IQR	(20.85,71.38)	(19.47,62.35)	(17.05,49.7)	(18.95,61)	(22.4,68.85)	(24.45,56.65)	(29.4,59.45)	(22.95,46.55)	(25.15,58.65)	(17.15,52.9)	(25.82,41.75)
Delta 2 Cells											
N	12	12	12	11	11	11	11	11	11	12	12
Mean	2.56	2.72	2.84	2.01	2.08	2.23	1.99	2.27	2.06	1.5	2.26
Median	1.17	2.29	1.73	1.07	1.73	1.64	1.32	1.17	1.21	1.04	1.42
Range	(0.09,11.4)	(0.06,8.9)	(0.14,10.4)	(0,5.93)	(0.18,6.3)	(0.06,6.8)	(0.06,4.39)	(0.06,9.09)	(0.05,7.14)	(0.19,6.78)	(0.05,7.39)
IQR	(0.39,3.29)	(0.39,3.93)	(0.51,3.55)	(0.44,3.38)	(0.5,3.08)	(0.75,3.37)	(0.61,3.84)	(0.72,3.05)	(0.58,2.79)	(0.51,1.44)	(0.39,3.17)

Table S218: Immune Cell Populations as Assessed by Flow Cytometry Over All Trial Visits. *(continued)*

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	Visit 11
Intermediate Monocytes											
N	12	12	12	11	11	11	11	11	11	12	12
Mean	50.78	59.83	59.23	56.65	53.91	55.94	52.35	57.88	56.2	61.29	58.71
Median	60	64.55	63.45	67	62.4	59.5	59.8	63.8	61.4	70.95	68.4
Range	(0,80.9)	(25.9,89.5)	(13.6,87.6)	(5.13,84.6)	(6.43,84.9)	(13.1,82.5)	(4.76,82.6)	(1.41,88.6)	(0.55,87.2)	(0,87.2)	(8.47,88.3)
IQR	(27.62,75.42)	(36.45,79.38)	(46.67,79.4)	(37.95,77.55)	(30.5,74.9)	(42.6,70.55)	(39.5,68.7)	(52.6,75.4)	(41.1,74.55)	(46.92,80.95)	(53.8,71.95)
NK Cells											
N	12	12	12	11	11	11	11	11	11	12	12
Mean	10.03	12.59	11.93	9.22	8.99	9.36	11.21	7.88	8.82	10.33	9.83
Median	5.95	8	8.61	6.78	4.62	6.14	5.66	6.12	5.84	5.62	5.46
Range	(0.31,31.4)	(0.55,52.7)	(0.61,41.4)	(0.52,28.9)	(0.35,39.6)	(0.37,32.3)	(0,33.7)	(0.3,23.2)	(0,32.3)	(0.29,36.3)	(0.36,34.2)
IQR	(3.37,12.2)	(3.97,15.4)	(4.29,13.7)	(2.58,13.25)	(2.54,11.45)	(4.49,11.19)	(3.5,16.23)	(3.6,9.53)	(3.79,7.48)	(2.73,15.2)	(1.64,14.03)
NKT Cells											
N	12	12	12	11	11	11	11	11	11	12	12
Mean	5.04	6.79	7.37	5.72	8.08	6.46	8.01	5.21	7.22	5.68	7
Median	3.51	2.55	3	4.21	5.39	2.95	1.4	2.04	1.15	2.3	4.62
Range	(0,18.5)	(0.43,29.7)	(0.35,34.4)	(0,20.7)	(0,22.5)	(0.4,24.5)	(0,36.7)	(0,17.3)	(0,29.6)	(0.44,20)	(0.41,20.2)
IQR	(0.44,7.08)	(0.93,8.29)	(0.98,8.84)	(0.69,5.5)	(0.5,14.96)	(0.86,7.62)	(0.36,11.61)	(0.38,8.87)	(0.47,12.19)	(1.23,5.77)	(1.12,14.1)
Non-Classical Monocytes											
N	12	12	12	11	11	11	11	11	11	12	12
Mean	4.56	1.99	3.03	2.15	2.31	3.09	2.26	2.02	2.04	1.54	1.48
Median	1.06	1.3	2.29	1.4	1.1	2.19	1.47	1.08	0.7	0.31	0.8

Table S218: Immune Cell Populations as Assessed by Flow Cytometry Over All Trial Visits. *(continued)*

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	Visit 11
Range	(0,34.6)	(0.06,5.24)	(0.09,7.63)	(0.05,7.61)	(0.08,10.1)	(0.09,10.3)	(0.09,9.3)	(0,7.83)	(0,8.38)	(0,7.59)	(0.06,5.87)
IQR	(0.8,3)	(0.77,3.74)	(0.83,5.46)	(0.62,2.53)	(0.7,2.14)	(1.02,4.52)	(1.17,2.32)	(0.46,3.1)	(0.24,2.69)	(0.21,1.57)	(0.61,1.48)
Th17 Cells											
N	12	12	12	11	11	11	11	11	11	12	12
Mean	4.1	3.38	4.57	3.57	4.17	3.69	3.82	3.41	3.19	2.84	4.06
Median	4.25	3.19	4.51	4.38	4.19	4.39	4.32	2.89	3.42	3.03	4.27
Range	(0.15,8.93)	(0.13,7.97)	(0,9.09)	(0,9.38)	(0.13,9.86)	(0.07,8.11)	(0.1,8.33)	(0,7.93)	(0,8.02)	(0.09,4.91)	(0.13,8.38)
IQR	(1.71,5.82)	(1.53,5.12)	(1.95,6.71)	(0.94,5.01)	(2.37,5.35)	(1.88,4.87)	(1.41,5.03)	(1.89,5.01)	(1.36,4.82)	(1.14,4.47)	(2.17,5.29)
Treg Cells											
N	12	12	12	11	11	11	11	11	11	12	12
Mean	5.84	6.08	5.79	5.57	5.44	6.35	5.9	9.06	5.87	6.58	6.12
Median	5.7	6.42	5.92	5.74	6.26	6.03	6.48	6.91	5.92	6.65	6.67
Range	(1.79,9.53)	(4.04,8.9)	(2.91,7.96)	(0,9.04)	(0,8.34)	(4.2,9.46)	(0,9.6)	(4.31,33.3)	(0,8.27)	(4.7,8.3)	(1.65,10)
IQR	(5.14,7.05)	(4.54,6.67)	(4.46,7.27)	(4.46,7.56)	(3.48,7.58)	(5.1,7.38)	(5.22,7.54)	(5.78,7.7)	(5.09,7.44)	(5.79,7.34)	(5.76,6.96)



Figure S52: Repeated measures plot of all immune cell populaions as assessed by flow cytometry at all trial visits

in the mITT population, presented by immune cell population. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

B Cells

Table S219: Summary of Immune B Cell Populations.

	B Cells		
	Visit 3	Follow-up Visit 10	Difference
N	12	12	12
Mean	49.37	53.14	3.78
Median	53.05	57	1.45
Range	(14.8,75.1)	(21.8,66.2)	(-18.4,50.4)
IQR	(45.22,59.25)	(48.45,62.42)	(-4.48,8.2)

Table S220: Patient level change in Immune B Cells Populations.

	B Cells			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
4	67.3	48.9	18.4	-27.34
17	75.1	61.5	13.6	-18.11
15	52.4	47.1	5.3	-10.11
1	62.7	58.5	4.2	-6.70
5	50.4	49.4	1.0	-1.98
8	21.1	21.8	0.7	3.32
7	53.3	55.5	2.2	4.13
14	58.1	66.2	8.1	13.94
2	52.8	61.3	8.5	16.10
18	54.7	65.2	10.5	19.20
3	29.7	37.1	7.4	24.92
6	14.8	65.2	50.4	340.54

Table S221: Average Difference in B Cell Immune Populations.

Absolute Difference	
N	12
Mean	10.86
Median	7.75
Range	(0.7,50.4)
IQR	(3.7,11.27)
Percentage Change	
N	12
Mean	29.82
Median	3.72
Range	(-27.34,340.54)
IQR	(-7.55,16.87)

CD3 Cells

Table S222: Summary of Immune CD3 Cell Populations.

	CD3 Cells		
	Visit 3	Follow-up Visit 10	Difference
N	12	12	12
Mean	45.8	48.27	2.48
Median	43.05	43.1	-0.65
Range	(20.4,80)	(17.4,87)	(-9.9,16.8)
IQR	(28.85,64.58)	(35.4,61.3)	(-3.23,11.6)

Table S223: Patient level change in Immune CD3 Cells Populations.

	CD3 Cells			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
17	30.0	20.1	9.9	-33.00
14	44.2	36.1	8.1	-18.33
8	20.4	17.4	3.0	-14.71
4	63.5	60.2	3.3	-5.20
2	67.8	64.6	3.2	-4.72
1	80.0	79.0	1.0	-1.25
6	33.6	33.3	0.3	-0.89
3	41.9	44.0	2.1	5.01
5	74.2	87.0	12.8	17.25
7	47.3	58.5	11.2	23.68
18	25.4	42.2	16.8	66.14
15	21.3	36.9	15.6	73.24

Table S224: Average Difference in CD3 Cell Immune Populations.

Absolute Difference	
N	12
Mean	7.28
Median	5.7
Range	(0.3,16.8)
IQR	(2.78,11.6)
Percentage Change	
N	12
Mean	8.94
Median	-1.07
Range	(-33,73.24)
IQR	(-7.57,18.86)

CD3 Negative CD56 Positive NK Cells

Table S225: Summary of Immune CD3 Negative CD56 Positive Cell Populations.

	CD3 Negative CD56 Positive Cells		
	Visit 3	Follow-up Visit 10	Difference
N	10	10	10
Mean	15.61	15.03	-0.58
Median	11.02	10.5	-0.68
Range	(1.29,50.6)	(0.17,54.1)	(-8.6,7.1)
IQR	(5.37,20)	(4.13,19.48)	(-2.77,2.17)

Table S226: Patient level change in Immune CD3 Negative CD56 Positive Cells Populations.

	CD3 Negative CD56 Positive Cells			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
6	6.41	0.62	5.79	-90.33
7	1.29	0.17	1.12	-86.82
14	29.60	21.00	8.60	-29.05
18	13.20	10.10	3.10	-23.48
3	16.70	14.90	1.80	-10.78
5	3.34	3.10	0.24	-7.19
8	50.60	54.10	3.50	6.92
17	8.84	10.90	2.06	23.30
15	21.10	28.20	7.10	33.65
4	5.02	7.22	2.20	43.82

Table S227: Average Difference in CD3 Negative CD56 Positive Cell Immune Populations.

Absolute Difference	
N	10
Mean	3.55
Median	2.65
Range	(0.24,8.6)
IQR	(1.86,5.22)
Percentage Change	
N	10
Mean	-14
Median	-8.98
Range	(-90.33,43.82)
IQR	(-27.66,19.21)

CD4 Cells

Table S228: Summary of Immune CD4 Cell Populations.

	CD4 Cells		
	Visit 3	Follow-up Visit 10	Difference
N	12	12	12
Mean	68.22	73.54	5.32
Median	70.55	73.45	0.75
Range	(36.4,85.6)	(60.3,86.2)	(-5.1,27.7)
IQR	(62.1,78.27)	(66.8,81.45)	(-1.3,9.5)

Table S229: Patient level change in Immune CD4 Cells Populations.

	CD4 Cells			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
5	65.1	60.3	4.8	-7.37
1	73.6	68.5	5.1	-6.93
7	85.6	82.8	2.8	-3.27
17	68.9	68.1	0.8	-1.16
4	82.7	82.2	0.5	-0.60
14	67.9	67.7	0.2	-0.29
2	84.5	86.2	1.7	2.01
15	76.8	78.9	2.1	2.73
8	72.2	81.2	9.0	12.47
3	53.1	64.1	11.0	20.72
18	51.9	78.4	26.5	51.06
6	36.4	64.1	27.7	76.10

Table S230: Average Difference in CD4 Cell Immune Populations.

Absolute Difference	
N	12
Mean	7.68
Median	3.8
Range	(0.2,27.7)
IQR	(1.48,9.5)
Percentage Change	
N	12
Mean	12.12
Median	0.86
Range	(-7.37,76.1)
IQR	(-1.69,14.53)

CD8 Cells

Table S231: Summary of Immune CD8 Cell Populations.

	CD8 Cells		
	Visit 3	**Follow-up Visit 10**	**Difference**
N	12	12	12
Mean	20.92	19.48	-1.44
Median	17.4	15.6	-0.65
Range	(9.1,39.7)	(11,37.5)	(-12,7.5)
IQR	(14.53,27.75)	(13.5,24.65)	(-6.05,3.4)

Table S232: Patient level change in Immune CD8 Cells Populations.

	CD8 Cells			
Patient Number	**Visit 3**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
18	27.1	15.1	12.0	-44.28
8	18.4	11.0	7.4	-40.22
3	39.7	29.0	10.7	-26.95
6	29.7	24.1	5.6	-18.86
2	13.4	12.3	1.1	-8.21
14	14.9	13.9	1.0	-6.71
15	16.4	16.1	0.3	-1.83
4	13.3	13.9	0.6	4.51
5	32.9	37.5	4.6	13.98
1	21.2	26.3	5.1	24.06
7	9.1	12.1	3.0	32.97
17	14.9	22.4	7.5	50.34

Table S233: Average Difference in CD8 Cell Immune Populations.

Absolute Difference	
N	12
Mean	4.91
Median	4.85
Range	(0.3,12)
IQR	(1.07,7.42)
Percentage Change	
N	12
Mean	-1.77
Median	-4.27
Range	(-44.28,50.34)
IQR	(-20.88,16.5)

Classical Monocytes

All samples (not stratified according to time since de-frost to analysis)

Table S234: Summary of Immune Classical Monocyte Populations (all samples).

	Classical Monocytes		
	Visit 3	**Follow-up Visit 10**	**Difference**
N	12	12	12
Mean	38.24	36.89	-1.35
Median	33.7	25.05	-4.1
Range	(11.6,85.4)	(12.5,96.3)	(-21.4,24.3)
IQR	(17.05,49.7)	(17.15,52.9)	(-9.4,5.75)

Table S235: Patient level change in Immune Classical Monocytes Populations (all samples).

	Classical Monocytes			
Patient Number	**Visit 3**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
3	48.7	27.3	21.4	-43.94
7	26.0	17.2	8.8	-33.85
4	41.4	29.5	11.9	-28.74
5	16.9	12.5	4.4	-26.04
8	25.7	19.6	6.1	-23.74
1	17.1	13.3	3.8	-22.22
18	85.4	74.2	11.2	-13.11
17	45.4	49.3	3.9	8.59
14	52.7	63.7	11.0	20.87
6	72.0	96.3	24.3	33.75
15	16.0	22.8	6.8	42.50
2	11.6	17.0	5.4	46.55

Table S236: Average Difference in Classical Monocytes Immune Populations (all samples).

Absolute Difference	
N	12
Mean	9.92
Median	7.8
Range	(3.8,24.3)
IQR	(5.15,11.38)
Percentage Change	
N	12
Mean	-3.28
Median	-17.67
Range	(-43.94,46.55)
IQR	(-26.71,24.09)

Samples which were left to rest over night before analysis



Figure S53: Repeated measures plot of immune classical monocyte populaions as assessed by flow cytometry at all trial visits in the mITT population for those samples which were rested before analysis. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Table S237: Classical Monocytes Immune Cell Populations as Assessed by Flow Cytometry Over All Trial Visits, rested samples only.

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	Visit 11
Classical Monocytes (rested samples only)											
N	7	7	7	6	6	6	6	6	6	7	7
Mean	33.24	28.21	33.39	37.47	35.18	32.95	38.78	35.15	35.4	30.44	33.67
Median	21.4	19.7	26	27.35	24.5	27.25	30.05	22.95	25.15	17.2	28.2
Range	(16.4,100)	(10.1,70.3)	(11.6,72)	(14.9,89.7)	(15,90.1)	(17.2,64.8)	(16.3,94)	(11.1,97.2)	(12.1,99.5)	(12.5,96.3)	(10.9,89.3)
IQR	(18.9,28.55)	(15.1,33.6)	(17,45.05)	(17.57,45.22)	(21.45,33.55)	(23.33,36.2)	(23.55,38.2)	(13.2,40.8)	(19.25,31.2)	(15.15,28.4)	(22.45,31.2)

Table S238: Summary of Immune Classical Monocyte Populations (rested samples only).

	Classical Monocytes		
	Visit 3	Follow-up Visit 10	Difference
N	7	7	7
Mean	33.39	30.44	-2.94
Median	26	17.2	-4.4
Range	(11.6,72)	(12.5,96.3)	(-21.4,24.3)
IQR	(17,45.05)	(15.15,28.4)	(-10.35,0.8)

Table S239: Patient level change in Immune Classical Monocytes Populations (rested samples only).

	Classical Monocytes			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
3	48.7	27.3	21.4	-43.94
7	26.0	17.2	8.8	-33.85
4	41.4	29.5	11.9	-28.74
5	16.9	12.5	4.4	-26.04
1	17.1	13.3	3.8	-22.22
6	72.0	96.3	24.3	33.75
2	11.6	17.0	5.4	46.55

Table S240: Average Difference in Classical Monocyte Immune Populations (rested samples only).

Absolute Difference	
N	7
Mean	11.43
Median	8.8
Range	(3.8,24.3)
IQR	(4.9,16.65)
Percentage Change	
N	7
Mean	-10.64
Median	-26.04
Range	(-43.94,46.55)
IQR	(-31.3,5.76)

Samples which were analysed immediately after de-frosting



Figure S54: Repeated measures plot of immune classical monocyte populaions as assessed by flow cytometry at all trial visits in the mITT population for those samples which were only defrosted before analysis. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded greyregion.

Table S241: Classical Monocytes Immune Cell Populations as Assessed by Flow Cytometry Over All Trial Visits, defrosted samples only.

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	Visit 11
Classical Monocytes (defrosted samples only)											
N	5	5	5	5	5	5	5	5	5	5	5
Mean	60.94	52.8	45.04	45.54	53.9	51.44	53.68	46.18	49.68	45.92	48.24
Median	68.4	59.7	45.4	55.3	62.7	49.6	58.9	33.9	52.4	49.3	35.6
Range	(30.7,87.1)	(20,72.7)	(16,85.4)	(13.5,69.9)	(19.7,79.5)	(23.4,84.6)	(31.2,79.8)	(31.7,84.5)	(31.2,66.8)	(19.6,74.2)	(25.9,84)
IQR	(38.2,80.3)	(40.7,70.9)	(25.7,52.7)	(22.3,66.7)	(32.6,75)	(35.9,63.7)	(38.5,60)	(32.4,48.4)	(33.1,64.9)	(22.8,63.7)	(35.5,60.2)

Table S242: Summary of Immune Classical Monocyte Populations (defrosted samples only).

	Classical Monocytes		
	Visit 3	Follow-up Visit 10	Difference
N	5	5	5
Mean	45.04	45.92	0.88
Median	45.4	49.3	3.9
Range	(16,85.4)	(19.6,74.2)	(-11.2,11)
IQR	(25.7,52.7)	(22.8,63.7)	(-6.1,6.8)

Table S243: Patient level change in Immune Classical Monocytes Populations (defrosted samples only).

	Classical Monocytes			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
8	25.7	19.6	6.1	-23.74
18	85.4	74.2	11.2	-13.11
17	45.4	49.3	3.9	8.59
14	52.7	63.7	11.0	20.87
15	16.0	22.8	6.8	42.50

Table S244: Average Difference in Classical Monocyte Immune Populations (defrosted samples only).

Absolute Difference	
N	5
Mean	7.8
Median	6.8
Range	(3.9,11.2)
IQR	(6.1,11)
Percentage Change	
N	5
Mean	7.02
Median	8.59
Range	(-23.74,42.5)
IQR	(-13.11,20.87)

Delta 2 Cells

Table S245: Summary of Immune Delta 2 Cell Populations.

	Delta 2 Cells		
	Visit 3	Follow-up Visit 10	Difference
N	12	12	12
Mean	2.84	1.5	-1.35
Median	1.73	1.04	-0.1
Range	(0.14,10.4)	(0.19,6.78)	(-9.82,0.36)
IQR	(0.51,3.55)	(0.51,1.44)	(-1.53,0.08)

Table S246: Patient level change in Immune Delta 2 Cells Populations.

	Delta 2 Cells			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
6	10.40	0.58	9.82	-94.42
18	3.37	0.98	2.39	-70.92
17	4.08	1.23	2.85	-69.85
8	0.27	0.19	0.08	-29.63
3	0.52	0.40	0.12	-23.08
4	2.15	1.72	0.43	-20.00
14	8.02	6.78	1.24	-15.46
15	1.30	1.34	0.04	3.08
1	2.48	2.84	0.36	14.52
2	0.48	0.55	0.07	14.58
7	0.91	1.11	0.20	21.98
5	0.14	0.25	0.11	78.57

Table S247: Average Difference in Delta 2 Cell Immune Populations.

Absolute Difference	
N	12
Mean	1.48
Median	0.28
Range	(0.04,9.82)
IQR	(0.1,1.53)
Percentage Change	
N	12
Mean	-15.89
Median	-17.73
Range	(-94.42,78.57)
IQR	(-39.69,14.53)

Intermediate Monocytes

All samples (not stratified according to time since de-frost to analysis)

Table S248: Summary of Immune Intermediate Monocyte Populations (all samples).

	Intermediate Monocytes		
	Visit 3	Follow-up Visit 10	Difference
N	12	12	12
Mean	59.23	61.29	2.07
Median	63.45	70.95	4.45
Range	(13.6,87.6)	(0,87.2)	(-25.4,24.5)
IQR	(46.67,79.4)	(46.92,80.95)	(-6.4,12)

Table S249: Patient level change in Immune Intermediate Monocytes Populations (all samples).

	Intermediate Monocytes			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
6	25.4	0.0	25.4	-100.00
14	46.0	36.2	9.8	-21.30
15	78.5	69.7	8.8	-11.21
2	87.6	82.0	5.6	-6.39
17	52.4	50.5	1.9	-3.63
1	82.1	86.4	4.3	5.24
5	82.6	87.2	4.6	5.57
8	68.7	75.4	6.7	9.75
7	68.4	80.6	12.2	17.84
4	58.5	70.5	12.0	20.51
3	46.9	71.4	24.5	52.24
18	13.6	25.6	12.0	88.24

Table S250: Average Difference in Intermediate Monocyte Immune Populations (all samples).

Absolute Difference	
N	12
Mean	10.65
Median	9.3
Range	(1.9,25.4)
IQR	(5.35,12.05)
Percentage Change	
N	12
Mean	4.74
Median	5.4
Range	(-100,88.24)
IQR	(-7.6,18.51)

Samples which were left to rest over night before analysis



Figure S55: Repeated measures plot of immune intermediate monocyte populaions as assessed by flow cytometry at all trial visits in the mITT population for those samples which were rested before analysis. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Table S251: Intermediate Monocytes Immune Cell Populations as Assessed by Flow Cytometry Over All Trial Visits, rested samples only.

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	Visit 11
Intermediate Monocytes (rested samples only)											
N	7	7	7	6	6	6	6	6	6	7	7
Mean	61.13	70.64	64.5	60.97	63.32	65.4	59.88	63.8	63.51	68.3	65.22
Median	75	78.9	68.4	71.6	74.6	70.55	68.7	75.4	74.55	80.6	71.5
Range	(0,80.9)	(28.5,89.5)	(25.4,87.6)	(5.13,84.6)	(6.43,84.9)	(32.8,82.5)	(4.76,82.6)	(1.41,88.6)	(0.55,87.2)	(0,87.2)	(8.47,88.3)
IQR	(57.8,78.2)	(64.55,84.25)	(52.7,82.35)	(53.8,81.67)	(65.32,76.53)	(62.17,75.1)	(61.27,73.95)	(58.62,85.58)	(67.53,77.9)	(70.95,84.2)	(68.4,75.75)

Table S252: Summary of Immune Intermediate Monocyte Populations (rested samples only).

	Intermediate Monocytes		
	Visit 3	Follow-up Visit 10	Difference
N	7	7	7
Mean	64.5	68.3	3.8
Median	68.4	80.6	4.6
Range	(25.4,87.6)	(0,87.2)	(-25.4,24.5)
IQR	(52.7,82.35)	(70.95,84.2)	(-0.65,12.1)

Table S253: Patient level change in Immune Intermediate Monocytes Populations (rested samples only).

	Intermediate Monocytes			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
6	25.4	0.0	25.4	-100.00
2	87.6	82.0	5.6	-6.39
1	82.1	86.4	4.3	5.24
5	82.6	87.2	4.6	5.57
7	68.4	80.6	12.2	17.84
4	58.5	70.5	12.0	20.51
3	46.9	71.4	24.5	52.24

Table S254: Average Difference in Intermediate Monocyte Immune Populations (rested samples only).

Absolute Difference	
N	7
Mean	12.66
Median	12
Range	(4.3,25.4)
IQR	(5.1,18.35)
Percentage Change	
N	7
Mean	-0.71
Median	5.57
Range	(-100,52.24)
IQR	(-0.58,19.17)

Samples which were analysed immediately after de-frosting



Figure S56: Repeated measures plot of immune classical monocyte populaions as assessed by flow cytometry at all trial visits in the mITT population for those samples which were only defrosted before analysis. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded greyregion.

Table S255: Classical Monocytes Immune Cell Populations as Assessed by Flow Cytometry Over All Trial Visits, defrosted samples only.

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	Visit 11
Intermediate Monocytes (defrosted samples only)											
N	5	5	5	5	5	5	5	5	5	5	5
Mean	36.3	44.7	51.84	51.46	42.62	44.58	43.32	50.78	47.42	51.48	49.6
Median	30.5	39.1	52.4	43.3	36.4	49.3	39.8	60.5	47.2	50.5	58.6
Range	(12,65.2)	(25.9,74.8)	(13.6,78.5)	(29.4,78.9)	(20,74.7)	(13.1,66.3)	(18.1,60)	(14.4,64.6)	(33.1,61.4)	(25.6,75.4)	(15.8,70.5)
IQR	(19,54.8)	(28.5,55.2)	(46,68.7)	(32.6,73.1)	(24.6,57.4)	(35.9,58.3)	(39.2,59.5)	(50.6,63.8)	(35,60.4)	(36.2,69.7)	(39.4,63.7)

Table S256: Summary of Immune Intermediate Monocyte Populations (defrosted samples only).

	Intermediate Monocytes		
	Visit 3	Follow-up Visit 10	Difference
N	5	5	5
Mean	51.84	51.48	-0.36
Median	52.4	50.5	-1.9
Range	(13.6,78.5)	(25.6,75.4)	(-9.8,12)
IQR	(46,68.7)	(36.2,69.7)	(-8.8,6.7)

Table S257: Patient level change in Immune Intermediate Monocytes Populations (defrosted samples only).

	Intermediate Monocytes			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
14	46.0	36.2	9.8	-21.30
15	78.5	69.7	8.8	-11.21
17	52.4	50.5	1.9	-3.63
8	68.7	75.4	6.7	9.75
18	13.6	25.6	12.0	88.24

Table S258: Average Difference in Intermediate Monocyte Immune Populations (defrosted samples only).

Absolute Difference	
N	5
Mean	7.84
Median	8.8
Range	(1.9,12)
IQR	(6.7,9.8)
Percentage Change	
N	5
Mean	12.37
Median	-3.63
Range	(-21.3,88.24)
IQR	(-11.21,9.75)

NK Cells

Table S259: Summary of Immune NK Cell Populations.

	NK Cells		
	Visit 3	**Follow-up Visit 10**	**Difference**
N	12	12	12
Mean	11.93	10.33	-1.61
Median	8.61	5.62	-0.26
Range	(0.61,41.4)	(0.29,36.3)	(-7.49,4.2)
IQR	(4.29,13.7)	(2.73,15.2)	(-4.61,1.03)

Table S260: Patient level change in Immune NK Cells Populations.

	NK Cells			
Patient Number	**Visit 3**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
6	8.13	0.64	7.49	-92.13
7	0.61	0.29	0.32	-52.46
18	9.09	4.64	4.45	-48.95
14	13.10	9.45	3.65	-27.86
2	28.50	22.60	5.90	-20.70
8	41.40	36.30	5.10	-12.32
1	2.81	2.60	0.21	-7.47
3	4.78	4.73	0.05	-1.05
15	12.10	13.70	1.60	13.22
17	5.49	6.50	1.01	18.40
5	15.50	19.70	4.20	27.10
4	1.68	2.77	1.09	64.88

Table S261: Average Difference in NK Cell Immune Populations.

Absolute Difference	
N	12
Mean	2.92
Median	2.62
Range	(0.05,7.49)
IQR	(0.84,4.61)
Percentage Change	
N	12
Mean	-11.61
Median	-9.9
Range	(-92.13,64.88)
IQR	(-33.14,14.52)

NKT Cells

Table S262: Summary of Immune NKT Cell Populations.

	NKT Cells		
	Visit 3	Follow-up Visit 10	Difference
N	12	12	12
Mean	7.37	5.68	-1.69
Median	3	2.3	-0.01
Range	(0.35,34.4)	(0.44,20)	(-32.44,18.04)
IQR	(0.98,8.84)	(1.23,5.77)	(-1.77,0.97)

Table S263: Patient level change in Immune NKT Cells Populations.

	NK Cells			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
7	34.40	1.96	32.44	-94.30
2	8.61	2.65	5.96	-69.22
18	3.23	1.24	1.99	-61.61
1	4.12	2.96	1.16	-28.16
14	0.58	0.47	0.11	-18.97
4	21.30	19.60	1.70	-7.98
8	1.11	1.21	0.10	9.01
15	0.35	0.44	0.09	25.71
3	9.54	12.20	2.66	27.88
5	2.76	3.63	0.87	31.52
17	0.48	1.76	1.28	266.67
6	1.96	20.00	18.04	920.41

Table S264: Average Difference in NKT Cell Immune Populations.

Absolute Difference	
N	12
Mean	5.53
Median	1.49
Range	(0.09,32.44)
IQR	(0.68,3.48)
Percentage Change	
N	12
Mean	83.41
Median	0.51
Range	(-94.3,920.41)
IQR	(-36.52,28.79)

Non-Classical Monocytes

All samples (not stratified according to time since de-frost to analysis)

Table S265: Summary of Immune Non-Classical Monocyte Populations (all samples).

	Non-Classical Monocytes		
	Visit 3	Follow-up Visit 10	Difference
N	12	12	12
Mean	3.03	1.54	-1.49
Median	2.29	0.31	-0.64
Range	(0.09,7.63)	(0,7.59)	(-7.41,2.16)
IQR	(0.83,5.46)	(0.21,1.57)	(-2.51,-0.14)

Table S266: Patient level change in Immune Non-Classical Monocytes Populations (all samples).

	Non-Classical Monocytes			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
6	2.33	0.00	2.33	-100.00
14	7.63	0.22	7.41	-97.12
17	2.24	0.19	2.05	-91.52
4	0.09	0.02	0.07	-75.86
18	0.95	0.23	0.72	-75.79
3	4.40	1.35	3.05	-69.32
1	0.83	0.27	0.56	-67.47
7	5.57	2.21	3.36	-60.32
5	0.51	0.35	0.16	-31.37
8	5.58	5.07	0.51	-9.14
2	0.83	0.99	0.16	19.28
15	5.43	7.59	2.16	39.78

Table S267: Average Difference in Non-Classical Monocytes Immune Populations (all samples).

Absolute Difference	
N	12
Mean	1.88
Median	1.39
Range	(0.07,7.41)
IQR	(0.42,2.51)
Percentage Change	
N	12
Mean	-51.57
Median	-68.39
Range	(-100,39.78)
IQR	(-79.78,-25.81)

Samples which were left to rest over night before analysis



Figure S57: Repeated measures plot of immune non-classical monocyte populaions as assessed by flow cytometry at all trial visits in the mITT population for those samples which were rested before analysis. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Table S268: Non-Classical Monocytes Immune Cell Populations as Assessed by Flow Cytometry Over All Trial Visits, rested samples only.

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	Visit 11
Non-Classical Monocytes (rested samples only)											
N	7	7	7	6	6	6	6	6	6	7	7
Mean	5.57	1.1	2.08	1.14	1.21	1.6	1.35	0.8	1.12	0.74	0.94
Median	0.9	0.9	0.83	0.88	1.17	1.42	1.17	0.46	0.65	0.35	0.75
Range	(0,34.6)	(0.06,3.62)	(0.09,5.57)	(0.05,2.56)	(0.08,2.53)	(0.09,4.25)	(0.09,3.17)	(0,3.07)	(0,3.6)	(0,2.21)	(0.06,2.53)
IQR	(0.29,1.46)	(0.37,1.21)	(0.67,3.37)	(0.39,1.88)	(0.71,1.62)	(0.43,2.12)	(0.8,1.65)	(0.2,0.63)	(0.2,1.51)	(0.15,1.17)	(0.52,1.12)

Table S269: Summary of Immune Non-Classical Monocyte Populations (rested samples only).

	Non-Classical Monocytes		
	Visit 3	Follow-up Visit 10	Difference
N	7	7	7
Mean	2.08	0.74	-1.34
Median	0.83	0.35	-0.56
Range	(0.09,5.57)	(0,2.21)	(-3.36,0.16)
IQR	(0.67,3.37)	(0.15,1.17)	(-2.69,-0.11)

Table S270: Patient level change in Immune Non-Classical Monocytes Populations (rested samples only).

	Non-Classical Monocytes			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
6	2.33	0.00	2.33	-100.00
4	0.09	0.02	0.07	-75.86
3	4.40	1.35	3.05	-69.32
1	0.83	0.27	0.56	-67.47
7	5.57	2.21	3.36	-60.32
5	0.51	0.35	0.16	-31.37
2	0.83	0.99	0.16	19.28

Table S271: Average Difference in Non-Classical Monocyte Immune Populations (rested samples only).

Absolute Difference	
N	7
Mean	1.38
Median	0.56
Range	(0.07,3.36)
IQR	(0.16,2.69)
Percentage Change	
N	7
Mean	-55.01
Median	-67.47
Range	(-100,19.28)
IQR	(-72.59,-45.85)

Samples which were analysed immediately after de-frosting



Figure S58: Repeated measures plot of immune non-classical monocyte populaions as assessed by flow cytometry at all trial visits in the mITT population for those samples which were only defrosted before analysis. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Table S272: Non-Classical Monocytes Immune Cell Populations as Assessed by Flow Cytometry Over All Trial Visits, defrosted samples only.

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	Visit 11
Non-Classical Monocytes (defrosted samples only)											
N	5	5	5	5	5	5	5	5	5	5	5
Mean	3.13	3.23	4.37	3.36	3.62	4.88	3.34	3.48	3.14	2.66	2.24
Median	2.64	4.1	5.43	2.5	1.09	4.78	2.05	3.13	1.31	0.23	0.84
Range	(0.89,6.99)	(1.21,5.24)	(0.95,7.63)	(0.74,7.61)	(0.43,10.1)	(1.12,10.3)	(1.31,9.3)	(1.08,7.83)	(0.14,8.38)	(0.19,7.59)	(0.13,5.87)
IQR	(1.06,4.08)	(1.41,4.17)	(2.24,5.58)	(1.4,4.56)	(0.83,5.66)	(2.35,5.84)	(1.47,2.59)	(1.53,3.82)	(0.34,5.54)	(0.22,5.07)	(0.72,3.65)

Table S273: Summary of Immune Non-Classical Monocyte Populations (defrosted samples only).

	Non-Classical Monocytes		
	Visit 3	Follow-up Visit 10	Difference
N	5	5	5
Mean	4.37	2.66	-1.71
Median	5.43	0.23	-0.72
Range	(0.95,7.63)	(0.19,7.59)	(-7.41,2.16)
IQR	(2.24,5.58)	(0.22,5.07)	(-2.05,-0.51)

Table S274: Patient level change in Immune Non-Classical Monocytes Populations (defrosted samples only).

	Non-Classical Monocytes			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
14	7.63	0.22	7.41	-97.12
17	2.24	0.19	2.05	-91.52
18	0.95	0.23	0.72	-75.79
8	5.58	5.07	0.51	-9.14
15	5.43	7.59	2.16	39.78

Table S275: Average Difference in Non-Classical Monocyte Immune Populations (defrosted samples only).

Absolute Difference	
N	5
Mean	2.57
Median	2.05
Range	(0.51,7.41)
IQR	(0.72,2.16)
Percentage Change	
N	5
Mean	-46.76
Median	-75.79
Range	(-97.12,39.78)
IQR	(-91.52,-9.14)

Th17 Cells

Table S276: Summary of Immune Th17 Cell Populations.

	Th17 Cells		
	Visit 3	Follow-up Visit 10	Difference
N	12	12	12
Mean	4.57	2.84	-1.73
Median	4.51	3.03	-0.92
Range	(0,9.09)	(0.09,4.91)	(-4.23,0.43)
IQR	(1.95,6.71)	(1.14,4.47)	(-3.92,0.07)

Table S277: Patient level change in Immune Th17 Cells Populations.

	Th17 Cells			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
6	3.86	0.45	3.41	-88.34
17	5.99	2.11	3.88	-64.77
4	9.09	4.86	4.23	-46.53
18	8.86	4.80	4.06	-45.82
2	9.03	4.91	4.12	-45.63
8	5.17	4.18	0.99	-19.15
1	5.22	4.36	0.86	-16.48
14	1.21	1.14	0.07	-5.79
3	3.36	3.43	0.07	2.08
5	2.20	2.63	0.43	19.55
15	0.82	1.13	0.31	37.80
7	0.00	0.09	0.09	Inf

Table S278: Average Difference in Th17 Cell Immune Populations.

Absolute Difference	
N	12
Mean	1.88
Median	0.92
Range	(0.07,4.23)
IQR	(0.25,3.92)
Percentage Change	
N	12
Mean	Inf
Median	-17.81
Range	(-88.34,Inf)
IQR	(-46,6.45)

Treg Cells

Table S279: Summary of Immune Treg Cell Populations.

	Treg Cells		
	Visit 3	Follow-up Visit 10	Difference
N	12	12	12
Mean	5.79	6.58	0.79
Median	5.92	6.65	0.75
Range	(2.91,7.96)	(4.7,8.3)	(-2.39,4.87)
IQR	(4.46,7.27)	(5.79,7.34)	(-0.19,1.5)

Table S280: Patient level change in Immune Treg Cells Populations.

	Treg Cells			
Patient Number	Visit 3	Follow-up Visit 10	Absolute Difference	Percentage change (%)
3	7.82	5.43	2.39	-30.56
17	7.96	5.80	2.16	-27.14
4	7.24	6.94	0.30	-4.14
2	5.92	5.77	0.15	-2.53
5	7.35	7.19	0.16	-2.18
15	7.12	7.80	0.68	9.55
8	5.93	7.07	1.14	19.22
14	3.88	4.70	0.82	21.13
18	4.58	5.83	1.25	27.29
1	4.12	6.36	2.24	54.37
6	4.64	8.30	3.66	78.88
7	2.91	7.78	4.87	167.35

Table S281: Average Difference in Treg Cell Immune Populations.

Absolute Difference	
N	12
Mean	1.65
Median	1.2
Range	(0.15,4.87)
IQR	(0.58,2.28)
Percentage Change	
N	12
Mean	25.94
Median	14.39
Range	(-30.56,167.35)
IQR	(-2.94,34.06)

in the composition of the scar tissue.

The following exploratory biomarkers were assessed:

- C3M,
- C4M2,
- C5M,
- COL-18N,
- ELM7,
- EL-NE,
- P4NP7S,
- PRO-C3, and
- PRO-C5.

Of the above list of biomarkers, some represent new matrix (increase fibrosis) while other represent breakdown (reduced fibrosis or remodelling). P4NP7S, PRO-C3, and PRO-C5 are synthesis (collagen formation) biomarkers; and C3M, C4M2, and C5M are degradation (collagen degradation) biomarkers. Finally COL-18N, EL-NE, and ELM7 are are exploratory, collagen 18 synthesis and elastin remodelling markers. While there is less evidence for the analysis of such biomarkers, they were included in case they were informative.

The results for each are shown separately. Tables are presented showing descriptive analyses of each exploratory biomarker measurement at visit 3 (first treatment visit, pre-infusion) and visit 10 (follow-up). Descriptive analyses regarding the differences in exploratory biomarker values between trial visits are also shown.

For each exploratory biomarker μ, the following calculations are made: The difference is calculated as

$$\text{Difference} = \mu_{\text{Visit 10}} - \mu_{\text{Visit 3 (pre-infusion)}} \tag{28}$$

and the percentage change is calculated as

$$\text{Percentage change} = \frac{\mu_{\text{Visit 10}} - \mu_{\text{Visit 3 (pre-infusion)}}}{\mu_{\text{Visit 3 (pre-infusion)}}} \tag{29}$$

Table S282: Exploratory Biomarker Results.

	Visit 3	Visit 7	Follow-up Visit 10	Follow-up Visit 11
C3M				
N	14	14	14	14
Mean	15.81	15.01	15.69	15.66
Median	15.5	14.75	16.15	15.4
Range	(8.4,22.6)	(10.9,23.9)	(9.8,23.7)	(10.5,20.8)
IQR	(13.7,17.9)	(12.15,17.05)	(12.25,18.15)	(12.025,19.3)
C4M2				
N	14	14	14	14
Mean	27.48	25.76	26.64	27.1
Median	27.2	26.3	26.1	27.25
Range	(8.9,51.2)	(6.8,43)	(8,44.8)	(8.7,44.9)
IQR	(23.575,29.725)	(21.975,30.9)	(19.65,32.55)	(21.3,33.9)
C5M				
N	14	14	14	14
Mean	4.79	4.56	4.86	4.73
Median	4.65	4.8	4.9	4.45
Range	(2,9.2)	(2,9.3)	(2,9.7)	(2,10.8)
IQR	(3.225,6.525)	(2.875,5.85)	(3.2,6.15)	(3.175,6.025)
COL-18N				
N	14	14	14	14
Mean	10.19	10.51	9.47	8.78
Median	4.8	5.3	4.8	6.85
Range	(4.8,34)	(4.8,35.9)	(4.8,40.5)	(4.8,24.4)
IQR	(4.8,11.8)	(4.8,12.1)	(4.8,10.6)	(4.8,10.425)
ELM7				
N	14	14	14	14
Mean	2.94	2.84	2.89	2.83
Median	2.805	3.1	2.96	2.765
Range	(0.9,5.12)	(1.14,4.15)	(1.05,4.53)	(1.32,4.55)
IQR	(2.5525,3.8175)	(2.4225,3.6025)	(2.69,3.5425)	(2.5675,3.435)
EL-NE				
N	14	14	14	14
Mean	5.02	5.06	5.16	4.83
Median	3.7	3.2	3.2	3.2
Range	(3.2,12.5)	(3.2,14)	(3.2,16.5)	(3.2,15.8)
IQR	(3.2,6.625)	(3.2,3.875)	(3.2,5.55)	(3.2,5.025)
P4NP7S				
N	14	14	14	14
Mean	248.67	218.56	243.45	245.58
Median	229	211.5	225.15	239.6
Range	(52.3,548.8)	(41.8,372.4)	(57.4,427.8)	(50.1,471.9)
IQR	(166.2,315.125)	(149.475,263.525)	(152.075,304.225)	(167.8,299.075)
PRO-C3				
N	14	14	14	14
Mean	23.9	23.74	22.54	25.67
Median	19.5	16.35	15.95	18.2
Range	(8.6,60.5)	(9.7,53.4)	(8.4,49.8)	(9.1,93.5)
IQR	(14.375,31.325)	(12.775,29.025)	(13.5,31.3)	(14.275,27.95)
PRO-C5				
N	14	14	14	14
Mean	530.96	471.78	572.83	538.64
Median	344.55	377.95	365.35	344.65
Range	(41.6,1288.6)	(41.6,1782.6)	(41.6,1738.2)	(41.6,1525.8)
IQR	(41.6,907.15)	(41.6,557.175)	(41.6,964.9)	(41.6,958.2)



Figure S59: Repeated measures plot of all exploratory biomarkers at all trial visits with loess smoother trend line in the mITT population, presented by exploratory biomarker.

C3M

Table S283: Summary of C3M between baseline and follow-up.

	C3M		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	14	14	14
Mean	15.81	15.69	-0.13
Median	15.5	16.15	-1.5
Range	(8.4,22.6)	(9.8,23.7)	(-3.6,4.3)
IQR	(13.7,17.9)	(12.25,18.15)	(-1.9,2.75)

Table S284: Patient level change in C3M.

	C3M			
Patient Number	**Visit 3 (pre-infusion)**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
18	13.4	9.8	3.6	-26.87
7	16.5	14.0	2.5	-15.15
1	13.5	11.6	1.9	-14.07
15	12.0	10.4	1.6	-13.33
9	17.6	15.5	2.1	-11.93
8	20.2	18.3	1.9	-9.41
3	19.5	17.7	1.8	-9.23
6	15.3	13.9	1.4	-9.15
19	18.0	16.8	1.2	-6.67
4	22.6	23.7	1.1	4.87
14	14.4	18.0	3.6	25.00
17	14.3	18.2	3.9	27.27
5	15.7	20.0	4.3	27.39
12	8.4	11.7	3.3	39.29

Table S285: Average Difference in C3M

Absolute Difference	
N	14
Mean	2.44
Median	2
Range	(1.1,4.3)
IQR	(1.65,3.525)
Percentage Change	
N	14
Mean	0.57
Median	-9
Range	(-27,39)
IQR	(-12.75,20)

C4M2

Table S286: Summary of C4M2 between baseline and follow-up.

	C4M2		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	14	14	14
Mean	27.48	26.64	-0.84
Median	27.2	26.1	-1.8
Range	(8.9,51.2)	(8,44.8)	(-8.8,10.3)
IQR	(23.575,29.725)	(19.65,32.55)	(-3.975,2.475)

Table S287: Patient level change in C4M2.

	C4M2			
Patient Number	**Visit 3 (pre-infusion)**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
15	29.8	21.0	8.8	-29.53
6	25.5	19.2	6.3	-24.71
3	27.9	23.6	4.3	-15.41
18	19.5	16.5	3.0	-15.38
5	51.2	44.8	6.4	-12.50
9	26.5	23.5	3.0	-11.32
12	8.9	8.0	0.9	-10.11
8	35.4	32.7	2.7	-7.63
19	29.5	28.6	0.9	-3.05
1	14.5	14.2	0.3	-2.07
4	39.6	43.9	4.3	10.86
7	28.7	32.1	3.4	11.85
14	23.3	30.1	6.8	29.18
17	24.4	34.7	10.3	42.21

Table S288: Average Difference in C4M2

Absolute Difference	
N	14
Mean	4.39
Median	3.85
Range	(0.3,10.3)
IQR	(2.775,6.375)
Percentage Change	
N	14
Mean	-2.71
Median	-9
Range	(-30,42)
IQR	(-14.5,7.75)

C5M

Table S289: Summary of C5M between baseline and follow-up.

	C5M		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	14	14	14
Mean	4.79	4.86	0.07
Median	4.65	4.9	0.05
Range	(2,9.2)	(2,9.7)	(-1.2,1.3)
IQR	(3.225,6.525)	(3.2,6.15)	(-0.15,0.45)

Table S290: Patient level change in C5M.

	C5M			
Patient Number	**Visit 3 (pre-infusion)**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
7	4.4	3.2	1.2	-27.27
19	6.3	5.1	1.2	-19.05
17	6.7	6.2	0.5	-7.46
9	3.3	3.1	0.2	-6.06
1	2.0	2.0	0.0	0.00
3	2.0	2.0	0.0	0.00
14	3.2	3.2	0.0	0.00
18	6.6	6.7	0.1	1.52
6	4.6	4.7	0.1	2.17
8	9.2	9.7	0.5	5.43
15	5.3	5.6	0.3	5.66
4	6.7	7.2	0.5	7.46
5	4.7	6.0	1.3	27.66
12	2.0	3.3	1.3	65.00

Table S291: Average Difference in C5M

Absolute Difference	
N	14
Mean	0.51
Median	0.4
Range	(0,1.3)
IQR	(0.1,1.025)
Percentage Change	
N	14
Mean	4
Median	1
Range	(-27,65)
IQR	(-4.5,5.75)

COL-18N

Table S292: Summary of COL-18N between baseline and follow-up.

	COL-18N		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	14	14	14
Mean	10.19	9.47	-0.72
Median	4.8	4.8	0
Range	(4.8,34)	(4.8,40.5)	(-14.5,6.5)
IQR	(4.8,11.8)	(4.8,10.6)	(0,0)

Table S293: Patient level change in COL-18N.

	COL-18N			
Patient Number	**Visit 3 (pre-infusion)**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
9	24.1	9.6	14.5	-60.17
17	16.6	10.7	5.9	-35.54
19	12.6	12.4	0.2	-1.59
1	4.8	4.8	0.0	0.00
3	4.8	4.8	0.0	0.00
4	4.8	4.8	0.0	0.00
5	4.8	4.8	0.0	0.00
6	4.8	4.8	0.0	0.00
7	4.8	4.8	0.0	0.00
12	4.8	4.8	0.0	0.00
14	4.8	4.8	0.0	0.00
18	9.4	10.7	1.3	13.83
8	34.0	40.5	6.5	19.12
15	7.6	10.3	2.7	35.53

Table S294: Average Difference in COL-18N

Absolute Difference	
N	14
Mean	2.22
Median	0
Range	(0,14.5)
IQR	(0,2.35)
Percentage Change	
N	14
Mean	-2.07
Median	0
Range	(-60,36)
IQR	(0,0)

ELM7

Table S295: Summary of ELM7 between baseline and follow-up.

	ELM7		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	14	14	14
Mean	2.94	2.89	-0.04
Median	2.805	2.96	0
Range	(0.9,5.12)	(1.05,4.53)	(-1.62,0.75)
IQR	(2.5525,3.8175)	(2.69,3.5425)	(-0.285,0.34)

Table S296: Patient level change in ELM7

	ELM7			
Patient Number	**Visit 3 (pre-infusion)**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
9	4.58	2.96	1.62	-35.37
3	1.35	1.05	0.30	-22.22
5	5.12	4.53	0.59	-11.52
6	4.29	3.92	0.37	-8.62
18	3.03	2.81	0.22	-7.26
15	3.86	3.62	0.24	-6.22
8	2.67	2.65	0.02	-0.75
7	2.94	2.96	0.02	0.68
17	2.66	2.86	0.20	7.52
19	3.69	4.03	0.34	9.21
4	2.55	3.09	0.54	21.18
14	2.56	3.31	0.75	29.30
1	0.90	1.24	0.34	37.78
12	0.90	1.48	0.58	64.44

Table S297: Average Difference in ELM7

Absolute Difference	
N	14
Mean	0.44
Median	0.34
Range	(0.02,1.62)
IQR	(0.225,0.57)
Percentage Change	
N	14
Mean	5.57
Median	0
Range	(-35,64)
IQR	(-8.5,18)

EL-NE

Table S298: Summary of EL-NE between baseline and follow-up.

	EL-NE		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	14	14	14
Mean	5.02	5.16	0.14
Median	3.7	3.2	-0.05
Range	(3.2,12.5)	(3.2,16.5)	(-2.5,6.2)
IQR	(3.2,6.625)	(3.2,5.55)	(-0.8,0)

Table S299: Patient level change in EL-NE.

	EL-NE			
Patient Number	**Visit 3 (pre-infusion)**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
5	7.6	5.1	2.5	-32.89
18	8.0	5.7	2.3	-28.75
8	7.5	5.8	1.7	-22.67
6	4.0	3.2	0.8	-20.00
9	4.0	3.2	0.8	-20.00
17	3.3	3.2	0.1	-3.03
15	3.8	3.7	0.1	-2.63
1	3.2	3.2	0.0	0.00
3	3.2	3.2	0.0	0.00
7	3.2	3.2	0.0	0.00
12	3.2	3.2	0.0	0.00
14	3.2	3.2	0.0	0.00
19	12.5	16.5	4.0	32.00
4	3.6	9.8	6.2	172.22

Table S300: Average Difference in EL-NE

Absolute Difference	
N	14
Mean	1.32
Median	0.45
Range	(0,6.2)
IQR	(0,2.15)
Percentage Change	
N	14
Mean	5.21
Median	-1.5
Range	(-33,172)
IQR	(-20,0)

P4NP7S

Table S301: Summary of P4NP7S between baseline and follow-up.

	P4NP7S		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	14	14	14
Mean	248.67	243.45	-5.22
Median	229	225.15	-10.4
Range	(52.3,548.8)	(57.4,427.8)	(-121,82.7)
IQR	(166.2,315.125)	(152.075,304.225)	(-34.475,33.025)

Table S302: Patient level change in P4NP7S

	P4NP7S			
Patient Number	**Visit 3 (pre-infusion)**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
18	160.3	119.8	40.5	-25.27
3	288.8	220.2	68.6	-23.75
5	548.8	427.8	121.0	-22.05
6	214.0	187.4	26.6	-12.43
19	323.9	286.8	37.1	-11.45
15	158.2	140.3	17.9	-11.31
9	230.9	216.6	14.3	-6.19
1	136.1	129.6	6.5	-4.78
8	380.4	395.2	14.8	3.89
12	52.3	57.4	5.1	9.75
7	248.4	287.5	39.1	15.74
4	328.3	399.8	71.5	21.78
17	183.9	230.1	46.2	25.12
14	227.1	309.8	82.7	36.42

Table S303: Average Difference in P4NP7S

Absolute Difference	
N	14
Mean	42.28
Median	38.1
Range	(5.1,121)
IQR	(15.575,63)
Percentage Change	
N	14
Mean	-0.21
Median	-5.5
Range	(-25,36)
IQR	(-11.75,14.5)

PRO-C3

Table S304: Summary of PRO-C3 between baseline and follow-up.

	PRO-C3		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	14	14	14
Mean	23.9	22.54	-1.36
Median	19.5	15.95	-0.2
Range	(8.6,60.5)	(8.4,49.8)	(-28.2,13.5)
IQR	(14.375,31.325)	(13.5,31.3)	(-3.25,2.75)

Table S305: Patient level change in PRO-C3

	PRO-C3			
Patient Number	**Visit 3 (pre-infusion)**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
15	60.5	32.3	28.2	-46.61
18	21.2	13.8	7.4	-34.91
19	17.1	13.4	3.7	-21.64
12	16.7	13.4	3.3	-19.76
3	20.5	17.4	3.1	-15.12
1	18.5	16.0	2.5	-13.51
6	8.6	8.4	0.2	-2.33
4	33.3	33.1	0.2	-0.60
5	25.4	28.3	2.9	11.42
17	44.4	49.8	5.4	12.16
9	13.6	15.9	2.3	16.91
7	9.0	11.2	2.2	24.44
8	12.4	15.7	3.3	26.61
14	33.4	46.9	13.5	40.42

Table S306: Average Difference in PRO-C3

Absolute Difference	
N	14
Mean	5.59
Median	3.2
Range	(0.2,28.2)
IQR	(2.35,4.975)
Percentage Change	
N	14
Mean	-1.79
Median	-1.5
Range	(-47,40)
IQR	(-18.75,15.75)

PRO-C5

Table S307: Summary of PRO-C5 between baseline and follow-up.

	PRO-C5		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	14	14	14
Mean	530.96	572.83	41.86
Median	344.55	365.35	0
Range	(41.6,1288.6)	(41.6,1738.2)	(-178.6,494.5)
IQR	(41.6,907.15)	(41.6,964.9)	(-26.325,61.45)

Table S308: Patient level change in PRO-C5

	PRO-C5

Patient Number	Visit 3 (pre-infusion)	Follow-up Visit 10	Absolute Difference	Percentage change (%)
5	287.7	137.0	150.7	-52.38
18	867.1	705.4	161.7	-18.65
8	1269.5	1090.9	178.6	-14.07
6	366.1	331.0	35.1	-9.59
1	41.6	41.6	0.0	0.00
3	41.6	41.6	0.0	0.00
7	41.6	41.6	0.0	0.00
12	41.6	41.6	0.0	0.00
14	41.6	41.6	0.0	0.00
9	659.3	675.0	15.7	2.38
17	920.5	1051.4	130.9	14.22
15	323.0	399.7	76.7	23.75
19	1288.6	1683.0	394.4	30.61
4	1243.7	1738.2	494.5	39.76

Table S309: Average Difference in PRO-C5

Absolute Difference	
N	14
Mean	117.02
Median	55.9
Range	(0,494.5)
IQR	(0,158.95)
Percentage Change	
N	14
Mean	1.14
Median	0
Range	(-52,40)
IQR	(-7.5,11)

D.10.27 Exploratory Biomarker Ratios

The following exploratory biomarkers ratios were assessed:

- C3M/PRO-C3,
- C4M2/P4NP7S, and
- C5M/PRO-C5.

The ratios of such biomarkers allow us to assess the balance between ECM synthesis and ECM degradation. These assays are perceived to be more information than the ELF test and aide in the understanding of the biology behind any changes we might see.

The results for each are shown separately. Tables are presented showing descriptive analyses of each exploratory biomarker ratio measurement at visit 3 (first treatment visit, pre-infusion) and visit 10 (follow-up). Descriptive analyses regarding the differences in exploratory biomarker ratio values between trial visits are also shown.

For each exploratory biomarker ratio μ, the following calculations are made: The difference is calculated as

$$\text{Difference} = \mu_{\text{Visit 10}} - \mu_{\text{Visit 3 (pre-infusion)}} \tag{30}$$

and the percentage change is calculated as

$$\text{Percentage change} = \frac{\mu_{\text{Visit 10}} - \mu_{\text{Visit 3 (pre-infusion)}}}{\mu_{\text{Visit 3 (pre-infusion)}}} \tag{31}$$

Table S310: Exploratory Biomarker Results.

	Visit 3	Visit 7	Follow-up Visit 10	Follow-up Visit 11
C3M/ProC3				
N	14	14	14	14
Mean	0.9	0.85	0.87	0.83
Median	0.7	0.85	0.8	0.79
Range	(0.2,1.83)	(0.23,1.48)	(0.32,1.65)	(0.2,1.53)
IQR	(0.53,1.23)	(0.63,1.13)	(0.71,1.13)	(0.69,0.9)
C4M2/P4NP7S				
N	14	14	14	14
Mean	0.12	0.12	0.12	0.12
Median	0.12	0.11	0.11	0.11
Range	(0.09,0.19)	(0.09,0.18)	(0.08,0.15)	(0.09,0.17)
IQR	(0.1,0.12)	(0.11,0.13)	(0.1,0.13)	(0.1,0.12)
C5M/ProC5				
N	12	12	11	11
Mean	0.02	0.02	0.02	0.02
Median	0.01	0.01	0.01	0.01
Range	(0,0.05)	(0,0.05)	(0,0.05)	(0,0.05)
IQR	(0.01,0.02)	(0.01,0.05)	(0.01,0.03)	(0.01,0.03)



Figure S60: Repeated measures plot of all exploratory biomarkers ratios at all trial visits in the mITT population, presented by exploratory biomarker ratio. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.



Figure S61: Repeated measures plot of the mean of exploratory biomarkers ratios at all trial visits with standard error of the mean error bars in the mITT population, presented by exploratory biomarker ratio.



Figure S62: Repeated measures plot of all exploratory biomarkers ratios at all trial visits, presented by exploratory biomarker ratio. The mean of each exploratory biomarkers ratios at all trial visits is shown in black with error bars depicting the standard error.

C3M/PRO-C3

Table S311: Summary of C3M/PRO-C3 between baseline and follow-up.

	C3M/PRO-C3		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	14	14	14
Mean	0.9	0.87	-0.04
Median	0.704204204204204	0.799067164179105	0.04
Range	(0.2,1.83)	(0.32,1.65)	(-0.58,0.37)
IQR	(0.53,1.23)	(0.71,1.13)	(-0.11,0.09)

Table S312: Patient level change in C3M/PRO-C3.

	C3M/PRO-C3			
Patient Number	**Visit 3 (pre-infusion)**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
7	1.83	1.25	0.58	-31.82
8	1.63	1.17	0.46	-28.45
9	1.29	0.97	0.32	-24.67
14	0.43	0.38	0.05	-10.98
6	1.78	1.65	0.12	-6.99
1	0.73	0.72	0.00	-0.65
4	0.68	0.72	0.04	5.50
3	0.95	1.02	0.07	6.94
18	0.63	0.71	0.08	12.35
17	0.32	0.37	0.04	13.47
5	0.62	0.71	0.09	14.33
19	1.05	1.25	0.20	19.10
15	0.20	0.32	0.12	62.33
12	0.50	0.87	0.37	73.59

Table S313: Average Difference in C3M/PRO-C3

Absolute Difference	
N	14
Mean	0.18
Median	0.11
Range	(0,0.58)
IQR	(0.05,0.29)
Percentage Change	
N	14
Mean	7.36
Median	6.5
Range	(-32,74)
IQR	(-10,13.75)

C4M2/P4NP7S

Table S314: Summary of C4M2/P4NP7S between baseline and follow-up.

	C4M2/P4NP7S		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	14	14	14
Mean	0.12	0.12	0
Median	0.12	0.11	0
Range	(0.09,0.19)	(0.08,0.15)	(-0.04,0.02)
IQR	(0.1,0.12)	(0.1,0.13)	(-0.01,0.01)

Table S315: Patient level change in C4M2/P4NP7S.

	C4M2/P4NP7S			
Patient Number	**Visit 3 (pre-infusion)**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
15	0.19	0.15	0.04	-20.54
12	0.17	0.14	0.03	-18.10
6	0.12	0.10	0.02	-14.02
8	0.09	0.08	0.01	-11.09
4	0.12	0.11	0.01	-8.97
9	0.11	0.11	0.01	-5.47
14	0.10	0.10	0.01	-5.30
7	0.12	0.11	0.00	-3.36
1	0.11	0.11	0.00	2.84
19	0.09	0.10	0.01	9.49
3	0.10	0.11	0.01	10.94
5	0.09	0.10	0.01	12.25
18	0.12	0.14	0.02	13.22
17	0.13	0.15	0.02	13.66

Table S316: Average Difference in C4M2/P4NP7S

Absolute Difference	
N	14
Mean	0.01
Median	0.01
Range	(0,0.04)
IQR	(0.01,0.02)
Percentage Change	
N	14
Mean	-1.71
Median	-4
Range	(-21,14)
IQR	(-10.5,10.5)

C5M/PRO-C5

Table S317: Summary of C5M/PRO-C5 between baseline and follow-up.

	C5M/PRO-C5		
	Visit 3 (pre-infusion)	**Follow-up Visit 10**	**Difference**
N	12	11	11
Mean	0.02	0.02	0
Median	0.01	0.01	0
Range	(0,0.05)	(0,0.05)	(0,0.03)
IQR	(0.01,0.02)	(0.01,0.03)	(0,0)

Table S318: Patient level change in C5M/PRO-C5.

	C5M/PRO-C5			
Patient Number	**Visit 3 (pre-infusion)**	**Follow-up Visit 10**	**Absolute Difference**	**Percentage change (%)**
4	0.01	0	0.01	-100
9	0.01	0	0.01	-100
19	0.00	0	0	-100
15	0.02	0.01	0.01	-39.06
6	0.01	0.01	0	-20.41
1	0.05	0.05	0	4
3	0.05	0.05	0	4
18	0.01	0.01	0	31.38
17	0.01	0.01	0	37.39
8	0.01	0.01	0	37.99
5	0.02	0.04	0.02	144.85
12	0.05			

Table S319: Average Difference in C5M/PRO-C5.

Absolute Difference	
N	11
Mean	0
Median	0
Range	(0,0.03)
IQR	(0,0)
Percentage Change	
N	11
Mean	11.45
Median	0
Range	(-38,168)
IQR	(-17,18)

D.10.28 Additional Analyses

Tables S320 and S321 show summary information of the additional biochemistry test across all trial visits pre- and post-infusion respectively. Tables S322 and S323 show the summary demographics of the results code for the additional biochemistry test over all trial visit pre- and post-infusion respectively.

Figure S63 shows a repeated measures plot of all additional biochemistry test at all measurement times across all trial visits with a loess smoother trend line, presented according to biochemistry test. Figure S64 restricts this to only pre-infusion results, and figure S65 shows only post-infusion results.

Table S320: Additional Biochemistry Tests: Pre-infusion Results.

	Screening Visit 1	Screening Visit 2	Visit 3 pre-dose	Visit 4 pre-dose	Visit 5 pre-dose	Visit 6 pre-dose	Visit 7 pre-dose	Visit 8 pre-dose	Visit 9 pre-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Bilirubin (total, umol/l)												
N	22	22	22	21	21	21	20	20	20	22	22	9
Mean	21.27	24.64	21.36	21.76	19.38	20.33	20.85	21.95	20.85	22.5	26.91	43.56
Median	18	20.5	18	18	14	20	16	20.5	17	20	21	27
Range	(4,47)	(4,57)	(4,49)	(3,60)	(4,47)	(3,45)	(4,50)	(4,43)	(3,49)	(4,58)	(6,148)	(8,189)
IQR	(13,29)	(14.25,31)	(12,29)	(10,30)	(11,24)	(12,28)	(11,30)	(8.75,31)	(10.75,32.25)	(12,30.5)	(11,31.5)	(19,34)
Sodium (mmol/L)												
N	22	22	22	21	21	21	20	21	20	22	22	9
Mean	139.73	139.5	139.09	139.14	139.38	139.19	139.7	138.57	139.35	139.27	139.23	139.44
Median	140	139	139	140	140	139	140	139	139	140	140	140
Range	(135,143)	(135,144)	(135,143)	(133,142)	(136,143)	(136,142)	(133,146)	(134,143)	(136,143)	(134,143)	(129,142)	(133,143)
IQR	(139,140.75)	(139,140.75)	(138,140)	(139,140)	(138,140)	(137,141)	(138,141)	(137,141)	(138,141)	(137.25,141)	(138.25,141)	(138,142)
Potassium (mmol/L)												
N	22	22	22	20	21	21	18	20	19	22	22	9
Mean	4.11	4.21	4.05	3.98	4	3.96	4.04	4.04	3.97	4.07	4.05	4.37
Median	4.1	4.1	4	4	3.9	4	4	4	3.9	4	4.1	4.5
Range	(3.6,4.6)	(3.5,4.9)	(3.4,4.8)	(3,4.6)	(3.3,4.7)	(3.1,4.5)	(3.4,4.9)	(3.4,4.7)	(3.3,4.6)	(3.4,4.9)	(3.1,4.6)	(3.6,4.8)
IQR	(3.9,4.3)	(3.9,4.5)	(3.8,4.27)	(3.77,4.23)	(3.8,4.3)	(3.8,4.1)	(3.73,4.3)	(3.9,4.32)	(3.7,4.2)	(3.82,4.3)	(3.9,4.27)	(4.1,4.7)

Table S320: Additional Biochemistry Tests: Pre-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 pre-dose	Visit 4 pre-dose	Visit 5 pre-dose	Visit 6 pre-dose	Visit 7 pre-dose	Visit 8 pre-dose	Visit 9 pre-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Urea (mmol/l)												
N	22	22	22	21	21	21	20	21	20	22	22	9
Mean	4.38	4.64	4.68	4.51	4.72	4.33	4.73	4.41	4.53	4.58	4.42	4.49
Median	4.35	4.35	4.7	4.4	4.6	4.4	4.65	4.3	4.9	4.65	4.3	4.5
Range	(2.9,6.6)	(3.1,7)	(2.9,7.5)	(2.9,6.6)	(2.5,7.2)	(2.6,6.6)	(2.8,7.8)	(3,6.7)	(2.2,6)	(2.3,6.7)	(2.3,6.2)	(2.7,6.9)
IQR	(3.5,5.25)	(3.9,5.27)	(3.62,5.47)	(3.7,5.2)	(3.9,5.6)	(3.4,5.1)	(4.08,5.4)	(3.8,4.9)	(3.55,5.53)	(3.73,5.4)	(3.8,5.35)	(4,4.9)
Creatinine (umol/L)												
N	22	22	22	21	21	21	20	21	20	22	22	9
Mean	65.32	67.68	66.77	67.95	67.19	66.38	68	65.43	66.4	67.41	67.45	74.78
Median	62	65.5	64	69	67	66	68.5	65	66	68	64	78
Range	(36,106)	(40,104)	(39,104)	(48,96)	(39,97)	(43,99)	(42,98)	(42,97)	(43,88)	(40,90)	(47,92)	(46,101)
IQR	(53,77.75)	(58.25,80.25)	(53.75,81.5)	(54,81)	(55,80)	(56,76)	(59.5,78.75)	(52,76)	(55.75,79.25)	(55.25,79.75)	(55.5,80)	(64,84)
Calcium (mmol/L)												
N	20	20	21	20	20	21	18	21	20	22	22	10
Mean	2.36	2.36	2.34	2.32	2.31	2.3	2.31	2.32	2.31	2.36	2.35	2.4
Median	2.36	2.34	2.36	2.31	2.29	2.28	2.31	2.34	2.33	2.36	2.34	2.39
Range	(2.1,2.72)	(2.2,2.6)	(2,2.59)	(2.09,2.51)	(2,2.51)	(2.09,2.5)	(2.08,2.43)	(2.11,2.41)	(2.13,2.51)	(2.18,2.63)	(2.17,2.65)	(2.26,2.73)
IQR	(2.29,2.44)	(2.29,2.43)	(2.29,2.4)	(2.26,2.39)	(2.26,2.38)	(2.25,2.35)	(2.27,2.37)	(2.29,2.37)	(2.24,2.37)	(2.27,2.44)	(2.28,2.39)	(2.34,2.41)
eGFR												
N	21	21	21	20	20	20	19	20	19	21	21	8

Table S320: Additional Biochemistry Tests: Pre-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 pre-dose	Visit 4 pre-dose	Visit 5 pre-dose	Visit 6 pre-dose	Visit 7 pre-dose	Visit 8 pre-dose	Visit 9 pre-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Mean	113.44	102.7	115.68	113.85	112.52	108.16	107.59	111.21	113.5	108.22	105.8	89.62
Median	96.8	90	90	100	90	90	90	90	90	90	90	90
Range	(64,204.3)	(65,163)	(65,185.6)	(72,181)	(71,180)	(69,177)	(74,162.5)	(71,175.8)	(79,203.2)	(73,187)	(75,175.6)	(68,126)
IQR	(90,130.8)	(90,116)	(90,147)	(89,139.05)	(90,135.32)	(90,123)	(90,122.65)	(90,122.75)	(90,132.55)	(90,130)	(90,120)	(81.75,90)

Table S321: Additional Biochemistry Tests: Post-infusion Results.

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Bilirubin (total, umol/l)												
N	22	22	22	21	21	20	20	20	20	22	22	9
Mean	21.27	24.64	20.45	22.52	21.1	21.95	22	22.2	21.4	22.5	26.91	43.56
Median	18	20.5	15	16	17	18	18	20	17.5	20	21	27
Range	(4,47)	(4,57)	(4,43)	(4,58)	(4,47)	(4,45)	(4,48)	(3,46)	(4,41)	(4,58)	(6,148)	(8,189)
IQR	(13,29)	(14.25,31)	(10,30.5)	(11,36)	(12,30)	(13.5,30.5)	(12.25,30.25)	(9.75,35)	(10.75,30.75)	(12,30.5)	(11,31.5)	(19,34)
Sodium (mmol/L)												
N	22	22	21	21	20	20	20	20	20	22	22	9
Mean	139.73	139.5	137.86	137.48	139.05	138.65	138.25	139.05	138.9	139.27	139.23	139.44
Median	140	139	138	137	139	139	138	139	140	140	140	140
Range	(135,143)	(135,144)	(135,141)	(135,143)	(130,150)	(135,142)	(134,145)	(135,143)	(134,143)	(134,143)	(129,142)	(133,143)
IQR	(139,140.75)	(139,140.75)	(137,139)	(136,138)	(137.75,140.2	(51)38,139.25)	(136.75,139.5()	137,141.25)	(137,140)	(137.25,141)	(138.25,141)	(138,142)
Potassium (mmol/L)												
N	22	22	20	19	19	19	20	20	20	22	22	9
Mean	4.11	4.21	4.13	4.22	4.03	4.04	4.11	4.02	3.95	4.07	4.05	4.37
Median	4.1	4.1	4.2	4.1	4.2	4	4	4.05	3.9	4	4.1	4.5
Range	(3.6,4.6)	(3.5,4.9)	(3.3,4.7)	(3.5,5.2)	(3.2,4.5)	(3.6,4.8)	(3.7,5.2)	(3.4,4.6)	(3.3,4.6)	(3.4,4.9)	(3.1,4.6)	(3.6,4.8)
IQR	(3.9,4.3)	(3.9,4.5)	(3.98,4.32)	(3.95,4.45)	(3.85,4.35)	(3.8,4.2)	(3.9,4.23)	(3.88,4.2)	(3.8,4.03)	(3.82,4.3)	(3.9,4.27)	(4.1,4.7)

Table S321: Additional Biochemistry Tests: Post-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Urea (mmol/l)												
N	22	22	22	21	20	20	20	20	20	22	22	9
Mean	4.38	4.64	4.71	4.8	4.96	4.55	4.87	4.66	4.67	4.58	4.42	4.49
Median	4.35	4.35	4.45	4.8	4.9	4.6	5	4.45	4.95	4.65	4.3	4.5
Range	(2.9,6.6)	(3.1,7)	(2.8,7.4)	(3.1,6.9)	(2.7,8.1)	(2.5,6.4)	(3,7.8)	(3,6.3)	(2.3,6.1)	(2.3,6.7)	(2.3,6.2)	(2.7,6.9)
IQR	(3.5,5.25)	(3.9,5.27)	(3.62,5.7)	(3.7,5.8)	(4.3,5.77)	(3.6,5.6)	(4.02,5.5)	(3.88,5.53)	(3.77,5.5)	(3.73,5.4)	(3.8,5.35)	(4,4.9)
Creatinine (umol/L)												
N	22	22	22	21	21	20	20	20	20	22	22	9
Mean	65.32	67.68	67.18	70	69.43	68.15	67.05	68.8	68.15	67.41	67.45	74.78
Median	62	65.5	65.5	67	71	68.5	68	66.5	65.5	68	64	78
Range	(36,106)	(40,104)	(38,99)	(45,105)	(43,101)	(43,96)	(33,95)	(44,100)	(38,102)	(40,90)	(47,92)	(46,101)
IQR	(53,77.75)	(58.25,80.25)	(59,77)	(57,81)	(60,81)	(60.25,76.5)	(58,75.25)	(59.75,77.25)	(59,80.5)	(55.25,79.75)	(55.5,80)	(64,84)
Calcium (mmol/L)												
N	20	20	22	20	20	19	19	20	20	22	22	10
Mean	2.36	2.36	2.31	2.33	2.31	2.29	2.3	2.3	2.28	2.36	2.35	2.4
Median	2.36	2.34	2.3	2.31	2.33	2.31	2.29	2.3	2.29	2.36	2.34	2.39
Range	(2.1,2.72)	(2.2,2.6)	(2.06,2.62)	(2.02,2.62)	(1.84,2.55)	(2.02,2.5)	(1.97,2.47)	(1.97,2.49)	(2.08,2.44)	(2.18,2.63)	(2.17,2.65)	(2.26,2.73)
IQR	(2.29,2.44)	(2.29,2.43)	(2.25,2.36)	(2.25,2.42)	(2.25,2.39)	(2.2,2.33)	(2.25,2.37)	(2.26,2.36)	(2.21,2.36)	(2.27,2.44)	(2.28,2.39)	(2.34,2.41)
eGFR												
N	21	21	21	20	20	18	19	19	19	21	21	8

Table S321: Additional Biochemistry Tests: Post-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Mean	113.44	102.7	110.1	108.48	109.58	108.52	110.96	108.84	113.92	108.22	105.8	89.62
Median	96.8	90	90	90	90	90	90	90	90	90	90	90
Range	(64,204.3)	(65,163)	(69,180)	(65,184.9)	(68,177)	(72,170.4)	(74,158)	(68,171.1)	(67,174.8)	(73,187)	(75,175.6)	(68,126)
IQR	(90,130.8)	(90,116)	(90,126)	(89.75,123.25()	90,123.25)	(90,126.75)	(90,133.5)	(90,122.5)	(89.5,142.9)	(90,130)	(90,120)	(81.75,90)

Table S322: Additional Biochemistry Test Result Codes: Pre-infusion Results.

	Screening Visit 1	Screening Visit 2	Visit 3 pre-dose	Visit 4 pre-dose	Visit 5 pre-dose	Visit 6 pre-dose	Visit 7 pre-dose	Visit 8 pre-dose	Visit 9 pre-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Bilirubin (total, umol/l)												
Normal	12 (54.55%)	12 (54.55%)	14 (63.64%)	13 (61.90%)	13 (61.90%)	12 (57.14%)	13 (61.90%)	11 (50.00%)	12 (57.14%)	11 (50.00%)	12 (54.55%)	4 (36.36%)
Abnormal, clinically insignificant	10 (45.45%)	8 (36.36%)	8 (36.36%)	7 (33.33%)	7 (33.33%)	8 (38.10%)	7 (33.33%)	9 (40.91%)	7 (33.33%)	10 (45.45%)	8 (36.36%)	5 (45.45%)
Abnormal, clinically significant	0 (0.00%)	1 (4.55%)	0 (0.00%)	1 (4.76%)	1 (4.76%)	1 (4.76%)	0 (0.00%)	0 (0.00%)	1 (4.76%)	1 (4.55%)	2 (9.09%)	0 (0.00%)
Missing	0 (0.00%)	1 (4.55%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.76%)	2 (9.09%)	1 (4.76%)	0 (0.00%)	0 (0.00%)	2 (18.18%)
Total	**22 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**22 (100.00%)**	**21 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**11 (100.00%)**
Sodium (mmol/l)												
Normal	22 (100.00%)	22 (100.00%)	22 (100.00%)	20 (95.24%)	21 (100.00%)	21 (100.00%)	19 (90.48%)	20 (90.91%)	20 (95.24%)	22 (100.00%)	21 (95.45%)	8 (72.73%)
Abnormal, clinically insignificant	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.76%)	0 (0.00%)	0 (0.00%)	1 (4.76%)	1 (4.55%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (9.09%)
Missing	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.76%)	1 (4.55%)	1 (4.76%)	0 (0.00%)	0 (0.00%)	2 (18.18%)
Total	**22 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**22 (100.00%)**	**21 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**11 (100.00%)**
Potassium (mmol/L)												

Table S322: Additional Biochemistry Test Result Codes: Pre-infusion Results. *(continued)*

	Screening Visit 1	**Screening Visit 2**	**Visit 3 pre-dose**	**Visit 4 pre-dose**	**Visit 5 pre-dose**	**Visit 6 pre-dose**	**Visit 7 pre-dose**	**Visit 8 pre-dose**	**Visit 9 pre-dose**	**Follow-up visit 10**	**Follow-up visit 11**	**Unscheduled**
Normal	22	22	21	19	19	19	16	18	18	21	21	9
	(100.00%)	(100.00%)	(95.45%)	(90.48%)	(90.48%)	(90.48%)	(76.19%)	(81.82%)	(85.71%)	(95.45%)	(95.45%)	(81.82%)
Abnormal, clinically	0	0	1	1	2	2	2	2	1	1	1	0
insignificant	(0.00%)	(0.00%)	(4.55%)	(4.76%)	(9.52%)	(9.52%)	(9.52%)	(9.09%)	(4.76%)	(4.55%)	(4.55%)	(0.00%)
Missing	0	0	0	1	0	0	3	2	2	0	0	2
	(0.00%)	(0.00%)	(0.00%)	(4.76%)	(0.00%)	(0.00%)	(14.29%)	(9.09%)	(9.52%)	(0.00%)	(0.00%)	(18.18%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**22**	**21**	**22**	**22**	**11**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Urea (mmol/l)												
Normal	21	21	19	21	18	19	16	20	16	20	19	8
	(95.45%)	(95.45%)	(86.36%)	(100.00%)	(85.71%)	(90.48%)	(76.19%)	(90.91%)	(76.19%)	(90.91%)	(86.36%)	(72.73%)
Abnormal, clinically	1	1	3	0	3	2	4	1	4	2	3	1
insignificant	(4.55%)	(4.55%)	(13.64%)	(0.00%)	(14.29%)	(9.52%)	(19.05%)	(4.55%)	(19.05%)	(9.09%)	(13.64%)	(9.09%)
Missing	0	0	0	0	0	0	1	1	1	0	0	2
	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(4.76%)	(4.55%)	(4.76%)	(0.00%)	(0.00%)	(18.18%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**22**	**21**	**22**	**22**	**11**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Creatinine (umol/L)												
Normal	13	16	13	15	14	15	16	14	12	17	17	8
	(59.09%)	(72.73%)	(59.09%)	(71.43%)	(66.67%)	(71.43%)	(76.19%)	(63.64%)	(57.14%)	(77.27%)	(77.27%)	(72.73%)
Abnormal, clinically	9	6	9	6	7	6	4	7	8	5	5	1
insignificant	(40.91%)	(27.27%)	(40.91%)	(28.57%)	(33.33%)	(28.57%)	(19.05%)	(31.82%)	(38.10%)	(22.73%)	(22.73%)	(9.09%)

Table S322: Additional Biochemistry Test Result Codes: Pre-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 pre-dose	Visit 4 pre-dose	Visit 5 pre-dose	Visit 6 pre-dose	Visit 7 pre-dose	Visit 8 pre-dose	Visit 9 pre-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Missing	0	0	0	0	0	0	1	1	1	0	0	2
	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(4.76%)	(4.55%)	(4.76%)	(0.00%)	(0.00%)	(18.18%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**22**	**21**	**22**	**22**	**11**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Calcium (mmol/L)												
Normal	18	20	19	18	19	19	17	21	20	19	21	9
	(81.82%)	(90.91%)	(86.36%)	(85.71%)	(90.48%)	(90.48%)	(80.95%)	(95.45%)	(95.24%)	(86.36%)	(95.45%)	(81.82%)
Abnormal, clinically	2	0	2	2	1	2	1	0	0	3	1	1
insignificant	(9.09%)	(0.00%)	(9.09%)	(9.52%)	(4.76%)	(9.52%)	(4.76%)	(0.00%)	(0.00%)	(13.64%)	(4.55%)	(9.09%)
Missing	2	2	1	1	1	0	3	1	1	0	0	1
	(9.09%)	(9.09%)	(4.55%)	(4.76%)	(4.76%)	(0.00%)	(14.29%)	(4.55%)	(4.76%)	(0.00%)	(0.00%)	(9.09%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**22**	**21**	**22**	**22**	**11**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Total Protein (g/l)												
Normal	15	13	16	17	17	19	15	15	13	18	16	7
	(68.18%)	(59.09%)	(72.73%)	(80.95%)	(80.95%)	(90.48%)	(71.43%)	(68.18%)	(61.90%)	(81.82%)	(72.73%)	(63.64%)
Abnormal, clinically	5	6	5	4	3	0	2	3	5	3	6	3
insignificant	(22.73%)	(27.27%)	(22.73%)	(19.05%)	(14.29%)	(0.00%)	(9.52%)	(13.64%)	(23.81%)	(13.64%)	(27.27%)	(27.27%)
Missing	2	3	1	0	1	2	4	4	3	1	0	1
	(9.09%)	(13.64%)	(4.55%)	(0.00%)	(4.76%)	(9.52%)	(19.05%)	(18.18%)	(14.29%)	(4.55%)	(0.00%)	(9.09%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**22**	**21**	**22**	**22**	**11**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
eGFR												

Table S322: Additional Biochemistry Test Result Codes: Pre-infusion Results. *(continued)*

	Screening Visit 1	**Screening Visit 2**	**Visit 3 pre-dose**	**Visit 4 pre-dose**	**Visit 5 pre-dose**	**Visit 6 pre-dose**	**Visit 7 pre-dose**	**Visit 8 pre-dose**	**Visit 9 pre-dose**	**Follow-up visit 10**	**Follow-up visit 11**	**Unscheduled**
Normal	19	20	19	19	19	19	19	19	18	19	20	7
	(86.36%)	(90.91%)	(86.36%)	(90.48%)	(90.48%)	(90.48%)	(90.48%)	(86.36%)	(85.71%)	(86.36%)	(90.91%)	(63.64%)
Abnormal, clinically	2	1	2	1	1	1	0	1	1	2	1	1
insignificant	(9.09%)	(4.55%)	(9.09%)	(4.76%)	(4.76%)	(4.76%)	(0.00%)	(4.55%)	(4.76%)	(9.09%)	(4.55%)	(9.09%)
Missing	1	1	1	1	1	1	2	2	2	1	1	3
	(4.55%)	(4.55%)	(4.55%)	(4.76%)	(4.76%)	(4.76%)	(9.52%)	(9.09%)	(9.52%)	(4.55%)	(4.55%)	(27.27%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**22**	**21**	**22**	**22**	**11**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**

Table S323: Additional Biochemistry Test Result Codes: Post-infusion Results.

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Bilirubin (total, umol/l)												
Normal	12 (54.55%)	12 (54.55%)	12 (54.55%)	12 (54.55%)	13 (61.90%)	12 (54.55%)	11 (52.38%)	11 (50.00%)	12 (57.14%)	11 (50.00%)	12 (54.55%)	4 (36.36%)
Abnormal, clinically insignificant	10 (45.45%)	8 (36.36%)	9 (40.91%)	8 (36.36%)	7 (33.33%)	7 (31.82%)	8 (38.10%)	8 (36.36%)	6 (28.57%)	10 (45.45%)	8 (36.36%)	5 (45.45%)
Abnormal, clinically significant	0 (0.00%)	1 (4.55%)	1 (4.55%)	1 (4.55%)	1 (4.76%)	1 (4.55%)	1 (4.76%)	1 (4.55%)	2 (9.52%)	1 (4.55%)	2 (9.09%)	0 (0.00%)
Missing	0 (0.00%)	1 (4.55%)	0 (0.00%)	1 (4.55%)	0 (0.00%)	2 (9.09%)	1 (4.76%)	2 (9.09%)	1 (4.76%)	0 (0.00%)	0 (0.00%)	2 (18.18%)
Total	**22 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**21 (100.00%)**	**22 (100.00%)**	**21 (100.00%)**	**22 (100.00%)**	**21 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**11 (100.00%)**
Sodium (mmol/l)												
Normal	22 (100.00%)	22 (100.00%)	21 (95.45%)	21 (95.45%)	18 (85.71%)	20 (90.91%)	20 (95.24%)	20 (90.91%)	20 (95.24%)	22 (100.00%)	21 (95.45%)	8 (72.73%)
Abnormal, clinically insignificant	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (9.52%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (9.09%)
Missing	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (4.55%)	1 (4.76%)	2 (9.09%)	1 (4.76%)	2 (9.09%)	1 (4.76%)	0 (0.00%)	0 (0.00%)	2 (18.18%)
Total	**22 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**21 (100.00%)**	**22 (100.00%)**	**21 (100.00%)**	**22 (100.00%)**	**21 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**11 (100.00%)**
Potassium (mmol/L)												

Table S323: Additional Biochemistry Test Result Codes: Post-infusion Results. *(continued)*

	Screening Visit 1	**Screening Visit 2**	**Visit 3 post-dose**	**Visit 4 post-dose**	**Visit 5 post-dose**	**Visit 6 post-dose**	**Visit 7 post-dose**	**Visit 8 post-dose**	**Visit 9 post-dose**	**Follow-up visit 10**	**Follow-up visit 11**	**Unscheduled**
Normal	22	22	19	19	17	19	20	19	19	21	21	9
	(100.00%)	(100.00%)	(86.36%)	(86.36%)	(80.95%)	(86.36%)	(95.24%)	(86.36%)	(90.48%)	(95.45%)	(95.45%)	(81.82%)
Abnormal, clinically	0	0	1	0	2	0	0	1	1	1	1	0
insignificant	(0.00%)	(0.00%)	(4.55%)	(0.00%)	(9.52%)	(0.00%)	(0.00%)	(4.55%)	(4.76%)	(4.55%)	(4.55%)	(0.00%)
Missing	0	0	2	3	2	3	1	2	1	0	0	2
	(0.00%)	(0.00%)	(9.09%)	(13.64%)	(9.52%)	(13.64%)	(4.76%)	(9.09%)	(4.76%)	(0.00%)	(0.00%)	(18.18%)
Total	**22**	**22**	**22**	**22**	**21**	**22**	**21**	**22**	**21**	**22**	**22**	**11**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Urea (mmol/l)												
Normal	21	21	21	21	18	19	19	20	18	20	19	8
	(95.45%)	(95.45%)	(95.45%)	(95.45%)	(85.71%)	(86.36%)	(90.48%)	(90.91%)	(85.71%)	(90.91%)	(86.36%)	(72.73%)
Abnormal, clinically	1	1	1	0	2	1	1	0	2	2	3	1
insignificant	(4.55%)	(4.55%)	(4.55%)	(0.00%)	(9.52%)	(4.55%)	(4.76%)	(0.00%)	(9.52%)	(9.09%)	(13.64%)	(9.09%)
Missing	0	0	0	1	1	2	1	2	1	0	0	2
	(0.00%)	(0.00%)	(0.00%)	(4.55%)	(4.76%)	(9.09%)	(4.76%)	(9.09%)	(4.76%)	(0.00%)	(0.00%)	(18.18%)
Total	**22**	**22**	**22**	**22**	**21**	**22**	**21**	**22**	**21**	**22**	**22**	**11**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Creatinine (umol/L)												
Normal	13	16	15	15	16	16	15	16	16	17	17	8
	(59.09%)	(72.73%)	(68.18%)	(68.18%)	(76.19%)	(72.73%)	(71.43%)	(72.73%)	(76.19%)	(77.27%)	(77.27%)	(72.73%)
Abnormal, clinically	9	6	7	6	5	4	5	4	4	5	5	1
insignificant	(40.91%)	(27.27%)	(31.82%)	(27.27%)	(23.81%)	(18.18%)	(23.81%)	(18.18%)	(19.05%)	(22.73%)	(22.73%)	(9.09%)

Table S323: Additional Biochemistry Test Result Codes: Post-infusion Results. *(continued)*

	Screening Visit 1	**Screening Visit 2**	**Visit 3 post-dose**	**Visit 4 post-dose**	**Visit 5 post-dose**	**Visit 6 post-dose**	**Visit 7 post-dose**	**Visit 8 post-dose**	**Visit 9 post-dose**	**Follow-up visit 10**	**Follow-up visit 11**	**Unscheduled**
Missing	0	0	0	1	0	2	1	2	1	0	0	2
	(0.00%)	(0.00%)	(0.00%)	(4.55%)	(0.00%)	(9.09%)	(4.76%)	(9.09%)	(4.76%)	(0.00%)	(0.00%)	(18.18%)
Total	**22**	**22**	**22**	**22**	**21**	**22**	**21**	**22**	**21**	**22**	**22**	**11**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Calcium (mmol/L)												
Normal	18	20	20	18	18	17	18	19	18	19	21	9
	(81.82%)	(90.91%)	(90.91%)	(81.82%)	(85.71%)	(77.27%)	(85.71%)	(86.36%)	(85.71%)	(86.36%)	(95.45%)	(81.82%)
Abnormal, clinically	2	0	2	2	2	2	1	1	2	3	1	1
insignificant	(9.09%)	(0.00%)	(9.09%)	(9.09%)	(9.52%)	(9.09%)	(4.76%)	(4.55%)	(9.52%)	(13.64%)	(4.55%)	(9.09%)
Missing	2	2	0	2	1	3	2	2	1	0	0	1
	(9.09%)	(9.09%)	(0.00%)	(9.09%)	(4.76%)	(13.64%)	(9.52%)	(9.09%)	(4.76%)	(0.00%)	(0.00%)	(9.09%)
Total	**22**	**22**	**22**	**22**	**21**	**22**	**21**	**22**	**21**	**22**	**22**	**11**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Total Protein (g/l)												
Normal	15	13	20	18	16	17	16	16	16	18	16	7
	(68.18%)	(59.09%)	(90.91%)	(81.82%)	(76.19%)	(77.27%)	(76.19%)	(72.73%)	(76.19%)	(81.82%)	(72.73%)	(63.64%)
Abnormal, clinically	5	6	1	3	4	2	3	4	4	3	6	3
insignificant	(22.73%)	(27.27%)	(4.55%)	(13.64%)	(19.05%)	(9.09%)	(14.29%)	(18.18%)	(19.05%)	(13.64%)	(27.27%)	(27.27%)
Missing	2	3	1	1	1	3	2	2	1	1	0	1
	(9.09%)	(13.64%)	(4.55%)	(4.55%)	(4.76%)	(13.64%)	(9.52%)	(9.09%)	(4.76%)	(4.55%)	(0.00%)	(9.09%)
Total	**22**	**22**	**22**	**22**	**21**	**22**	**21**	**22**	**21**	**22**	**22**	**11**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
eGFR												

Table S323: Additional Biochemistry Test Result Codes: Post-infusion Results. *(continued)*

	Screening Visit 1	**Screening Visit 2**	**Visit 3 post-dose**	**Visit 4 post-dose**	**Visit 5 post-dose**	**Visit 6 post-dose**	**Visit 7 post-dose**	**Visit 8 post-dose**	**Visit 9 post-dose**	**Follow-up visit 10**	**Follow-up visit 11**	**Unscheduled**
Normal	19	20	20	19	19	17	19	18	17	19	20	7
	(86.36%)	(90.91%)	(90.91%)	(86.36%)	(90.48%)	(77.27%)	(90.48%)	(81.82%)	(80.95%)	(86.36%)	(90.91%)	(63.64%)
Abnormal, clinically	2	1	1	1	1	1	0	1	2	2	1	1
insignificant	(9.09%)	(4.55%)	(4.55%)	(4.55%)	(4.76%)	(4.55%)	(0.00%)	(4.55%)	(9.52%)	(9.09%)	(4.55%)	(9.09%)
Missing	1	1	1	2	1	4	2	3	2	1	1	3
	(4.55%)	(4.55%)	(4.55%)	(9.09%)	(4.76%)	(18.18%)	(9.52%)	(13.64%)	(9.52%)	(4.55%)	(4.55%)	(27.27%)
Total	**22**	**22**	**22**	**22**	**21**	**22**	**21**	**22**	**21**	**22**	**22**	**11**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**



Figure S63: Repeated measures plot of additional biochemistry tests at all trial visits in the mITT population, presented by biochemistry test. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.



Figure S64: Repeated measures plot of additional biochemsitry tests at pre-BTT1023 infusion in the mITT population, presented by biochemistry test. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.



Figure S65: Repeated measures plot of additional biochemistry tests at post-BTT1023 infusion in the mITT population, presented by biochemistry test. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.

Tables S324 and S325 show summary information of the additional haematology test across all trial visits pre-

and post-infusion respectively. Tables S326 and S327 show the summary demographics of the results code for the additional haematology test over all trial visit pre- and post-infusion respectively.

Figure S66 shows a repeated measures plot of all additional biochemistry test at all measurement times across all trial visits with a loess smoother trend line, presented according to biochemistry test. Figure S67 restricts this to only pre-infusion results, and figure S68 shows only post-infusion results.

Table S324: Additional Haematology Tests: Pre-infusion Results.

	Screening Visit 1	Screening Visit 2	Visit 3 pre-dose	Visit 4 pre-dose	Visit 5 pre-dose	Visit 6 pre-dose	Visit 7 pre-dose	Visit 8 pre-dose	Visit 9 pre-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Haemoglobin (g/L)												
N	20	22	22	21	21	21	20	21	19	22	21	6
Mean	136.25	140.59	135.45	132.76	131.24	131.14	131.15	128.95	130.05	131.95	132.33	134.67
Median	134	140	136	138	133	133	131.5	130	132	132	134	133
Range	(114,157)	(113,163)	(110,156)	(110,148)	(108,152)	(107,144)	(100,148)	(96,147)	(98,149)	(103,154)	(105,153)	(117,159)
IQR	(130.25,144.2	(51)	33.5,147.75()	130.25,144)	(127,139)	(126,140)	(129,138)	(128,141.75)	(124,137)	(124,141)	(128.25,138.5()	127,138)	(129.75,136.25)
Platelets (10^9/L)												
N	20	22	22	21	21	21	20	21	19	22	21	6
Mean	207.25	228.23	218.91	225	224.71	223.71	226.85	228.33	220.16	221.68	222.19	205.17
Median	205.5	230	227.5	254	245	251	248.5	265	249	242	237	206
Range	(73,375)	(86,461)	(75,422)	(69,406)	(78,475)	(76,377)	(78,440)	(79,418)	(73,434)	(72,465)	(72,405)	(109,299)
IQR	(137,266.5)	(139.75,291.5()	143.25,282.2	(51)	69,300)	(161,282)	(148,287)	(149.5,296.25()	168,286)	(121,284)	(144,284.25)	(153,277)	(122,289.25)
Red Blood Cells (10^12/L)												
N	20	22	22	21	21	21	20	21	19	22	21	6
Mean	4.5	4.62	4.47	4.37	4.33	4.36	4.36	4.32	4.35	4.42	4.49	4.29
Median	4.51	4.62	4.5	4.44	4.43	4.4	4.38	4.37	4.43	4.38	4.37	4.23
Range	(3.57,5.35)	(3.51,5.54)	(3.17,5.48)	(3.3,5.1)	(3.36,5.18)	(3.28,5.22)	(3.28,5.1)	(3.38,5.25)	(3.34,5.09)	(3.67,5.05)	(3.53,5.16)	(3.46,5.27)
IQR	(4.17,4.87)	(4.45,4.86)	(4.18,4.86)	(4.06,4.66)	(3.99,4.59)	(4.06,4.63)	(4.09,4.68)	(4.08,4.5)	(4.06,4.74)	(4.16,4.79)	(4.28,4.79)	(4.08,4.47)
White Blood Cells (10^9/L)												
N	20	22	22	21	21	21	20	21	19	22	21	6
Mean	6.11	6.93	6.56	6.72	6.2	6.71	6.41	6.55	6.37	6.47	6.45	6.58

Table S324: Additional Haematology Tests: Pre-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 pre-dose	Visit 4 pre-dose	Visit 5 pre-dose	Visit 6 pre-dose	Visit 7 pre-dose	Visit 8 pre-dose	Visit 9 pre-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Median	5.75	6.85	5.9	6.6	6.1	6.5	6.1	6.1	6.4	6.2	6	6.3
Range	(2.6,10.5)	(3.3,12.2)	(2.5,13.8)	(2.7,13.7)	(2.6,11)	(3.1,15.5)	(2.6,10.3)	(3.3,11.2)	(3.5,11.3)	(3,10.7)	(3.2,11.6)	(3.8,10.4)
IQR	(5,6.65)	(5.12,8.4)	(5.32,8.2)	(5.3,8)	(5.5,6.8)	(4.8,7.3)	(5.62,7.53)	(5.4,7.6)	(5.3,6.7)	(5.2,7.2)	(4.9,7.4)	(4.4,8.27)
Haematocrit (L/L)												
N	20	22	22	21	21	21	20	21	19	22	21	6
Mean	0.41	0.42	0.4	0.39	0.39	0.39	0.39	0.39	0.39	0.39	0.4	0.4
Median	0.41	0.42	0.4	0.4	0.39	0.39	0.39	0.39	0.39	0.38	0.39	0.4
Range	(0.35,0.49)	(0.35,0.49)	(0.32,0.46)	(0.33,0.45)	(0.32,0.46)	(0.33,0.43)	(0.31,0.45)	(0.3,0.44)	(0.29,0.45)	(0.31,0.46)	(0.33,0.45)	(0.35,0.47)
IQR	(0.38,0.43)	(0.4,0.44)	(0.38,0.43)	(0.37,0.41)	(0.37,0.41)	(0.38,0.42)	(0.38,0.41)	(0.37,0.41)	(0.37,0.42)	(0.37,0.42)	(0.38,0.42)	(0.38,0.4)
Mean Cell Volume (fL)												
N	20	22	22	21	21	21	20	21	19	22	21	6
Mean	90.91	90.9	90.62	90.54	90.66	90.9	90.67	90.25	89.44	89.46	88.81	93.35
Median	91.1	91	90.5	90.5	90.7	91	90.65	91	90	90.75	90.2	92.75
Range	(76.6,100.5)	(75.5,103.2)	(75.7,100.6)	(75.3,101.2)	(76.2,101.7)	(76.8,99.9)	(78.6,103.5)	(74.1,99.8)	(75.6,99.6)	(73.8,99.9)	(74.8,98.3)	(88.1,102.3)
IQR	(89.52,94.22)	(89.25,93.75)	(89.15,93.67)	(89.2,93.8)	(89.3,93.9)	(88.8,94)	(88.65,93.1)	(87.7,94)	(87.3,92.55)	(86.23,92.9)	(85.7,93)	(89.65,94.87)
Mean Cell Haemoglobin (PG)												
N	20	22	22	21	21	21	20	21	19	22	21	6
Mean	30.39	30.71	30.42	30.35	30.38	30.13	30.18	29.96	29.98	29.96	29.54	31.48
Median	30.9	30.75	30.85	30.6	30.6	30.5	30.5	30.5	30.2	30.75	29.9	31.35
Range	(24.5,35.5)	(24,35.2)	(24.5,34.6)	(24.9,34.4)	(23.6,34.1)	(23.9,35.2)	(24,34.1)	(23.2,33.2)	(23.6,33.5)	(23.2,34.5)	(23.2,34.7)	(30.2,33.8)
IQR	(29.75,31.4)	(29.93,31.82)	(29.92,31.3)	(29.5,31.5)	(29.8,31.2)	(28.5,31.4)	(28.98,31.55)	(29.6,31.6)	(28.8,31.5)	(28.72,31.4)	(29.2,30.8)	(30.48,31.85)

Table S324: Additional Haematology Tests: Pre-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 pre-dose	Visit 4 pre-dose	Visit 5 pre-dose	Visit 6 pre-dose	Visit 7 pre-dose	Visit 8 pre-dose	Visit 9 pre-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Neutrophils (10^9/L)												
N	20	22	22	21	21	21	20	21	19	22	21	6
Mean	3.75	4.26	4.19	4.16	3.79	4.74	4.12	4.33	4.04	4.14	4	4.28
Median	3.6	3.9	3.55	3.7	3.5	4.1	4.1	3.9	4.2	3.9	3.8	3.65
Range	(1.4,5.9)	(2.1,8.4)	(1.5,8.3)	(1.7,7.7)	(1.5,8.5)	(2.1,13.1)	(1.6,7.3)	(2.1,8.8)	(2.3,7.2)	(1.8,8.2)	(2,6.3)	(2.3,7)
IQR	(2.98,4.45)	(3.2,5.42)	(2.95,5.15)	(3.2,4.7)	(3.3,4.2)	(2.8,5.5)	(3.27,4.83)	(3.3,5.2)	(3.15,4.5)	(3.25,4.47)	(3.2,4.8)	(2.7,5.95)
Lymphocytes (10^9/L)												
N	20	22	22	21	21	21	20	21	19	22	21	6
Mean	1.52	1.65	1.45	1.52	1.5	1.5	1.44	1.35	1.49	1.69	1.51	1.43
Median	1.4	1.35	1.5	1.4	1.3	1.5	1.3	1.3	1.4	1.4	1.4	1.4
Range	(0.6,2.8)	(0.6,2.9)	(0.5,3.1)	(0.6,3.4)	(0.6,3)	(0.7,3.2)	(0.7,3.1)	(0.6,2.3)	(0.6,3.1)	(0.6,6)	(0.7,2.8)	(0.9,1.9)
IQR	(1.08,2)	(1.12,2.27)	(0.95,1.85)	(1.1,1.9)	(1.1,1.7)	(1,1.9)	(1.08,1.65)	(0.8,1.7)	(1.05,1.85)	(1.12,1.98)	(1,2.1)	(1.33,1.62)
Monocytes (10^9/L)												
N	20	22	22	21	21	21	20	21	19	22	21	6
Mean	0.5	0.56	0.48	0.55	0.52	0.54	0.52	0.55	0.54	0.57	0.53	0.57
Median	0.5	0.55	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.6
Range	(0.2,0.9)	(0.2,1)	(0.2,1)	(0.2,0.9)	(0.2,1)	(0.1,1.2)	(0.2,0.8)	(0.2,1)	(0.2,0.9)	(0.3,0.9)	(0.2,0.9)	(0.1,1.2)
IQR	(0.4,0.52)	(0.4,0.7)	(0.4,0.6)	(0.4,0.7)	(0.4,0.6)	(0.4,0.6)	(0.4,0.62)	(0.5,0.6)	(0.4,0.65)	(0.4,0.7)	(0.4,0.7)	(0.38,0.6)

Table S324: Additional Haematology Tests: Pre-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 pre-dose	Visit 4 pre-dose	Visit 5 pre-dose	Visit 6 pre-dose	Visit 7 pre-dose	Visit 8 pre-dose	Visit 9 pre-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Eosinophils (10^9/L)												
N	20	22	22	21	21	21	20	21	19	22	21	6
Mean	0.26	0.39	0.38	0.42	0.33	0.32	0.32	0.27	0.26	0.26	0.33	0.27
Median	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.15	0.2	0.25
Range	(0,1.2)	(0,3.1)	(0,3.8)	(0,4.1)	(0,2)	(0,2.2)	(0,1.8)	(0,1.3)	(0,1.3)	(0,1.8)	(0,2.1)	(0.1,0.6)
IQR	(0.1,0.2)	(0.1,0.4)	(0.1,0.3)	(0.1,0.4)	(0.1,0.3)	(0.1,0.3)	(0.1,0.43)	(0.1,0.3)	(0.1,0.3)	(0.1,0.27)	(0.1,0.3)	(0.12,0.3)
Basophils (10^9/L)												
N	20	22	22	21	21	21	20	21	19	22	21	6
Mean	0.04	0.05	0.05	0.04	0.04	0.06	0.04	0.04	0.04	0.05	0.05	0.03
Median	0	0	0.05	0	0	0.1	0	0	0	0.05	0	0
Range	(0,0.1)	(0,0.1)	(0,0.2)	(0,0.1)	(0,0.1)	(0,0.2)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)
IQR	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.08)
APTT (ratio)												
N	17	18	17	16	14	14	15	17	15	17	16	3
Mean	1.14	1.12	1.11	1.06	1.07	1.11	1.09	1.08	1.04	1.1	1.1	1.1
Median	1.1	1.1	1.1	1.05	1.1	1.1	1.1	1.1	1	1.1	1.1	1.1
Range	(1,1.5)	(1,1.4)	(1,1.4)	(0.9,1.3)	(0.8,1.4)	(1,1.3)	(1,1.3)	(1,1.3)	(0.9,1.2)	(1,1.4)	(1,1.3)	(1,1.2)
IQR	(1,1.2)	(1.02,1.2)	(1,1.2)	(1,1.1)	(1,1.1)	(1.02,1.17)	(1,1.15)	(1,1.1)	(1,1.1)	(1,1.1)	(1,1.2)	(1.05,1.15)

Table S325: Additional Haematology Tests: Post-infusion Results.

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Haemoglobin (g/L)												
N	20	22	21	21	21	20	20	20	20	22	21	6
Mean	136.25	140.59	132.57	132.57	129.14	129.35	129.8	128.15	126.1	131.95	132.33	134.67
Median	134	140	135	136	133	132	131.5	131.5	127	132	134	133
Range	(114,157)	(113,163)	(108,151)	(110,152)	(104,151)	(102,151)	(100,153)	(96,145)	(93,147)	(103,154)	(105,153)	(117,159)
IQR	(130.25,144.2	(51)	33.5,147.75()	128,139)	(124,141)	(126,137)	(122.5,140)	(124.5,136.25()	124.25,136)	(120.5,139)	(128.25,138.5()	127,138)
												(129.75,136.25)
Platelets (10^9/L)												
N	20	22	21	21	21	20	20	20	20	22	21	6
Mean	207.25	228.23	218.62	223.1	218.95	224.8	219.9	224.6	218.45	221.68	222.19	205.17
Median	205.5	230	229	233	224	240	240.5	259.5	236.5	242	237	206
Range	(73,375)	(86,461)	(77,443)	(67,449)	(69,468)	(80,434)	(74,485)	(78,441)	(69,455)	(72,465)	(72,405)	(109,299)
IQR	(137,266.5)	(139.75,291.5()	168,267)	(178,284)	(147,278)	(133.75,293)	(121.5,277)	(131,282.5)	(141,283.25)	(144,284.25)	(153,277)	(122,289.25)
Red Blood Cells (10^12/L)												
N	20	22	21	21	21	20	20	20	20	22	21	6
Mean	4.5	4.62	4.39	4.39	4.27	4.3	4.28	4.29	4.23	4.42	4.49	4.29
Median	4.51	4.62	4.36	4.43	4.31	4.33	4.29	4.36	4.31	4.38	4.37	4.23
Range	(3.57,5.35)	(3.51,5.54)	(3.21,5.09)	(3.24,5.15)	(3.07,4.97)	(3.19,5.05)	(3.08,5.2)	(3.21,5.19)	(3.02,4.98)	(3.67,5.05)	(3.53,5.16)	(3.46,5.27)
IQR	(4.17,4.87)	(4.45,4.86)	(4.19,4.69)	(3.99,4.78)	(4.07,4.53)	(3.98,4.62)	(4,4.66)	(4.19,4.44)	(4.05,4.57)	(4.16,4.79)	(4.28,4.79)	(4.08,4.47)
White Blood Cells (10^9/L)												
N	20	22	21	21	21	20	20	20	20	22	21	6
Mean	6.11	6.93	7.21	7.77	7.28	7.34	7.55	7.09	6.84	6.47	6.45	6.58

Table S325: Additional Haematology Tests: Post-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Median	5.75	6.85	6.7	7.8	6.6	6.6	7.1	6.75	6.3	6.2	6	6.3
Range	(2.6,10.5)	(3.3,12.2)	(3.5,18.1)	(3.1,14.7)	(2.7,17.5)	(4,14.7)	(2.8,13.1)	(2.9,11.1)	(3.2,12.5)	(3,10.7)	(3.2,11.6)	(3.8,10.4)
IQR	(5,6.65)	(5.12,8.4)	(4.4,8.1)	(6.1,9.6)	(5,8.8)	(5.45,8.2)	(6.1,9.65)	(6.07,8.47)	(5.42,7.9)	(5.2,7.2)	(4.9,7.4)	(4.4,8.27)
Haematocrit (L/L)												
N	20	22	21	21	21	20	20	20	20	22	21	6
Mean	0.41	0.42	0.39	0.39	0.39	0.39	0.38	0.38	0.38	0.39	0.4	0.4
Median	0.41	0.42	0.4	0.39	0.39	0.4	0.39	0.39	0.38	0.38	0.39	0.4
Range	(0.35,0.49)	(0.35,0.49)	(0.33,0.45)	(0.32,0.45)	(0.31,0.45)	(0.3,0.45)	(0.3,0.46)	(0.29,0.44)	(0.29,0.43)	(0.31,0.46)	(0.33,0.45)	(0.35,0.47)
IQR	(0.38,0.43)	(0.4,0.44)	(0.38,0.41)	(0.37,0.42)	(0.37,0.42)	(0.37,0.41)	(0.37,0.4)	(0.37,0.4)	(0.36,0.4)	(0.37,0.42)	(0.38,0.42)	(0.38,0.4)
Mean Cell Volume (fL)												
N	20	22	21	21	21	20	20	20	20	22	21	6
Mean	90.91	90.9	90.3	90.17	91.09	90.42	89.91	89.92	89.63	89.46	88.81	93.35
Median	91.1	91	91	90.1	91	90.85	90.2	91.1	90.65	90.75	90.2	92.75
Range	(76.6,100.5)	(75.5,103.2)	(77.8,101.4)	(75.9,101.5)	(77.4,101.4)	(75.5,103.3)	(76.7,99.3)	(74.2,99.4)	(74.5,101.7)	(73.8, 99.9)	(74.8,98.3)	(88.1,102.3)
IQR	(89.52,94.22)	(89.25,93.75)	(88.2,93.3)	(89.2,92)	(89.9,93.9)	(88.8,92.55)	(88.7,92.78)	(86.68,93.2)	(87.15,92.2)	(86.23,92.9)	(85.7,93)	(89.65,94.87)
Mean Cell Haemoglobin (PG)												
N	20	22	21	21	21	20	20	20	20	22	21	6
Mean	30.39	30.71	30.32	30.36	30.31	30.23	30.34	30.02	29.9	29.96	29.54	31.48
Median	30.9	30.75	30.9	30.4	30.4	30.45	30.5	30.1	29.85	30.75	29.9	31.35
Range	(24.5,35.5)	(24,35.2)	(24.8,34)	(23.9,34.9)	(24.5,33.8)	(24.3,34.9)	(23.9,34.7)	(22.9,33.7)	(23.4,35.5)	(23.2,34.5)	(23.2,34.7)	(30.2,33.8)
IQR	(29.75,31.4)	(29.93,31.82)	(29.5,31.6)	(29.9,31.4)	(29.6,31.6)	(29.82,31.33)	(29.32,31.7)	(29.08,31.57)	(28.68,31.33)	(28.72,31.4)	(29.2,30.8)	(30.48,31.85)

Table S325: Additional Haematology Tests: Post-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Neutrophils (10^9/L)												
N	20	22	21	21	21	20	20	20	20	22	21	6
Mean	3.75	4.26	5.65	6.27	5.98	5.41	5.66	5.15	4.76	4.14	4	4.28
Median	3.6	3.9	4.9	6.1	5.4	4.4	5.35	4.85	4.25	3.9	3.8	3.65
Range	(1.4,5.9)	(2.1,8.4)	(2.2,17.1)	(2.7,10.5)	(1.6,16.6)	(2.8,13.1)	(1.8,11.5)	(2.2,9.2)	(2.5,10.9)	(1.8,8.2)	(2,6.3)	(2.3,7)
IQR	(2.98,4.45)	(3.2,5.42)	(3.8,6.5)	(4.6,8.3)	(4.1,7.5)	(3.68,6.08)	(3.95,7.2)	(3.77,6.4)	(3.5,5.48)	(3.25,4.47)	(3.2,4.8)	(2.7,5.95)
Lymphocytes (10^9/L)												
N	20	22	21	21	21	20	20	20	20	22	21	6
Mean	1.52	1.65	1.19	0.94	0.9	1.27	1.26	1.26	1.59	1.69	1.51	1.43
Median	1.4	1.35	1.1	0.8	0.8	1.2	1.25	1.35	1.55	1.4	1.4	1.4
Range	(0.6,2.8)	(0.6,2.9)	(0.1,4)	(0.3,3.2)	(0.3,3)	(0.3,2.8)	(0.3,2.9)	(0.3,2.5)	(0.3,4)	(0.6,6)	(0.7,2.8)	(0.9,1.9)
IQR	(1.08,2)	(1.12,2.27)	(0.7,1.3)	(0.6,1.1)	(0.6,1.1)	(0.7,1.65)	(0.6,1.63)	(0.57,1.92)	(0.82,2.23)	(1.12,1.98)	(1,2.1)	(1.33,1.62)
Monocytes (10^9/L)												
N	20	22	21	21	21	20	20	20	20	22	21	6
Mean	0.5	0.56	0.24	0.2	0.21	0.38	0.32	0.39	0.38	0.57	0.53	0.57
Median	0.5	0.55	0.2	0.1	0.1	0.4	0.2	0.4	0.4	0.5	0.5	0.6
Range	(0.2,0.9)	(0.2,1)	(0,0.8)	(0,0.9)	(0,1)	(0,1.2)	(0,0.8)	(0,1)	(0,0.9)	(0.3,0.9)	(0.2,0.9)	(0.1,1.2)
IQR	(0.4,0.52)	(0.4,0.7)	(0.1,0.3)	(0.1,0.2)	(0.1,0.2)	(0.1,0.52)	(0.1,0.52)	(0.1,0.6)	(0.1,0.52)	(0.4,0.7)	(0.4,0.7)	(0.38,0.6)

Table S325: Additional Haematology Tests: Post-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Eosinophils (10^9/L)												
N	20	22	21	21	21	20	20	20	20	22	21	6
Mean	0.26	0.39	0.23	0.22	0.15	0.24	0.24	0.24	0.2	0.26	0.33	0.27
Median	0.2	0.2	0	0	0	0.1	0.1	0.1	0.1	0.15	0.2	0.25
Range	(0,1.2)	(0,3.1)	(0,3.4)	(0,4)	(0,2)	(0,2)	(0,1.9)	(0,1.5)	(0,1.1)	(0,1.8)	(0,2.1)	(0.1,0.6)
IQR	(0.1,0.2)	(0.1,0.4)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.23)	(0,0.32)	(0,0.23)	(0.08,0.23)	(0.1,0.27)	(0.1,0.3)	(0.12,0.3)
Basophils (10^9/L)												
N	20	22	21	21	21	20	20	20	20	22	21	6
Mean	0.04	0.05	0.02	0.02	0.02	0.03	0.04	0.04	0.04	0.05	0.05	0.03
Median	0	0	0	0	0	0	0	0	0	0.05	0	0
Range	(0,0.1)	(0,0.1)	(0,0.2)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)
IQR	(0,0.1)	(0,0.1)	(0,0)	(0,0)	(0,0)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.1)	(0,0.08)
APTT (ratio)												
N	17	18	17	17	13	12	16	13	15	17	16	3
Mean	1.14	1.12	1.09	1.06	1.09	1.12	1.09	1.09	1.05	1.1	1.1	1.1
Median	1.1	1.1	1.1	1.1	1.1	1.1	1	1.1	1.1	1.1	1.1	1.1
Range	(1,1.5)	(1,1.4)	(1,1.4)	(0.9,1.3)	(1,1.4)	(1,1.4)	(0.9,1.5)	(0.9,1.4)	(0.9,1.2)	(1,1.4)	(1,1.3)	(1,1.2)
IQR	(1,1.2)	(1.02,1.2)	(1,1.1)	(1,1.1)	(1,1.1)	(1,1.12)	(1,1.2)	(1,1.1)	(1,1.1)	(1,1.1)	(1,1.2)	(1.05,1.15)

Table S326: Additional Haematology Test Result Codes: Pre-infusion Results.

	Screening Visit 1	Screening Visit 2	Visit 3 pre-dose	Visit 4 pre-dose	Visit 5 pre-dose	Visit 6 pre-dose	Visit 7 pre-dose	Visit 8 pre-dose	Visit 9 pre-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Haemoglobin (g/L)												
Normal	12	20	14	13	11	13	10	9	11	13	13	3
	(54.55%)	(90.91%)	(63.64%)	(61.90%)	(52.38%)	(61.90%)	(47.62%)	(42.86%)	(52.38%)	(59.09%)	(59.09%)	(50.00%)
Abnormal, clinically	8	2	8	8	10	8	10	12	8	9	8	3
insignificant	(36.36%)	(9.09%)	(36.36%)	(38.10%)	(47.62%)	(38.10%)	(47.62%)	(57.14%)	(38.10%)	(40.91%)	(36.36%)	(50.00%)
Missing	2	0	0	0	0	0	1	0	2	0	1	0
	(9.09%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(4.76%)	(0.00%)	(9.52%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Platelets (10^9/L)												
Normal	14	15	16	16	15	15	15	16	13	15	16	3
	(63.64%)	(68.18%)	(72.73%)	(76.19%)	(71.43%)	(71.43%)	(71.43%)	(76.19%)	(61.90%)	(68.18%)	(72.73%)	(50.00%)
Abnormal, clinically	5	6	5	4	6	5	5	4	4	6	3	3
insignificant	(22.73%)	(27.27%)	(22.73%)	(19.05%)	(28.57%)	(23.81%)	(23.81%)	(19.05%)	(19.05%)	(27.27%)	(13.64%)	(50.00%)
Abnormal, clinically	1	1	1	1	0	1	0	1	2	1	2	0
significant	(4.55%)	(4.55%)	(4.55%)	(4.76%)	(0.00%)	(4.76%)	(0.00%)	(4.76%)	(9.52%)	(4.55%)	(9.09%)	(0.00%)
Missing	2	0	0	0	0	0	1	0	2	0	1	0
	(9.09%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(4.76%)	(0.00%)	(9.52%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Red Blood Cells (10^12/L)												

Table S326: Additional Haematology Test Result Codes: Pre-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 pre-dose	Visit 4 pre-dose	Visit 5 pre-dose	Visit 6 pre-dose	Visit 7 pre-dose	Visit 8 pre-dose	Visit 9 pre-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Normal	15	16	15	12	14	14	12	15	11	12	16	4
	(68.18%)	(72.73%)	(68.18%)	(57.14%)	(66.67%)	(66.67%)	(57.14%)	(71.43%)	(52.38%)	(54.55%)	(72.73%)	(66.67%)
Abnormal, clinically	5	6	7	9	7	7	8	6	8	10	5	2
insignificant	(22.73%)	(27.27%)	(31.82%)	(42.86%)	(33.33%)	(33.33%)	(38.10%)	(28.57%)	(38.10%)	(45.45%)	(22.73%)	(33.33%)
Missing	2	0	0	0	0	0	1	0	2	0	1	0
	(9.09%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(4.76%)	(0.00%)	(9.52%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
White Blood Cells (10^9/L)												
Normal	19	17	17	18	19	17	18	18	16	21	19	5
	(86.36%)	(77.27%)	(77.27%)	(85.71%)	(90.48%)	(80.95%)	(85.71%)	(85.71%)	(76.19%)	(95.45%)	(86.36%)	(83.33%)
Abnormal, clinically	0	4	4	2	1	3	1	2	3	0	1	1
insignificant	(0.00%)	(18.18%)	(18.18%)	(9.52%)	(4.76%)	(14.29%)	(4.76%)	(9.52%)	(14.29%)	(0.00%)	(4.55%)	(16.67%)
Abnormal, clinically	1	1	1	1	1	1	1	1	0	1	1	0
significant	(4.55%)	(4.55%)	(4.55%)	(4.76%)	(4.76%)	(4.76%)	(4.76%)	(4.76%)	(0.00%)	(4.55%)	(4.55%)	(0.00%)
Missing	2	0	0	0	0	0	1	0	2	0	1	0
	(9.09%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(4.76%)	(0.00%)	(9.52%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Haematocrit (L/L)												
Normal	15	19	14	12	12	11	10	10	11	12	11	3
	(68.18%)	(86.36%)	(63.64%)	(57.14%)	(57.14%)	(52.38%)	(47.62%)	(47.62%)	(52.38%)	(54.55%)	(50.00%)	(50.00%)

Table S326: Additional Haematology Test Result Codes: Pre-infusion Results. *(continued)*

	Screening Visit 1	**Screening Visit 2**	**Visit 3 pre-dose**	**Visit 4 pre-dose**	**Visit 5 pre-dose**	**Visit 6 pre-dose**	**Visit 7 pre-dose**	**Visit 8 pre-dose**	**Visit 9 pre-dose**	**Follow-up visit 10**	**Follow-up visit 11**	**Unscheduled**
Abnormal, clinically	5	3	8	9	9	10	10	11	8	10	10	3
insignificant	(22.73%)	(13.64%)	(36.36%)	(42.86%)	(42.86%)	(47.62%)	(47.62%)	(52.38%)	(38.10%)	(45.45%)	(45.45%)	(50.00%)
Missing	2	0	0	0	0	0	1	0	2	0	1	0
	(9.09%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(4.76%)	(0.00%)	(9.52%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Mean Cell Volume (fL)												
Normal	18	20	20	19	19	19	18	18	17	19	18	5
	(81.82%)	(90.91%)	(90.91%)	(90.48%)	(90.48%)	(90.48%)	(85.71%)	(85.71%)	(80.95%)	(86.36%)	(81.82%)	(83.33%)
Abnormal, clinically	2	2	2	2	2	2	2	3	2	3	3	1
insignificant	(9.09%)	(9.09%)	(9.09%)	(9.52%)	(9.52%)	(9.52%)	(9.52%)	(14.29%)	(9.52%)	(13.64%)	(13.64%)	(16.67%)
Missing	2	0	0	0	0	0	1	0	2	0	1	0
	(9.09%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(4.76%)	(0.00%)	(9.52%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Mean Cell Haemoglobin (PG)												
Normal	18	20	19	19	19	19	18	19	17	19	17	5
	(81.82%)	(90.91%)	(86.36%)	(90.48%)	(90.48%)	(90.48%)	(85.71%)	(90.48%)	(80.95%)	(86.36%)	(77.27%)	(83.33%)
Abnormal, clinically	2	2	3	2	2	2	2	2	2	3	4	1
insignificant	(9.09%)	(9.09%)	(13.64%)	(9.52%)	(9.52%)	(9.52%)	(9.52%)	(9.52%)	(9.52%)	(13.64%)	(18.18%)	(16.67%)

Table S326: Additional Haematology Test Result Codes: Pre-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 pre-dose	Visit 4 pre-dose	Visit 5 pre-dose	Visit 6 pre-dose	Visit 7 pre-dose	Visit 8 pre-dose	Visit 9 pre-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Missing	2 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.76%)	0 (0.00%)	2 (9.52%)	0 (0.00%)	1 (4.55%)	0 (0.00%)
Total	**22 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**6 (100.00%)**
Neutrophils (10^9/L)												
Normal	19 (86.36%)	21 (95.45%)	18 (81.82%)	20 (95.24%)	19 (90.48%)	19 (90.48%)	19 (90.48%)	20 (95.24%)	19 (90.48%)	21 (95.45%)	21 (95.45%)	6 (100.00%)
Abnormal, clinically insignificant	1 (4.55%)	1 (4.55%)	3 (13.64%)	1 (4.76%)	1 (4.76%)	2 (9.52%)	1 (4.76%)	1 (4.76%)	0 (0.00%)	1 (4.55%)	0 (0.00%)	0 (0.00%)
Abnormal, clinically significant	0 (0.00%)	0 (0.00%)	1 (4.55%)	0 (0.00%)	1 (4.76%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Missing	2 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.76%)	0 (0.00%)	2 (9.52%)	0 (0.00%)	1 (4.55%)	0 (0.00%)
Total	**22 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**6 (100.00%)**
Lymphocytes (10^9/L)												
Normal	16 (72.73%)	19 (86.36%)	16 (72.73%)	17 (80.95%)	18 (85.71%)	18 (85.71%)	17 (80.95%)	15 (71.43%)	15 (71.43%)	18 (81.82%)	17 (77.27%)	5 (83.33%)
Abnormal, clinically insignificant	4 (18.18%)	3 (13.64%)	4 (18.18%)	4 (19.05%)	2 (9.52%)	3 (14.29%)	3 (14.29%)	6 (28.57%)	4 (19.05%)	4 (18.18%)	4 (18.18%)	1 (16.67%)

Table S326: Additional Haematology Test Result Codes: Pre-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 pre-dose	Visit 4 pre-dose	Visit 5 pre-dose	Visit 6 pre-dose	Visit 7 pre-dose	Visit 8 pre-dose	Visit 9 pre-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Abnormal, clinically	0	0	2	0	1	0	0	0	0	0	0	0
significant	(0.00%)	(0.00%)	(9.09%)	(0.00%)	(4.76%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)
Missing	2	0	0	0	0	0	1	0	2	0	1	0
	(9.09%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(4.76%)	(0.00%)	(9.52%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Monocytes (10^9/L)												
Normal	20	20	20	19	21	19	20	20	17	22	20	4
	(90.91%)	(90.91%)	(90.91%)	(90.48%)	(100.00%)	(90.48%)	(95.24%)	(95.24%)	(80.95%)	(100.00%)	(90.91%)	(66.67%)
Abnormal, clinically	0	2	2	2	0	2	0	1	2	0	1	2
insignificant	(0.00%)	(9.09%)	(9.09%)	(9.52%)	(0.00%)	(9.52%)	(0.00%)	(4.76%)	(9.52%)	(0.00%)	(4.55%)	(33.33%)
Missing	2	0	0	0	0	0	1	0	2	0	1	0
	(9.09%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(4.76%)	(0.00%)	(9.52%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Eosinophils (10^9/L)												
Normal	17	17	19	17	17	17	14	17	15	19	16	5
	(77.27%)	(77.27%)	(86.36%)	(80.95%)	(80.95%)	(80.95%)	(66.67%)	(80.95%)	(71.43%)	(86.36%)	(72.73%)	(83.33%)
Abnormal, clinically	3	5	3	4	4	4	6	4	4	3	5	1
insignificant	(13.64%)	(22.73%)	(13.64%)	(19.05%)	(19.05%)	(19.05%)	(28.57%)	(19.05%)	(19.05%)	(13.64%)	(22.73%)	(16.67%)

Table S326: Additional Haematology Test Result Codes: Pre-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 pre-dose	Visit 4 pre-dose	Visit 5 pre-dose	Visit 6 pre-dose	Visit 7 pre-dose	Visit 8 pre-dose	Visit 9 pre-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Missing	2	0	0	0	0	0	1	0	2	0	1	0
	(9.09%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(4.76%)	(0.00%)	(9.52%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Basophils (10^9/L)												
Normal	18	21	21	19	20	19	19	19	18	20	20	6
	(81.82%)	(95.45%)	(95.45%)	(90.48%)	(95.24%)	(90.48%)	(90.48%)	(90.48%)	(85.71%)	(90.91%)	(90.91%)	(100.00%)
Abnormal, clinically	2	1	1	2	1	2	1	2	1	2	1	0
insignificant	(9.09%)	(4.55%)	(4.55%)	(9.52%)	(4.76%)	(9.52%)	(4.76%)	(9.52%)	(4.76%)	(9.09%)	(4.55%)	(0.00%)
Missing	2	0	0	0	0	0	1	0	2	0	1	0
	(9.09%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(4.76%)	(0.00%)	(9.52%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
APTT (ratio)												
Normal	10	16	13	13	11	10	9	13	12	10	10	3
	(45.45%)	(72.73%)	(59.09%)	(61.90%)	(52.38%)	(47.62%)	(42.86%)	(61.90%)	(57.14%)	(45.45%)	(45.45%)	(50.00%)
Abnormal, clinically	7	2	4	3	3	4	6	4	3	7	6	0
insignificant	(31.82%)	(9.09%)	(18.18%)	(14.29%)	(14.29%)	(19.05%)	(28.57%)	(19.05%)	(14.29%)	(31.82%)	(27.27%)	(0.00%)
Missing	5	4	5	5	7	7	6	4	6	5	6	3
	(22.73%)	(18.18%)	(22.73%)	(23.81%)	(33.33%)	(33.33%)	(28.57%)	(19.05%)	(28.57%)	(22.73%)	(27.27%)	(50.00%)
Total	22	22	22	21	21	21	21	21	21	22	22	6
	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)

Table S327: Additional Haematology Test Result Codes: Post-infusion Results.

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Haemoglobin (g/L)												
Normal	12	20	13	12	10	10	10	8	7	13	13	3
	(54.55%)	(90.91%)	(59.09%)	(57.14%)	(47.62%)	(47.62%)	(47.62%)	(38.10%)	(33.33%)	(59.09%)	(59.09%)	(50.00%)
Abnormal, clinically	8	2	8	9	11	10	10	12	13	9	8	3
insignificant	(36.36%)	(9.09%)	(36.36%)	(42.86%)	(52.38%)	(47.62%)	(47.62%)	(57.14%)	(61.90%)	(40.91%)	(36.36%)	(50.00%)
Missing	2	0	1	0	0	1	1	1	1	0	1	0
	(9.09%)	(0.00%)	(4.55%)	(0.00%)	(0.00%)	(4.76%)	(4.76%)	(4.76%)	(4.76%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Platelets (10^9/L)												
Normal	14	15	16	16	14	14	13	14	13	15	16	3
	(63.64%)	(68.18%)	(72.73%)	(76.19%)	(66.67%)	(66.67%)	(61.90%)	(66.67%)	(61.90%)	(68.18%)	(72.73%)	(50.00%)
Abnormal, clinically	5	6	4	4	6	5	6	5	5	6	3	3
insignificant	(22.73%)	(27.27%)	(18.18%)	(19.05%)	(28.57%)	(23.81%)	(28.57%)	(23.81%)	(23.81%)	(27.27%)	(13.64%)	(50.00%)
Abnormal, clinically	1	1	1	1	1	1	1	1	2	1	2	0
significant	(4.55%)	(4.55%)	(4.55%)	(4.76%)	(4.76%)	(4.76%)	(4.76%)	(4.76%)	(9.52%)	(4.55%)	(9.09%)	(0.00%)
Missing	2	0	1	0	0	1	1	1	1	0	1	0
	(9.09%)	(0.00%)	(4.55%)	(0.00%)	(0.00%)	(4.76%)	(4.76%)	(4.76%)	(4.76%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**

Table S327: Additional Haematology Test Result Codes: Post-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Red Blood Cells (10^12/L)												
Normal	15 (68.18%)	16 (72.73%)	13 (59.09%)	12 (57.14%)	13 (61.90%)	11 (52.38%)	9 (42.86%)	12 (57.14%)	9 (42.86%)	12 (54.55%)	16 (72.73%)	4 (66.67%)
Abnormal, clinically insignificant	5 (22.73%)	6 (27.27%)	8 (36.36%)	9 (42.86%)	7 (33.33%)	9 (42.86%)	11 (52.38%)	8 (38.10%)	11 (52.38%)	10 (45.45%)	5 (22.73%)	2 (33.33%)
Abnormal, clinically significant	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.76%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Missing	2 (9.09%)	0 (0.00%)	1 (4.55%)	0 (0.00%)	0 (0.00%)	1 (4.76%)	1 (4.76%)	1 (4.76%)	1 (4.76%)	0 (0.00%)	1 (4.55%)	0 (0.00%)
Total	**22 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**6 (100.00%)**
White Blood Cells (10^9/L)												
Normal	19 (86.36%)	17 (77.27%)	16 (72.73%)	18 (85.71%)	16 (76.19%)	18 (85.71%)	17 (80.95%)	18 (85.71%)	16 (76.19%)	21 (95.45%)	19 (86.36%)	5 (83.33%)
Abnormal, clinically insignificant	0 (0.00%)	4 (18.18%)	5 (22.73%)	2 (9.52%)	4 (19.05%)	2 (9.52%)	3 (14.29%)	2 (9.52%)	3 (14.29%)	0 (0.00%)	1 (4.55%)	1 (16.67%)
Abnormal, clinically significant	1 (4.55%)	1 (4.55%)	0 (0.00%)	1 (4.76%)	1 (4.76%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.76%)	1 (4.55%)	1 (4.55%)	0 (0.00%)

Table S327: Additional Haematology Test Result Codes: Post-infusion Results. *(continued)*

	Screening Visit 1	**Screening Visit 2**	**Visit 3 post-dose**	**Visit 4 post-dose**	**Visit 5 post-dose**	**Visit 6 post-dose**	**Visit 7 post-dose**	**Visit 8 post-dose**	**Visit 9 post-dose**	**Follow-up visit 10**	**Follow-up visit 11**	**Unscheduled**
Missing	2	0	1	0	0	1	1	1	1	0	1	0
	(9.09%)	(0.00%)	(4.55%)	(0.00%)	(0.00%)	(4.76%)	(4.76%)	(4.76%)	(4.76%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Haematocrit (L/L)												
Normal	15	19	13	9	11	12	9	10	8	12	11	3
	(68.18%)	(86.36%)	(59.09%)	(42.86%)	(52.38%)	(57.14%)	(42.86%)	(47.62%)	(38.10%)	(54.55%)	(50.00%)	(50.00%)
Abnormal, clinically	5	3	8	11	10	8	11	10	12	10	10	3
insignificant	(22.73%)	(13.64%)	(36.36%)	(52.38%)	(47.62%)	(38.10%)	(52.38%)	(47.62%)	(57.14%)	(45.45%)	(45.45%)	(50.00%)
Missing	2	0	1	1	0	1	1	1	1	0	1	0
	(9.09%)	(0.00%)	(4.55%)	(4.76%)	(0.00%)	(4.76%)	(4.76%)	(4.76%)	(4.76%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Mean Cell Volume (fL)												
Normal	18	20	19	19	19	18	18	18	18	19	18	5
	(81.82%)	(90.91%)	(86.36%)	(90.48%)	(90.48%)	(85.71%)	(85.71%)	(85.71%)	(85.71%)	(86.36%)	(81.82%)	(83.33%)
Abnormal, clinically	2	2	2	2	2	2	2	2	2	3	3	1
insignificant	(9.09%)	(9.09%)	(9.09%)	(9.52%)	(9.52%)	(9.52%)	(9.52%)	(9.52%)	(9.52%)	(13.64%)	(13.64%)	(16.67%)
Missing	2	0	1	0	0	1	1	1	1	0	1	0
	(9.09%)	(0.00%)	(4.55%)	(0.00%)	(0.00%)	(4.76%)	(4.76%)	(4.76%)	(4.76%)	(0.00%)	(4.55%)	(0.00%)

Table S327: Additional Haematology Test Result Codes: Post-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Mean Cell Haemoglobin (PG)												
Normal	18	20	19	19	19	18	18	18	17	19	17	5
	(81.82%)	(90.91%)	(86.36%)	(90.48%)	(90.48%)	(85.71%)	(85.71%)	(85.71%)	(80.95%)	(86.36%)	(77.27%)	(83.33%)
Abnormal, clinically	2	2	2	2	2	2	2	2	3	3	4	1
insignificant	(9.09%)	(9.09%)	(9.09%)	(9.52%)	(9.52%)	(9.52%)	(9.52%)	(9.52%)	(14.29%)	(13.64%)	(18.18%)	(16.67%)
Missing	2	0	1	0	0	1	1	1	1	0	1	0
	(9.09%)	(0.00%)	(4.55%)	(0.00%)	(0.00%)	(4.76%)	(4.76%)	(4.76%)	(4.76%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Neutrophils (10^9/L)												
Normal	**19**	**21**	**17**	**14**	**15**	**16**	**14**	**18**	**18**	**21**	**21**	**6**
	(86.36%)	**(95.45%)**	**(77.27%)**	**(66.67%)**	**(71.43%)**	**(76.19%)**	**(66.67%)**	**(85.71%)**	**(85.71%)**	**(95.45%)**	**(95.45%)**	**(100.00%)**
Abnormal, clinically	1	1	4	7	6	4	6	2	2	1	0	0
insignificant	(4.55%)	(4.55%)	(18.18%)	(33.33%)	(28.57%)	(19.05%)	(28.57%)	(9.52%)	(9.52%)	(4.55%)	(0.00%)	(0.00%)
Missing	2	0	1	0	0	1	1	1	1	0	1	0
	(9.09%)	(0.00%)	(4.55%)	(0.00%)	(0.00%)	(4.76%)	(4.76%)	(4.76%)	(4.76%)	(0.00%)	(4.55%)	(0.00%)

Table S327: Additional Haematology Test Result Codes: Post-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Total	**22 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**6 (100.00%)**
Lymphocytes (10^9/L)												
Normal	16 (72.73%)	19 (86.36%)	12 (54.55%)	7 (33.33%)	6 (28.57%)	12 (57.14%)	11 (52.38%)	11 (52.38%)	13 (61.90%)	18 (81.82%)	17 (77.27%)	5 (83.33%)
Abnormal, clinically insignificant	4 (18.18%)	3 (13.64%)	8 (36.36%)	14 (66.67%)	15 (71.43%)	7 (33.33%)	9 (42.86%)	9 (42.86%)	7 (33.33%)	4 (18.18%)	4 (18.18%)	1 (16.67%)
Abnormal, clinically significant	0 (0.00%)	0 (0.00%)	1 (4.55%)	0 (0.00%)	0 (0.00%)	1 (4.76%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Missing	2 (9.09%)	0 (0.00%)	1 (4.55%)	0 (0.00%)	0 (0.00%)	1 (4.76%)	1 (4.76%)	1 (4.76%)	1 (4.76%)	0 (0.00%)	1 (4.55%)	0 (0.00%)
Total	**22 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**21 (100.00%)**	**22 (100.00%)**	**22 (100.00%)**	**6 (100.00%)**
Monocytes (10^9/L)												
Normal	20 (90.91%)	20 (90.91%)	14 (63.64%)	11 (52.38%)	11 (52.38%)	15 (71.43%)	16 (76.19%)	13 (61.90%)	15 (71.43%)	22 (100.00%)	20 (90.91%)	4 (66.67%)
Abnormal, clinically insignificant	0 (0.00%)	2 (9.09%)	6 (27.27%)	10 (47.62%)	10 (47.62%)	5 (23.81%)	4 (19.05%)	7 (33.33%)	5 (23.81%)	0 (0.00%)	1 (4.55%)	2 (33.33%)
Abnormal, clinically significant	0 (0.00%)	0 (0.00%)	1 (4.55%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Table S327: Additional Haematology Test Result Codes: Post-infusion Results. *(continued)*

	Screening Visit 1	**Screening Visit 2**	**Visit 3 post-dose**	**Visit 4 post-dose**	**Visit 5 post-dose**	**Visit 6 post-dose**	**Visit 7 post-dose**	**Visit 8 post-dose**	**Visit 9 post-dose**	**Follow-up visit 10**	**Follow-up visit 11**	**Unscheduled**
Missing	2	0	1	0	0	1	1	1	1	0	1	0
	(9.09%)	(0.00%)	(4.55%)	(0.00%)	(0.00%)	(4.76%)	(4.76%)	(4.76%)	(4.76%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Eosinophils (10^9/L)												
Normal	17	17	17	18	17	16	14	14	17	19	16	5
	(77.27%)	(77.27%)	(77.27%)	(85.71%)	(80.95%)	(76.19%)	(66.67%)	(66.67%)	(80.95%)	(86.36%)	(72.73%)	(83.33%)
Abnormal, clinically insignificant	3	5	4	3	4	4	6	6	3	3	5	1
	(13.64%)	(22.73%)	(18.18%)	(14.29%)	(19.05%)	(19.05%)	(28.57%)	(28.57%)	(14.29%)	(13.64%)	(22.73%)	(16.67%)
Missing	2	0	1	0	0	1	1	1	1	0	1	0
	(9.09%)	(0.00%)	(4.55%)	(0.00%)	(0.00%)	(4.76%)	(4.76%)	(4.76%)	(4.76%)	(0.00%)	(4.55%)	(0.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
Basophils (10^9/L)												
Normal	18	21	19	20	19	18	19	18	18	20	20	6
	(81.82%)	(95.45%)	(86.36%)	(95.24%)	(90.48%)	(85.71%)	(90.48%)	(85.71%)	(85.71%)	(90.91%)	(90.91%)	(100.00%)
Abnormal, clinically insignificant	2	1	2	1	2	2	1	2	2	2	1	0
	(9.09%)	(4.55%)	(9.09%)	(4.76%)	(9.52%)	(9.52%)	(4.76%)	(9.52%)	(9.52%)	(9.09%)	(4.55%)	(0.00%)
Missing	2	0	1	0	0	1	1	1	1	0	1	0
	(9.09%)	(0.00%)	(4.55%)	(0.00%)	(0.00%)	(4.76%)	(4.76%)	(4.76%)	(4.76%)	(0.00%)	(4.55%)	(0.00%)

Table S327: Additional Haematology Test Result Codes: Post-infusion Results. *(continued)*

	Screening Visit 1	Screening Visit 2	Visit 3 post-dose	Visit 4 post-dose	Visit 5 post-dose	Visit 6 post-dose	Visit 7 post-dose	Visit 8 post-dose	Visit 9 post-dose	Follow-up visit 10	Follow-up visit 11	Unscheduled
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**
APTT (ratio)												
Normal	10	16	14	13	11	9	8	10	12	10	10	3
	(45.45%)	(72.73%)	(63.64%)	(61.90%)	(52.38%)	(42.86%)	(38.10%)	(47.62%)	(57.14%)	(45.45%)	(45.45%)	(50.00%)
Abnormal, clinically	7	2	3	4	2	3	8	3	3	7	6	0
insignificant	(31.82%)	(9.09%)	(13.64%)	(19.05%)	(9.52%)	(14.29%)	(38.10%)	(14.29%)	(14.29%)	(31.82%)	(27.27%)	(0.00%)
Missing	5	4	5	4	8	9	5	8	6	5	6	3
	(22.73%)	(18.18%)	(22.73%)	(19.05%)	(38.10%)	(42.86%)	(23.81%)	(38.10%)	(28.57%)	(22.73%)	(27.27%)	(50.00%)
Total	**22**	**22**	**22**	**21**	**21**	**21**	**21**	**21**	**21**	**22**	**22**	**6**
	(100.00%)	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**	**(100.00%)**



Figure S66: Repeated measures plot of additional haematology tests at all trial visits in the mITT population, presented by haematology test. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.



Figure S67: Repeated measures plot of additional haematology tests at pre-BTT1023 infusion in the mITT population, presented by haematology test. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.


Haematology Test
APTT (ratio)
Basophils (10^9/L)
Eosinophils (10^9/L)
Haematocrit (L/L)
Haemoglobin (g/L)
Lymphocytes (10^9/L)
Mean Cell Haemoglobin (PG)
Mean Cell Volume (fL)
Monocytes (10^9/L)
Neutrophils (10^9/L)
Platelets (10^9/L)
Red Blood Cells (10^12/L)



Figure S68: Repeated measures plot of additional haematology tests at post-BTT1023 infusion in the mITT population, presented by haematology test. A loess smoother trend line is shown in dark blue (thicker line) with uncertainty depicted by the shaded grey region.